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ABSTRACT 
Malignant hyperthermia (MH) is an autosomal dominant, pharmacogenetic disorder primarily 
caused by RYR1 mutations which result in calcium dysregulation within skeletal muscle. 
Genetically susceptible individuals are at risk of potentially fatal hypermetabolic reactions 
when exposed to volatile anaesthetics and the muscle relaxant succinylcholine. MH 
susceptibility is diagnosed through the in vitro contracture test (IVCT) by challenging muscle 
biopsies with triggering agents, or by genetic screening for known familial mutations. 
Genome-wide gene expression was compared before and after IVCT, from MH-
susceptible (MHS) and non-susceptible (MHN) skeletal muscle by RNA sequencing. A 
downregulation of genes related to oxidative phosphorylation (OXPHOS) was observed in 
MHS samples at baseline, suggesting a metabolic defect. Mitochondrial function was assessed 
by high resolution respirometry, measuring oxygen consumption rates in permeabilised muscle 
fibres. Results showed evidence of reduced OXPHOS capacity, complex II deficiency and 
increased mitochondrial content in MHS muscle at baseline. Exposure to halothane triggered a 
hypermetabolic response in MHS mitochondria which significantly increased oxygen 
consumption rates in several respiratory states, whilst MHN samples were unaltered. 
Genome-wide gene expression and mitochondrial function was also studied at baseline 
and after halothane challenge, using transgenic mouse models of MH to investigate RYR1 
variant-specific effects. At baseline, fatty acid oxidation and mitochondria-related gene 
expression was downregulated in mice homozygous (HOM) for G2435R-RYR1 and 
heterozygous (HET) for T4826I-RYR1. In comparison to wild-type, mitochondria from 
G2435R-RYR1 HOM mice showed an increase in complex I-facilitated OXPHOS and reduced 
mitochondrial content at baseline. Mitochondria from transgenic mice also showed evidence 
of increased sensitivity to both halothane and calcium in comparison to wild-type. 
This study presents evidence of mitochondrial dysfunction in human and mouse MHS 
skeletal muscle, which is correlated with gene expression changes associated with oxidative 
metabolism.  Functional defects in mitochondria are therefore potential contributors to 
phenotypic variability observed in MH. 
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1 GENERAL INTRODUCTION 
 
In modern day medicine, the application of general anaesthesia (GA) using gaseous substances 
or intravenous medicine, alleviates distress in patients undergoing invasive and painful medical 
procedures. GA is usually considered as a safe process, but complications can occur, ranging 
from milder symptoms such as dizziness and vomiting, to more serious complications which 
are potentially fatal (NHS, 2018). GA-associated deaths are very rare and difficult to quantify 
as they are usually multifactorial (Gottschalk et al., 2011). An example of a potentially fatal 
complication is the pharmacogenetic disorder malignant hyperthermia (MH), which has a 
mortality rate of 4% within the UK (Gupta and Hopkins, 2017). This thesis will explore skeletal 
muscle gene expression and metabolic function in the context of MH. The general introduction 
will provide the relevant background on skeletal muscle function, Ca2+ regulation, excitation-
contraction coupling, muscle metabolism and MH genetics - all of which are key areas related 
to MH pathology. 
 
1.1 SKELETAL MUSCLE STRUCTURE AND FUNCTION 
 
Skeletal muscle occupies approximately 40% of human body weight, composed of water 
(~75%), protein (~20%) and a mixture of fat and carbohydrates (~5%) (Frontera and Ochala, 
2015). The main function of skeletal muscle is to convert chemical energy into mechanical 
energy for movement, posture maintenance and general applications of force (Trovato et al., 
2016). Additional functions include protecting inner organs, acting as a storage site for 
carbohydrates and amino acids, and the maintenance of core body temperature through muscle 
contraction. Amino acids, carbohydrates and fats stored in skeletal muscle also contribute to 
the maintenance of blood glucose levels during periods of starvation (Frontera and Ochala, 
2015). The structure of skeletal muscle is highly organized, containing muscle fibre bundles 
(fascicles) separated by three layers of connective tissue which maintain its integrity 
(epimysium, perimysium, and endomysium) (Figure 1.1).  
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Figure 1.1. An overview of skeletal muscle structure. In brief, the epimysium surrounds the outer 
layer of the muscle, in which numerous muscle fibre bundles reside, known as fascicles. Fascicles are 
surrounded by the perimysium and muscle fibres are separated by the endomysium. Each individual 
muscle fibre is surrounded by a plasma membrane called the sarcolemma (Frontera and Ochala, 2015). 
Muscle fibres are composed of actin and myosin myofibrils which are organised and repeated as 
sarcomeres, the basic functional unit of skeletal muscle. This image is an adaptation from (OpenStax, 
2013), which is made available under the terms of the Creative Commons Attribution 4.0 international 
license (https://creativecommons.org/licenses/by/4.0/deed.en). 
Individual muscle fibres contain repetitive functional units called sarcomeres, which 
contain actin (thin) and myosin (thick) myofilaments. There can be thousands of sarcomeres 
within a single muscle cell and the myofilament arrangements give skeletal muscle a striated 
appearance (Krans, 2010). Skeletal muscle contraction is described by the sliding filament 
theory, which involves the shortening of sarcomeres through a molecular interaction known as 
cross bridge cycling (Squire, 2016; Huxley and Hanson, 1954; Huxley and Niedergerke, 1954). 
A cross bridge is formed when the head of a myosin myofilaments binds onto actin and pulls 
it along using the energy supplied by adenosine triphosphate (ATP) hydrolysis (Figure 1.2). 
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Figure 1.2. Schematic representation of sarcomere structure. The darker A band contains myosin, 
whilst the lighter I band contains actin. The binding of myosin to actin is regulated by the two proteins 
troponin and tropomyosin. At rest, tropomyosin blocks the myosin binding site, preventing contraction. 
For binding to occur, Ca2+ must bind to troponin, which in turn shifts the position of tropomyosin away 
from the myosin binding site. Successful binding of the myosin head onto actin, initiates cross bridge 
cycling. The actin myofilaments are tethered to structures located at the lateral ends of each sarcomere 
(Z lines), and subsequent cross bridging results in the entire sarcomere shortening. This image was 
taken from (OpenStax, 2013), which is made available under the terms of the Creative Commons 
Attribution 4.0 international license (https://creativecommons.org/licenses/by/4.0/deed.en). 
Mammalian skeletal muscle can be categorised into different fibre types which allow 
functional adaptation to different scenarios. The most basic classification broadly divides 
muscle fibres into slow-twitch type I and fast-twitch type II fibres which are specialised for 
oxidative and glycolytic metabolism, respectively. This classification of type II fibres can be 
further divided into fast-twitch oxidative type IIA and fast-twitch glycolytic type IIX and IIB, 
due to the heterogeneity within type II muscle fibres (Schiaffino and Reggiani, 2011; Talbot 
and Maves, 2016). Type I muscle fibres are defined by a red appearance (high myoglobin 
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content), slow contraction times, high resistance to fatigue and high oxidative capacity due to 
high mitochondrial content - suitable for sustained aerobic activity requiring low-level force 
production such as walking (Scott et al., 2001). Type IIA muscle fibres function as a hybrid 
between type I and type II, with a red appearance, strong contractures, intermediate resistance 
to fatigue and a high capacity for both oxidative and glycolytic metabolism. Finally, both IIX 
and type IIB have a white appearance due to low levels of myoglobin and mitochondria. These 
fibres favour anaerobic metabolism and are highly sensitive to fatigue, best for short anaerobic 
activities requiring strong contractions such as sprinting and jumping (Schiaffino and Reggiani, 
2011). 
Mature muscle fibres are post-mitotic but have a high capacity for regeneration due to 
adult muscle stem cells known as satellite cells, which reside between the basal lamina and the 
sarcolemma (Nguyen et al., 2019). In the event of muscle damage (i.e. through exercise), 
satellite cells activate to regenerate new muscle fibres for growth and repair (Yin et al., 2013). 
Activated satellite cells proliferate and undergo differentiation to form myoblasts, defined as 
embryonic precursors of muscle cells. These myoblasts can then differentiate further and merge 
into multinucleated muscle fibres in vitro (myotubes), a process governed by a network of 
transcription factors (Yin et al., 2013; Mukund and Subramaniam, 2020).  
 
1.1.1 Calcium signalling in skeletal muscle 
 
Ca2+ is a ubiquitous messenger, responsible for the regulation of many cellular processes 
including skeletal muscle function. Ca2+ in skeletal muscle is stored within the sarcoplasmic 
reticulum (SR), at an estimated concentration of 0.3 mM (Rudolf et al., 2006). In contrast, the 
resting Ca2+ concentration ([Ca2+]rest) within the cytosol is much lower (~100 nM) and acute 
alterations in [Ca2+]rest are required to regulate muscle contraction and relaxation mechanisms 
(Calderon et al., 2014; Kuo and Ehrlich, 2015). Rapid changes in [Ca2+]rest are a result of Ca
2+ 
efflux from the SR which is triggered by the propagation of action potentials across the 
sarcolemma (Gehlert et al., 2015). The efflux of Ca2+ from the SR is dependent on the 
molecular interactions between the L-type voltage-gated Ca2+ channel, dihydropyridine 
receptors (DHPR), and the isoform 1 Ca2+ release channel ryanodine receptors (RyR1).  The 
process in which an electrical stimulus is converted into a mechanical response is known as  
excitation-contraction coupling (1.3) (Sandow, 1952). 
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Figure 1.3. An overview of excitation-contraction coupling. In brief, when an action potential has 
been initiated and reaches the neuromuscular junction, vesicles of acetylcholine are released which bind 
to receptors on the motor end plate. This results in the activation of sodium ion channels and the 
depolarisation of the sarcolemma, creating another action potential. This action potential travels across 
invaginations in the sarcolemma called the t-tubules, and the voltage change is detected by the voltage-
gated Ca2+ channel DHPR. DHPR then interacts with RyR1 which results in Ca2+ efflux from the SR. 
Elevations in [Ca2+]rest activates the contractile apparatus and the subsequent interactions between 
myofilaments, lead to muscle contraction through the shortening of sarcomeres. This image is an 
adaptation taken from (OpenStax, 2013), which is made available under the terms of the Creative 
Commons Attribution 4.0 international license (https://creativecommons.org/licenses/by/4.0/deed.en). 
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Following muscle contraction, [Ca2+]rest is returned to basal level primarily though SR 
replenishment and extracellular Ca2+ entry. The reuptake of Ca2+ back into the SR is facilitated 
by ATP-dependent sarcoplasmic/endoplasmic reticulum calcium ATPase pumps (SERCA) on 
the SR membrane (Stammers et al., 2015). The Ca2+ within the SR is buffered by the luminal 
protein calsequestrin (CASQ), which prevents the SR from swelling in the presence of high 
[Ca2+] (Murphy et al., 2009a). Alongside SERCA, the replenishing of SR Ca2+ is assisted by 
store operated Ca2+ entry (SOCE), which facilitates the transport of extracellular Ca2+ into the 
cytosol (Trebak et al., 2013).  
SOCE is dependent on the interactions between the Ca2+ channel Orai1 (present on the 
sarcolemma) and the Ca2+ sensor stromal interaction molecule 1 (STIM1) (present on the SR 
membrane), both of which activate in response to the depletion of Ca2+ from the SR (Cho et al., 
2017) (Figure 1.4). The entry of extracellular Ca2+ from SOCE is important for Ca2+ 
homeostasis and assists the maintenance (but not initiation) of muscle contraction in addition 
to muscle differentiation and growth, through the activation of Ca2+-dependent pathways 
(Kiviluoto et al., 2011; Cho et al., 2017).  
 
 
 
 
 
 
 
 
 
 
Figure 1.4. Modes of Ca2+ homeostasis in skeletal muscle. A schematic diagram outlining the 
different modes of Ca2+ transport within skeletal muscle. This image was drawn based on information 
from (Gehlert et al., 2015; Cho et al., 2017; Contreras et al., 2010). 
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1.1.2 Mitochondrial function 
 
Ca2+ handling by mitochondria is important for energy production, [Ca2+]rest maintenance and 
determining cell fate (Contreras et al., 2010). Mitochondria are known as the powerhouses of 
the cell and provide the ATP required for muscle contraction and Ca2+ homeostasis through 
oxidative phosphorylation (OXPHOS). Physical training through repeated bouts of endurance 
exercise promotes mitochondrial biogenesis in skeletal muscle, which reflects an increase in 
mitochondrial content and/or a change in mitochondrial composition (Ljubicic et al., 2010). 
This remodelling of skeletal muscle mitochondria helps the muscle to adapt and serve different 
functions more efficiently and reduce its sensitivity to fatigue.  
In addition to the activity of SERCA and SOCE, studies have shown that mitochondria 
also act as Ca2+ buffers and secondary Ca2+ stores to help regulate [Ca2+]rest (Contreras et al., 
2010). Ca2+ signalling regulates mitochondrial function by altering the activity of 
dehydrogenase enzymes which are sensitive to changes in cytosolic and mitochondrial [Ca2+] 
(Denton, 2009). The uptake of Ca2+ in mitochondria is facilitated by the mitochondrial Ca2+ 
uniporter (MCU) and expelled from the organelle through sodium (Na+)/Ca2+ antiporters 
(NCX) (Figure 1.4) (Mishra et al., 2017; Palty et al., 2010). During pathological instances of 
mitochondrial Ca2+ overload, the mitochondrial permeability transition pore (MPTP) can 
activate which causes mitochondrial swelling and initiates apoptotic mechanisms (Rasola and 
Bernardi, 2007). 
 
1.1.3 Oxidative phosphorylation  
 
Most of the energy production in skeletal muscle occurs through OXPHOS, where electrons 
and oxygen are converted into energy in the form of ATP (Mitchell and Moyle, 1967). This 
process takes place in the inner mitochondrial membrane through the electron transport system 
(ETS), which consists of several multi-subunit enzymes: NADH dehydrogenase (complex I), 
Succinate dehydrogenase (complex II), cytochrome c oxidoreductase (complex III), 
cytochrome c oxidase (complex IV) and ATP synthase (complex V) (Chaban et al., 2014). 
OXPHOS requires the donation of electrons from nicotinamide adenine dinucleotide (NADH) 
and flavin adenine dinucleotide (FADH2), produced by fatty acid oxidation and the citric acid 
cycle within the mitochondrial matrix, and by glycolysis within the cytosol. The ETS utilizes 
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the energy from electron transport to transfer protons across the inner mitochondrial membrane 
which generates a proton gradient. The ETS is known to as a ‘coupled’ system as transfer of 
protons is dependent on the transport of electrons. The proton gradient generated is used by 
ATP synthase to generate ATP from adenosine diphosphate (ADP) (Figure 1.5) (Berg et al., 
2002).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5. Schematic representation of the mitochondrial electron transport system. In brief, 
OXPHOS is initiated by the transfer of electrons from NADH to complex I and FADH2 to complex II. 
NADH and FADH2 are the first electron donors generated through glycolysis, fatty acid oxidation and 
the citric acid cycle. These electrons are then transferred to complex III and complex IV by the mobile 
electron carriers, ubiquinone (Q) and cytochrome c (Cyt c), respectively. Finally, these electrons are 
donated to the final electron acceptor, molecular oxygen, to generate water. The energy released from 
the transfer of electrons is used to pump protons through the inner mitochondrial membrane and into 
the intermembrane space to generate a proton gradient. The movement of protons occur at complexes 
I, III and IV. Complex V (ATP Synthase) uses this proton gradient to drive the conversion of ADP to 
ATP (Berg et al., 2002; Chaban et al., 2014). Image was taken from the public domain and adapted. 
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1.1.4 Ryanodine receptors 
 
The ryanodine receptor (RyR) is a type of intracellular Ca2+ channel, responsible for the release 
of Ca2+ from the endoplasmic reticulum (ER)/SR. In humans, there are three RyR isoforms 
(RyR1, RyR2, RyR3), which are expressed in a wide range of cell types (Lanner et al., 2010). 
The first isoform RyR1 was cloned in 1990 and is localized primarily in skeletal muscle 
(Zorzato et al., 1990). The second isoform RyR2 is found in cardiac cells (Otsu et al., 1990). 
RyR3, formally known as the brain isoform, was first identified in brain tissue (Hakamata et 
al., 1992). The function of RyRs are vital for excitation-contraction coupling in skeletal/cardiac 
muscle and Ca2+ homeostasis.  
For this thesis, RyR1 will be the primary focus and will be discussed in greater detail. 
The RyR1 is a large channel with a molecular mass of ~2.3 MDa and a homotetrameric 
structure consisting of four protomers, each containing ~5000 amino acid residues (Imagawa 
et al., 1987; Inui et al., 1987). Cryo-electron microscopy (Cryo-EM) reports have revealed that 
these protomers are built on an extended α-solenoid scaffold surrounding a transmembrane 
pore with a general structure belonging to the six-transmembrane ion channel superfamily 
(Zalk et al., 2015; Yan et al., 2015).  
Binding sites for Ca2+, ATP, caffeine and ryanodine have been identified in RyR1 (des 
Georges et al., 2016). The binding sites for Ca2+, caffeine and ATP are located at interdomain 
interfaces of the C-terminal domain and successful binding of these activating ligands result in 
conformational changes that lead to the opening of RyR1 (Figure 1.6). The Ca2+ binding sites 
on RyR1 are divided into high affinity activating sites and low affinity inactivating sites which 
regulate RyR1 in a concentration-dependent manner (des Georges et al., 2016). The activity of 
RyR1 is also modulated through interactions with the DHPR, intracellular molecules (e.g. Ca2+, 
Mg2+, ATP), and Ca2+-handling proteins (e.g. CASQ and Calmodulin) and through post-
translational modifications (e.g. oxidation, phosphorylation) (Lanner et al., 2010; Hernandez-
Ochoa et al., 2015).  
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Figure 1.6. Structure of RyR1. A) Tetrameric structure of RyR1 and its orientation on the SR 
membrane. The binding sites for Ca2+, caffeine and ATP are located at interdomain interfaces of the 
C-terminal domain their approximate locations are indicated by the arrows. B) Schematic diagram of 
RyR1 domain organisation. This image is adapted from (Yan et al., 2015).  
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The gene encoding RyR1 (RYR1) is located on chromosome 19q13.2, and RYR1 
mutations have been associated with several inherited skeletal muscle disorders with both 
dominant and recessive modes of inheritance (Kushnir et al., 2018). Examples of these include 
MH, central core disease, multi-minicore disease, nemaline myopathy and centronuclear 
myopathy (Kushnir et al., 2018; Robinson et al., 2006). These conditions all feature RyR1-
related Ca2+ dysregulation which impairs excitation-contraction coupling and general skeletal 
muscle function. 
 
1.1.5 The Dihydropyridine receptor 
 
The DHPR is an L-type voltage-gated Ca2+ channel situated in the sarcolemma at t-tubules. 
The DHPR has a molecular mass of 450 kDa, consisting of five subunits (α1, α2, δ, β and γ) 
and is essential for excitation-contraction coupling and Ca2+ homeostasis (Hu et al., 2015; 
Sandow, 1952). DHPRs are mechanically coupled to RyR1 at sites known as calcium release 
units (CRU), referring to junctions where the sarcolemma and SR membrane are in proximity 
(Franzini-Armstrong and Jorgensen, 1994). In response to membrane depolarisation (via action 
potentials), DHPRs undergo conformational changes which in turn triggers the activation of 
RyR1, resulting in the rapid release of Ca2+ from the SR into the cytosol (Calderon et al., 2014). 
The α1 subunit of DHPR is encoded by the CACNA1S gene (also known as CACNL1A3) which 
is mapped to chromosome 1q32.1, and mutations within this gene have been associated with 
MH and hypokalemic periodic paralysis type 1 (Monnier et al., 1997; Ptacek et al., 1994). 
 
1.2 MALIGNANT HYPERTHERMIA 
 
MH (MIM# 145600) is a potentially fatal, pharmacogenetic disorder which affects Ca2+ 
homeostasis in skeletal muscle. Individuals susceptible to MH (MHS) undergo hypermetabolic 
reactions when exposed to volatile anaesthetics (e.g. halothane, sevoflurane, isoflurane) and 
the muscle relaxant succinylcholine (Hopkins, 2011). The first case of human MH 
susceptibility was described in 1960, featuring a family in which 10 out of 38 members died 
after exposure to GA (Denborough et al., 1962). MH is known to be inherited in an autosomal 
dominant mendelian fashion, but there is increasing evidence which supports a threshold (non-
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mendelian) genetic model with genetic modifiers of phenotype (Robinson et al., 2000; Monnier 
et al., 2002; Robinson et al., 2003a; Carpenter et al., 2009b; Miller et al., 2018). MH 
susceptibility is associated with mutations in RYR1, CACNA1S and STAC3, all of which encode 
proteins directly involved with excitation-contraction coupling (Robinson et al., 2006; Monnier 
et al., 1997; Horstick et al., 2013).  
Clinical features of an MH reaction include an increase in carbon dioxide (CO2) 
production and oxygen consumption, followed by tachycardia, hyperthermia, sustained muscle 
contracture and progressive muscle rigidity (Rosenberg et al., 2015; Larach et al., 2008). 
Without intervention, prolonged MH reactions progress to respiratory and metabolic acidosis 
due to skeletal muscle ATP depletion. Life-threatening complications include rhabdomyolysis, 
acute renal failure, heart failure, and disseminated intravascular coagulation (Rosenberg et al., 
2015; Gupta and Hopkins, 2017). The only drug specifically used to treat MH is Dantrolene, 
which acts as an RyR1 agonist and halts the Ca2+ efflux from the SR thereby interrupting 
muscle contraction (Glahn et al., 2010; Bannister, 2013).  
 
1.2.1 Epidemiology 
 
In the UK population, the incidence of MH reactions occurring under anaesthesia has been 
estimated to be within the range of 1:50,000 to 1:70,000 anaesthetic procedures (Gupta and 
Hopkins, 2017). However, these estimations do not reflect the true prevalence of MH within 
the population, as there is incomplete penetrance of the genetic trait. Many individuals who 
were later found to be MHS, did not have MH reactions upon first exposure to triggering agents 
(Ibarra Moreno et al., 2019). Some may also never experience procedures requiring 
anaesthesia, which contributes towards an underestimation of prevalence. It is therefore 
accepted that the genetic traits for MH may require the contributions of additional genetic or 
non-genetic factors to manifest, which makes it difficult to estimate disease penetrance (Shaw 
and Hopkins, 2019). Despite these difficulties, the estimated prevalence for carrying a 
pathogenic RYR1 mutation was estimated to be as high as 1:1500 (Shaw and Hopkins, 2019), 
which accounts for approximately 76% of MH families within the UK (Miller et al., 2018). 
MH can affect all ethnicities but there is evidence of higher incidence in males (2:1) and those 
who are of a younger age demographic (Riazi et al., 2014; Rosenberg et al., 2015).  
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1.2.2 Diagnosis  
 
The diagnosis of MH susceptibility can be achieved through the in vitro contracture test 
(IVCT), which involves challenging a muscle biopsy with halothane and caffeine (EMHG, 
1984). The IVCT is standardised across Europe by the European Malignant Hyperthermia 
Group (EMHG) and is known to have a high sensitivity (99%) and specificity (94%) (Hopkins 
et al., 2015). It remains as the only definitive method used to confirm MH susceptibility, but 
some individuals can be diagnosed through genetic testing if they are from families with a 
known causative MH mutation (Hopkins et al., 2015; Urwyler et al., 2001). The first individual 
to have an MH reaction within a family (proband/index case) and relatives from MH families 
without known causative mutations are always referred for the IVCT (Hopkins et al., 2015). 
The only exclusion criteria are children under the age of 10, due to lack of sensitivity data 
below that age, and children who weigh less than 30 kg, due to sample length requirements 
(Gupta and Hopkins, 2017). Muscle biopsies for the IVCT are taken from the vastus medialis 
(one of the four muscles that make up the quadriceps) and they are exposed to incremental 
concentrations of halothane (0.5, 1.0, 2.0 Vol%) (Figure 1.7) and caffeine (0.5; 1.0; 1.5; 2.0; 
3.0; 4.0; and 32 mmol L-1) (EMHG, 1984).  
The force of muscle contracture in response to each drug is measured at each 
concentration and the diagnosis is dependent on whether it meets the required diagnostic 
threshold (Hopkins et al., 2015). A more detailed description of this procedure can be found in 
chapter 2, section 2.2.2. The outcome of the IVCT assigns everyone to one of four IVCT 
phenotypes: MH non-susceptible (MHN), MHSh (abnormal reaction to halothane only), MHShc 
(abnormal reaction to both halothane and caffeine) and MHSc (abnormal response to caffeine 
only). People with an IVCT phenotype corresponding to an abnormal response to either 
halothane, caffeine, or both, are managed as individuals clinically at risk of MH (Hopkins et 
al., 2015).  
Genetic screening is an alternative, less invasive means for MH diagnosis using blood 
samples. The relatives of MHS individuals with known causative mutations are usually referred 
for genotyping to screen for familial variants (Urwyler et al., 2001). If the familial variant is 
identified, MHS diagnosis in these cases can be based on the results of genetic screening alone. 
Relatives who are genotyped and are absent for the familial mutation are subsequently referred 
to IVCT for diagnosis (Hopkins et al., 2015). At present, the prospective genetic screening for 
MH susceptibility involves a panel of 50 functionally characterised mutations (48 variants in 
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RYR1 and two variants in CACNA1S), recognised by the EMHG (www.emhg.org, 2020). This 
list is constantly updated as more genetic variants are discovered and functionally 
characterised. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7. In vitro contracture test using halothane. These are representative IVCT traces using for 
an A) MHN and B) MHS individual using incremental concentrations of halothane (Predose, 0.5, 1.0, 
2.0 Vol%). The muscle biopsy viability is dependent on the quality of the muscle twitch. The initial 
tension is measured after applying electrical stimulation and this is used as a reference to scale the 
measurement made at 2.0 Vol% halothane (indicated by the red arrow). Muscle tension (g) is measured 
over time and a positive (abnormal) response to halothane corresponds to a contracture strength of 0.2g 
at 2.0 Vol% (EMHG, 1984; Hopkins et al., 2015). 
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1.2.3 Causative mutations 
 
Mutations in RYR1 account for the majority of MHS individuals (~70%), whilst CACNA1S and 
STAC3 account for <2% of cases (Robinson et al., 2006; Monnier et al., 1997; Horstick et al., 
2013; Carpenter et al., 2009a). A significant proportion (~30%) of the MHS population still do 
not have pathogenic mutations assigned, which highlights the need for further investigation. 
RyR mutations were first identified as a candidate for human MH through a linkage study with 
MH families, where co-segregation of the MH phenotype was observed with RYR markers 
(MacLennan et al., 1990). Since then, hundreds of RYR1 mutations have been associated with 
MH but only a small proportion is used for diagnostic genetic testing. The most prevalent 
mutation within the UK is the RYR1 c.7300G>A variant which accounts for 16% of MHS 
families (Miller et al., 2018). Mutations in RYR1 cause a gain-of-function effect in skeletal 
muscle which increases RyR1 sensitivity to activation. This results in Ca2+ dysregulation, 
impaired excitation-contraction coupling and the involuntary opening of RyR1 when exposed 
to MH triggering agents. Although rare, some cases of human MH have also been reported 
with homozygous and compound heterozygous RyR1 mutation carriers (Lynch et al., 1997; 
Rueffert et al., 2001; Monnier et al., 2002).  
Mutations in CACNA1S were first associated with MH after its identification in a large 
French pedigree (Monnier et al., 1997). Functional analysis of CACNA1S mutations have 
shown to cause a similar gain-of-function effect in skeletal muscle which results in Ca2+ 
dysregulation and heightened RyR1 sensitivity (Weiss et al., 2004). The third candidate gene 
for human MH, STAC3, encodes a muscle-specific adaptor protein, which has been shown to 
modulate SR Ca2+ release and the conformational coupling between RyR1 and DHPR (Nelson 
et al., 2013; Polster et al., 2016). It is associated with native American myopathy and mutations 
in STAC3 were found to decrease excitation-contraction coupling  (Horstick et al., 2013).  
 
1.2.4 Discordance 
 
The main challenge in the diagnosis of MH is the high degree of genotype-phenotype 
discordance observed in this disorder (Miller et al., 2018). Discordance in the context of MH, 
refers to MHS individuals (diagnosed through IVCT) who lack the familial mutation, or 
individuals who are MHN (diagnosed through IVCT) and have been confirmed to carry the 
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familial variant (Robinson et al., 2003b). There have been many reports of discordance within 
MH families in the past (Deufel et al., 1995; Fagerlund et al., 1997; Fortunato et al., 1999; 
Heytens, 2007) and two of the largest studies were reported within the UK population 
(Robinson et al., 2002; Miller et al., 2018). In 2002, a study observed genotype-phenotype 
discordance in nine out of 297 individuals within the UK, in which five individuals were false-
positive and four were false-negative (Robinson et al., 2002). A more recent study reported 
higher rates of discordance having found genotype-phenotype discrepancies in 86 out of 328 
MH families (Miller et al., 2018). These results show that reliable diagnoses of MH cannot be 
based on genetic testing alone. All discordant individuals who are mutation negative but IVCT 
positive are therefore still managed as clinically at risk of MH and relatives who lack the 
familial variant, are always referred to IVCT to minimise the chance of false-negative 
diagnoses (Hopkins et al., 2015; Robinson et al., 2003b). The discordance observed in MH 
indicates further genetic complexity and may be due to a combination of genetic and 
environmental modifiers of phenotype yet to be discovered.  
 
1.2.5 Disorders associated with malignant hyperthermia 
 
As MH is predominantly caused by mutations in RYR1, it is associated with several RyR1-
related myopathies such as central core disease and multi-minicore disease (Litman et al., 
2018). Central core disease (MIM# 117000) is defined as an inherited neuromuscular disorder 
characterised by central cores in skeletal muscle and clinical features of congenital myopathy. 
Central cores refer to regions devoid of mitochondria, predominantly in type I fibres and are 
consequently deficient in oxidative metabolism (Jungbluth, 2007). Central core disease can be 
inherited in an autosomal dominant and recessive fashion (Manzur et al., 1998), and often 
manifests in infancy, with variable clinical features ranging from asymptomatic to mild/severe 
muscle stiffness, weakness, muscle atrophy and skeletal deformities such as scoliosis 
(Jungbluth, 2007).  
Multi-minicore disease (MIM# 255320) is also a neuromuscular disorder, defined by 
‘minicores’ which refer to areas of sarcomeric disorganisation and diminished oxidative 
activity due to lack of mitochondria. Multi-minicore disease is another early onset congenital 
myopathy but features an autosomal recessive mode of inheritance (Wei and Dirksen, 2010). 
Typical clinical features include: hypotonia, developmental delay, muscle weakness and 
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scoliosis. Both central core disease and multi-minicore disease are rare congenital myopathies 
which share an overlap in RYR1 mutations also associated with MH, making those conditions 
a significant risk factor (Robinson et al., 2006). Individuals who have central core disease were 
also reported to have more severe MH phenotypes based on IVCT data (Robinson et al., 2002). 
 
1.2.6 Animal models for malignant hyperthermia 
 
MH susceptibility is not specific to humans, and has also been reported in dogs, horses, giraffes, 
pigs and genetically engineered mice (Roberts et al., 2001; Aleman et al., 2004; Citino et al., 
1984; Harrison, 1975; Chelu et al., 2006). A lot of early MH research involved MHS pigs, but 
unlike humans, MH susceptibility in pigs arises from autosomal recessive inheritance of RYR1 
mutations which also predisposes them to an overt sensitivity to stress (Fujii et al., 1991; 
Fletcher et al., 1991a). These stress-induced MH reactions in pigs mimic those triggered by 
GA in MHS humans, characterised by muscle rigidity, tachycardia, metabolic acidosis, 
hyperthermia, and death (Mitchell and Heffron, 1982). Human MH is typically triggered by 
anaesthetic means but there have been cases of ‘awake’ MH episodes triggered by heat stress, 
similar to those experienced in MHS pigs, in the absence of anaesthesia (Gronert et al., 1980; 
Groom et al., 2011; Nishio et al., 2009; Carsana, 2013). 
 Modern MH research has now adopted the use of transgenic mice after the first RYR1 
knock-in mouse model of MH was developed (Chelu et al., 2006). There are currently four MH 
mouse models available, created using different RYR1 mutations associated with MH 
susceptibility in humans (Table 1.1).  RYR1-knock in mice typically feature elevated [Ca2+]rest, 
increased oxidative stress and increased sensitivity to temperature, caffeine, and volatile 
anaesthetics. Mice with homozygous expression of the RYR1 mutation often have increased 
phenotype severity, or result in non-viable offspring, depending on the variant used to create it 
(Chelu et al., 2006; Yang et al., 2006; Yuen et al., 2012; Lopez et al., 2018). Skeletal muscle 
from porcine and murine models of MH, both have higher [Ca2+]rest (approximately three-fold 
greater) in comparison to non-susceptible muscle (Yang et al., 2006; Lopez et al., 1986), and 
exposure to clinically relevant doses of volatile anaesthetics has been shown to further elevate 
[Ca2+]rest by several fold (Barrientos et al., 2012; Lopez et al., 1988).  
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RYR1 
mutation 
Exon Mutation position (Amino acid 
change) 
Disease Reference 
Y522S 14 1565A>C (Tyrosine to Serine) MH/central 
core disease 
Chelu et al., 
2006 
R163C 6 487C>T (Arginine to Cysteine) MH/central 
core disease 
Yang et al., 
2006 
T4826I 100 14477C>T (Threonine to Isoleucine) MH Yuen et al., 
2012 
G2435R 45 7300G>A (Glycine to Arginine) MH Lopez et al., 
2018 
 
Table 1.1. RYR1 knock-in mouse models of malignant hyperthermia. A summary of the RYR1 
knock-in mouse models that have been developed based on human RYR1 mutations associated with  
MH and central core disease (Chelu et al., 2006; Yang et al., 2006; Yuen et al., 2012; Lopez et al., 
2018). 
 
1.3 THESIS AIMS AND RESULT CHAPTER SUMMARIES 
 
This thesis aims to identify potential modifiers of the MH phenotype by comparing genome-
wide gene expression and mitochondrial function between MHS and MHN skeletal muscle, 
before and after drug challenge. This project is divided into four separate results chapters, each 
with chapter-specific introductions, followed by methods, results and discussion. A summary 
of each chapter is described below. 
 
• Chapter two describes a next generation RNA sequencing (RNAseq) experiment to 
investigate differential gene expression between MHN and MHS skeletal muscle. 
mRNA was extracted from MHN and MHS human muscle biopsies, and gene 
expression profiles were compared at baseline and after IVCT. Lists of differentially 
expressed genes were functionally annotated, and genes of interest were validated using 
real-time polymerase chain reactions (RT-PCR). Bioinformatic tools were then used to 
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investigate genes of interest for regulatory elements which may contribute to MH 
phenotype variability. 
 
• Chapter three describes a high-resolution respirometry experiment using human muscle 
biopsies. This chapter aimed to identify differences in mitochondrial function between 
MH phenotypes which may contribute towards phenotypic variability and the muscle-
related symptoms experienced by MHS individuals in absence of triggering agents. 
Mitochondrial function was assessed by measuring oxygen consumption rates in 
permeabilized muscle fibres using the Oroboros respiratory analyser (Oroboros 
Instruments, Innsbruk, Austria). Differences in functional capacity between phenotypes 
were compared at baseline and in response to IVCT. 
 
• Chapter four describes an RNAseq experiment, using the G2435R-RYR1 knock-in 
mouse model of MH. This mouse model carries an RYR1 mutation equivalent to the 
most common human MH mutation within the UK (c.7300G>A). The aim of this 
chapter was to provide the first analysis of gene expression in the new RYR1 knock-in 
mouse model by exploring gene expression differences between mouse genotypes. 
Soleus muscles taken from wild-type and RYR1 knock-in mice were exposed to 
halothane for 30 minutes before mRNA was extracted. RNAseq was performed using 
these samples and the gene expression profiles were compared with and without 
exposure to halothane. Lists of differentially expressed genes were functionally 
annotated to identify pathways and biological processes of interest in relation to MH. 
 
• Chapter five describes a high-resolution respirometry experiment aimed to assess 
mitochondrial function in the G2435R-RYR1 knock-in mouse model for the first time. 
Oxygen consumption rates were measured in permeabilized muscle fibres using the 
Oroboros respiratory analyser and these were compared between wild-type and RYR1 
knock-in genotypes. Mitochondrial function was also assessed in the same manner, in 
response to halothane treatment and elevated [Ca2+]. 
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2 IDENTIFICATION OF GENES ASSOCIATED WITH MALIGNANT 
HYPERTHERMIA AND RELATED PHENOTYPES  
 
2.1 INTRODUCTION 
 
The early diagnosis of an MH reaction is crucial to reduce rates of morbidity and mortality, but 
this can be difficult due to the variable nature of the MH phenotype. Consistent monitoring of 
clinical signs after anaesthesia is important as MHS probands can not only have reactions 
promptly after application but can also have slow response times causing delayed management 
(Carpenter et al., 2009b). In addition, some MHS probands are also known to have had previous 
anaesthetic history without triggering MH reactions which lead to underestimations of disease 
prevalence. Aside from clinical observations, muscle biopsies taken for IVCT also exhibit 
variability in the laboratory phenotype, with some MHS samples responding only to one or 
both muscle stimulants (halothane and caffeine)(Carpenter et al., 2009b; Robinson et al., 2002).  
A few studies have attempted to make genotype-phenotype correlations by comparing 
IVCT contracture data between individuals carrying a range of RYR1 variants associated with 
MH (Manning et al., 1998; Fiege et al., 2002; Carpenter et al., 2009b; Robinson et al., 2002). 
Fiege et al. found that IVCT data from MHS individuals carrying the C487-T RYR1 mutation 
had lower halothane and caffeine threshold concentrations compared to those with other 
variants, indicating differences in RYR1 sensitivity (Fiege et al., 2002). Carpenter et al., also 
showed that individuals with certain RYR1 variants had increased muscle contracture strengths 
and shorter response times to IVCT, introducing the concept of weak and strong MH mutations 
based on laboratory phenotype (Carpenter et al., 2009b). Other observations of disparity 
include sex-related analyses showing increased IVCT contracture strengths and shorter 
response times in male MHS individuals (Robinson et al., 2002) and epigenetic studies showing 
a parent-of-origin effect with children of affected mothers having increased chances of having 
MH (Robinson et al., 2009).  
The cause of phenotype variability in MH is still a subject of debate. MH is traditionally 
seen as a genetic condition with an autosomal dominant mode of inheritance but increasing 
evidence supports a multifactorial model. The high rates of genotype-phenotype discordancy 
remain as the largest problem associated with genetic diagnosis of MH susceptibility. A 
significant number of individuals diagnosed as MHS, do not have causative mutations 
assigned, indicating the presence of unidentified variants, genes or factors contributing to MH 
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yet to be discovered. Throughout the years there have been many novel variants in RYR1 and 
CACNA1S associated with MH, but only a small number have been functionally characterised 
for predictive diagnostic DNA screening (Brandom et al., 2013; Kim et al., 2013; Fiszer et al., 
2015; Levano et al., 2017). Excluding RYR1 and CACNA1S, the only other gene found to be 
causative of MH is STAC3, responsible for Native American myopathy (Horstick et al., 2013). 
Other gene loci of interest include CASQ1 encoding calsequestrin (Capacchione et al., 2010) 
and JSRP1 encoding JP-45, another integral SR protein (Yasuda et al., 2013). Despite modern 
advances, MH susceptibility caused by non-RYR1/CACNA1S/STAC3 variants is still 
estimated to occur in 14-23% of MH families (Miller et al., 2018). On that basis, there is still 
a lot to be achieved before comprehensive genetic screening is available for MH. Ongoing 
research aims to reduce this population of unaccounted families by functionally characterising 
new mutations and by exploring potential modifiers of phenotype.  
One approach used to investigate disease phenotype variability is through identifying 
genetic variants in regions that can alter gene expression and contribute to disease. Researchers 
investigating different disease models have found that certain disease traits are associated with 
variants in modifier genes. Modifier genes are defined as genes which can influence the 
expression of other genes and alters disease penetrance, dominance, expressivity, and 
pleiotropy (Haldane, 1941; Nadeau, 2001). An example of this would be the disease model for 
cystic fibrosis. Cystic fibrosis is caused by mutations in the cystic fibrosis transmembrane 
conductance regulator (CFTR)  gene but a range of modifier genes have been associated with 
variable phenotypic traits such as liver disease (SERPINA1), diabetes (TCF7L2) and pulmonary 
function (EDNRA, IFRD1, IL8) (Bartlett et al., 2009; Blackman et al., 2009; Darrah et al., 2010; 
Gu et al., 2009; Hillian et al., 2008).  
On a broader scale, this concept is also applied to expression quantitative trait loci 
(eQTL), which refer to larger genomic regions containing single nucleotide polymorphisms 
(SNPs) that have the potential to influence mRNA expression levels. These eQTLs can either 
be local within 1 Mb of the transcription start site (TSS) (cis-eQTL), or distant at over 5 Mb 
away from the TSS or on a different chromosome (trans-eQTL) (Nica and Dermitzakis, 2013). 
Identification of eQTLs is  often achieved through direct associations made between genotype 
data through genome wide association studies (GWAS) and gene expression data from 
transcriptome analyses (Sun, 2012). The largest available resource for eQTL data is currently 
the Genotype-Tissue Expression (GTEx) consortium, which is a publicly available database 
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containing information on over 1000 individuals across 54 types of non-diseased tissue 
(Consortium, 2013).  
Studies indicate that most of the regulatory control takes place locally near the genes 
of interest, having identified many more cis-eQTLs than trans-eQTLs (Dixon et al., 2007).  
This may be attributed to eQTLs being enriched in enhancer elements - defined as cis-acting 
DNA sequences which regulation gene expression by increasing transcription levels (Garieri 
et al., 2017). Enhancers contain binding sites for transcription factors (TF) and are situated 
remotely from promoter regions, upstream or downstream of their associated gene targets 
(Figure 2.1). The method at which enhancers interact with gene promoters is thought to be 
through mechanisms of DNA looping, which bring the enhancers within proximity of target 
genes (Ong and Corces, 2011). Genetic variation within enhancers have shown to result in 
phenotypic variation. An example being the malformation of limbs due to mutations within 
enhancers that regulate limb-specific SHH expression, which is vital for distal limb 
development (Sagai et al., 2005). Information on known human enhancers can be found on 
GeneHancer, an open access database which has compiled enhancer-gene associations from 
four different genome-wide databases (Fishilevich et al., 2017).  
 
 
 
 
 
 
 
 
Figure 2.1. A schematic diagram of gene expression regulatory mechanisms. The eQTL window 
contains candidate SNPs which are associated with regulating the expression target genes. SNPs which 
are in proximity of the target gene (within 1 Mb of TSS) are referred to as cis-eQTLs whilst SNPs which 
modify distant gene expression are trans-eQTLs (>5 Mb of TSS). Enhancers activated through TF 
binding interact with the promoters of target genes to promote gene expression. 
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Due to the complexities of MH genetics, the concept of gene expression modifiers is an 
area of interest and thought to contribute towards the genotype-phenotype variability seen in 
MHS individuals. This chapter presents an investigation into gene expression modifiers aimed 
to identify candidate modifier loci containing regulatory elements capable of influencing the 
MH phenotype. This will be achieved by addressing the following research questions:  
 
• What genes are differentially expressed in skeletal muscle at baseline, between 
MHN and MHS phenotypes? 
• What genes are differentially expressed in skeletal muscle after exposure to 
halothane and caffeine? 
• Do these differentially expressed genes have similar functional properties? 
• Using bioinformatic resources, what regulatory elements modulate the 
expression of these differentially expressed genes?  
 
Finally, any eQTLs found associated with genes of interest are presented as potential 
contributors to MH phenotype diversity which will need to be confirmed in larger cohorts of 
MHN and MHS individuals through SNP genotyping.  
 
 
2.2 MATERIALS AND METHODS 
 
2.2.1 Human muscle samples 
 
The samples used to study human MH were provided by the Leeds MH Unit, where skeletal 
muscle biopsies are routinely collected for the IVCT. Patients gave written informed consent 
to the study that was approved by Leeds (East) Research Ethics Committee (reference 
10/H1306/70). Each individual had six muscle fascicles (typical dimensions 25 mm x 4 mm x 
3mm) excised from the vastus medialis under femoral nerve block and immediately placed in 
oxygenated Krebs-Ringer solution (118.1 mM NaCl, 3.4 mM KCl, 0.8 mM MgSO4, 1.2 mM 
KH2PO4, 11.1 mM Glucose, 25.0 mM NaHCO3, 2.5 mM CaCl2, pH 7.4) at room temperature 
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and taken to the MH laboratory. The samples were then kept at room temperature in the Krebs-
Ringer solution, which was perfused continuously with carbogen (95% O2, 5% CO2), until used 
for IVCT. Biopsy samples are frozen in RNAlater for long term storage at -80 oC once IVCT 
is complete. Muscle samples which did not undergo IVCT were used as control samples for 
subsequent experiments. Further details regarding the choice of control sample can be found 
in section 2.2.5. 
 
2.2.2 In vitro contracture test  
 
IVCTs were conducted by Ms Catherine Daly (Laboratory Manager of the MH Unit) and Dr 
Dorota Miller (Postdoctoral Researcher at the MH Unit), according to the protocol outlined by 
the EMHG (Hopkins et al., 2015). Muscle biopsies weighing between 100-200 mg are sutured 
and suspended in a tissue bath for five minutes whilst optimal tissue length is determined. The 
initial length of tissue is measured between sutures and held for four minutes before electrically 
stimulated (1-2 ms supramaximal stimulus at a frequency of 0.2 Hz) and slowly stretched at a 
force of 2mN (0.2g) to achieve optimal twitch readings (2-3g or 120-150% of initial length). 
This new length is referred to as the optimal tissue length and is held for 15 minutes for 
stabilisation.  
Caffeine treatment was applied through perfusing the tissue bath with incremental 
increases of caffeine concentration at 0.5; 1.0; 1.5; 2.0; 3.0; 4.0; and 32 mmol L-1. Each 
increment was applied after three minutes of exposure with the previous concentration. The 
muscle contracture strength in response to drug treatment was measured and a contracture of 2 
mN (0.2g) at 2 mmol L-1 corresponds to a positive caffeine result. Likewise, halothane 
treatment was applied through perfusing the tissue bath with incremental increases of halothane 
concentration through a serviced and calibrated vaporizer. Incremental concentrations of 0.11; 
0.22; and 0.44 mmol L-1 were used, equivalent to 0.5, 1.0, 2.0 Vol%. A contracture threshold 
of 2 mN (0.2g) at 2.0 Vol% halothane corresponds to a positive halothane result. The results 
of IVCT generate phenotype groupings, individuals with a positive test are referred to as MHS 
and those with negative results are deemed MHN. The umbrella term MHS is further split into 
three categories: MHShc (positive response to halothane and caffeine), MHSh (positive response 
to halothane only), and MHSc (positive response to caffeine only). All MHS groups are 
managed as individuals clinically at risk of MH.  
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2.2.3 Total RNA extraction and clean up 
 
All muscle samples selected for gene expression studies (Microarray, RNAseq, Biomark™, 
QuantiStudio™ 7) had total RNA extracted using a chloroform/isopropanol extraction method, 
followed by a clean-up procedure to remove contaminants. These muscle samples were first 
placed in 1ml TRIzol® before being processed using an IKA T-10 basic ULTRA-TURRAX® 
homogeniser and left at room temperature for five minutes. Each sample was then transferred 
into a clean 1.5 ml Eppendorf tube with 200 µl of chloroform. This was thoroughly mixed and 
placed in a micro-centrifuge for 10 minutes at 13,000 rpm (4 oC) to create two distinct phases. 
The upper aqueous layer (containing the total RNA) was carefully extracted and transferred 
into a new clean 1.5 ml Eppendorf tube and mixed with 1:1 ratio isopropanol (approximately 
600 µl) to precipitate the RNA overnight at -80 oC.  
The following day, the samples were spun down in a micro-centrifuge for 30 minutes 
at 13,000 rpm (4 oC) and the supernatant was then removed. The remaining RNA pellet is then 
washed with 500 µl 75% ethanol and micro-centrifuged again for 10 min at 13,000 rpm (4 oC). 
This washing procedure is repeated twice before the pellet is air-dried to remove residual 
ethanol and dissolved in nuclease-free water for further cleaning using the RNAeasy microkit 
(QIAGEN) with on-column DNase treatment, according to manufacturer’s instructions.  
 
2.2.4 RNA sample quality check  
 
The quality control check for all RNA samples was done on the Agilent 4200 Tapestation 
which uses electrophoresis to generate RINe numbers representing RNA integrity. RNA 
samples with integrity scores of RINe >7.0 were classed as good quality and acceptable for 
further use. The gel images and electropherograms were visually inspected to ensure no 
significant DNA or chemical contamination remained which could interfere with downstream 
processes (Figure 2.2).  
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Figure 2.2. Tapestation: Quality assessment of RNA samples. A) Example of electrophoresis gel 
and B) electropherogram generated from Tapestation (Agilent) showing the quality assessment of a 
batch of RNA samples (RINe) with clear bands and peaks representing 18S and 28s rRNA with no other 
signs of prominent banding or peaks indicating DNA or chemical contamination. 
 
2.2.5 Affymetrix Clariom S Microarray 
 
Each individual undergoing IVCT had four different types of muscle biopsy collected and 
frozen at -80 oC, all of which were utilized in different experiments. In addition to a halothane-
46 
 
treated and caffeine-treated sample, two untreated samples were used as controls. These being 
the snap frozen tissue, frozen immediately in RNAlater at -80 oC upon receipt and the re-
oxygenated tissue, kept re-oxygenated at room temperature whilst the rest of the tissue was 
undergoing IVCT. To assess which untreated sample type was most appropriate for gene 
expression study, RNA from one snap frozen muscle sample and one re-oxygenated muscle 
sample was extracted from each MHN individuals (n=10) and sent to the Sheffield Institute for 
Translational Neuroscience (SITraN) to process on two Affymetrix Clariom S microarrays.  
Samples were diluted down to a concentration of 70 ng/µl, quality checked for an RINe 
value of >7.0, before being pooled together into two different sample groups and investigated 
on separate chips. One chip had 10 RNA samples extracted from snap frozen muscle and the 
other had 10 RNA samples from re-oxygenated muscle. The Clariom S microarray screened 
for 21448 probe sets, each representing a gene based on the GRCh38.p7 annotation of the 
human genome. CEL expression files were imported into Expression Console (Affymetrix) for 
gene-level normalization (GAPDH, ACTB) and signal summarization. Resulting CHP files 
were then imported into the Transcriptome Analysis Console TAC 4.0 (Affymetrix) for result 
summary and visualisation. Gene expression signals were converted into relative logs and the 
differences between two chips were compared as expression fold changes. 
 
2.2.6 RNAseq experimental design 
 
12 individuals (four MHN, four MHSh and four MHShc) who previously had IVCT at the Leeds 
MH Unit (Table 2.1), were chosen for RNAseq and RNA was extracted from vastus medialis 
muscle biopsies taken from long term -80 oC storage. All RNA samples were prepared as 
described in section 2.2.3 and 2.2.4. The purpose of this experiment was to investigate 
differential gene expression between MHN and MHS muscle, both at baseline and after drug 
exposure through the IVCT. Only male individuals were selected to remove gender variability 
and all participants were unrelated to each other. The control samples selected were re-
oxygenated tissue biopsies taken from MHN individuals with negative IVCT results for both 
halothane and caffeine. The sample selection for the MHS phenotype had several criteria: all 
MHS samples required a unique familial RYR1 variant confirmed through genotyping and a 
strong positive contracture response to halothane (0.5g contracture at 2 Vol% halothane). 
Additionally, MHShc samples required a strong response of 0.5g contracture strength at 2 Vol% 
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halothane and a 0.2g contracture strength response to 2mmol L-1 caffeine. The majority of 
MHS individuals met these criteria aside from two MHSh individuals (Patient 6 and 8) which 
had lower contractures at 2 Vol% halothane, one of which also did not have a confirmed 
familial RYR1 variant (Patient 6). This was due to limitations in MHSh sample availability but 
were still included and taken into consideration when interpreting results.  
 
 
 
 
 
 
 
 
 
 
Table 2.1. Summary of patient details selected for RNAseq. This table summarises the gender, 
biopsy age, MH status, IVCT contracture strengths (halothane and caffeine) and familial RYR1 variant 
for everyone selected for RNAseq. 
 
2.2.7 Truseq® Stranded mRNA library preparation 
 
The polyA selected mRNA libraries were created by Ms Catherine Daly (Laboratory Manager 
of the MH Unit). RNA samples were first quantified using the Qubit™ RNA HS Assay Kit, 
before used to create libraries using the Truseq Stranded mRNA library preparation kit 
(Illumina®), according to manufacturer’s guidelines. All cDNA libraries were quality checked 
using the Agilent D1000 screentape and quantified using the Quant-iT™ PicoGreen® dsDNA 
assay according to manufacturer’s guidelines. 
Patient Gender
Age at time of 
biopsy
MH 
status
Contracture at 2%  
halothane
Contracture at 2 
mM caffeine
RYR1  Family variant
1 M 13 MHN 0 0 c.7361G>A (negative)
2 M 11 MHN 0 0 c.1840C>T (negative)
3 M 19 MHN 0 0 c.7361G>A (negative)
4 M 19 MHN 0 0 c.6617C>T (negative)
5 M 12 MHSh 1.169g 0 c.7007G>A
6 M 39 MHSh 0.236g 0 No familial variant
7 M 30 MHSh 0.728g 0  c.4293G>A, c.7879G>A
8 M 12 MHSh 0.234g 0 c.5183C>T
9 M 18 MHShc 0.644g 2.094g c.12700G>C
10 M 11 MHShc 1.785g 0.605g c.7292A>T
11 M 16 MHShc 1.607g 0.387g c.14201G>A 
12 M 14 MHShc 0.905g 0.602g c.6617C>T
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2.2.8 Illumina® HiSeq® NGS 
 
Illumina NGS sequencing is comprised of four steps: library preparation, cluster generation, 
sequencing, and data analysis. In brief, library preparation involves fragmenting cDNA 
samples and ligating specialised adapters to both fragment ends. These single stranded 
fragments are distributed across flow cells (glass slide with lanes) which contain a dense lawn 
of primers that hybridize to the two types of adapter on the DNA fragments. Unlabelled 
nucleotides are then added along with DNA polymerase to initiate clonal bridge amplification. 
In this process, the DNA strand folds over attaching the second adapter to the alternative primer 
on the flow cell. Polymerases generate the complementary strand resulting in a double stranded 
bridge which gets denatured, forming two single stranded molecules (forward strand and 
reverse stand). This is repeated for all the fragments simultaneously creating clusters of 
clonally amplified fragments (Figure 2.3).  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Schematic diagram of clonal bridge amplification. This process involves 1) DNA 
fragment hybridization, 2) DNA folding, 3) polymerase initiating amplification, 4) complementary 
strand formation, 5) denaturing of double stranded bridge and the 6) clustering of clonal copies. This 
image is adapted from a graphic produced by DMLapato, made available under the terms of the Creative 
Commons Attribution 4.0 international license (https://creativecommons.org/licenses/by/4.0/deed.en). 
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Sequencing of both forward and reverse strands occurs through fragment extension 
using fluorescent nucleotides that excite the clusters with a light source, emitting a 
characteristic fluorescent signal. This process is also known as sequencing by synthesis. 
Sequences from pooled libraries are separated based on the unique indices introduced during 
sample preparation. These reads are then aligned to a reference genome, quantified, and 
annotated using bioinformatic tools.  
In this study, all 36 mRNA-enriched cDNA libraries were sequenced by the NGS 
facility using Illumina’s HiSeq® 3000 platform. Libraries were indexed and compiled into a 
singular pool at equimolar concentrations, which was then distributed across three HiSeq 3000 
150-bp paired-end lanes, achieving an average of 25M reads per sample. Sequencing generated 
raw data in the form of a forward and reverse FASTQ file for each sample on each lane which 
was exported for analysis.  
 
2.2.9 Differential gene expression analysis 
 
Raw sequencing data (FASTQ files) were initially processed using the Medical Advanced 
Research Computer (MARC1) - a high-performance computer cluster at the University of 
Leeds. The FASTQ files for each technical replicate across HiSeq lanes were combined and 
trimmed using the command-line tool Cutadapt to remove all adapter sequences and bad quality 
base calls from each read (<10) (Martin, 2011). Quality assessment of data was then compared 
before and after Cutadapt trimming using the quality control application FastQC (Figure 2.4) 
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/), designed for high throughput 
sequence data (Cock et al., 2010).   
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Figure 2.4. FastQC: Adapter content removal from sequencing data. FASTQC report showing 
“Adapter content” in the sequencing data. The top figure A) shows evidence of Illumina Universal 
Adapter contamination towards the higher base-pair read positions (red line), B) this contamination is 
removed after trimming with Cutadapt as seen in the bottom image. 
 
All 36 samples generated good quality libraries for sequencing (Figure 2.5, 2.6) and 
aligned to the human reference genome GRCh38.p13 using the STAR aligner (Dobin et al., 
2013) before being quantified using featureCounts (Liao et al., 2014). Processed count data 
was then imported into RStudio (RStudio Team, 2015). RStudio is an open-source integrated 
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development environment for R, a programming language for statistical computing and 
graphics. The RStudio package DESeq2 was used to analyse gene count data and generate lists 
of differential expressed genes (Love et al., 2014). In brief, DESeq2 achieves this by fitting 
generalised linear models to each gene assuming negative binomial distribution. Dispersion 
estimates are calculated using maximum likelihoods which weigh log2 fold changes (log2FC) 
relative to gene-wise variation and the mean-dispersion relationship (Love et al., 2014). The p-
values generated from DESeq2 were adjusted for multiple testing using the Benjamini-
Hochberg (BH) adjustment (Benjamini and Hochberg, 1995). The R package ggplot2 was used 
to create MA plots and principle component analysis (PCA) plots for the visualisation of global 
gene expression between phenotypes (Wickham, 2016). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5. FastQC Quality scores across all bases. Box-Whisker type plot generated by FastQC 
showing an overview of the range of quality values across all bases at each position in the FASTQ file. 
The quality scores (y-axis) at each read position (x-axis) is drawn with the graph background dividing 
the y axis base calls into very good quality (green), reasonable quality (orange) and poor quality (red). 
The central red line is the median value and the yellow box represents the inter-quartile range. The 
whiskers shown represent the 10% and 90% points and the blue line represents the mean quality.
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Figure 2.6. FastQC GC distribution over all sequences. The ‘per sequence GC content’ module measures the GC content across the whole length of each 
sequence in a file and compares it to a modelled normal distribution of GC content. The theoretical distribution (blue line) of GC content is compared to the 
GC count for reads (red line). The red curve did not exhibit an irregular shape and did not appear to shift, indicating no systemic bias or library contamination.
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An overview of all the computational steps required to process sequencing data for differential 
gene expression analysis is presented in Figure 2.7. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7. RNAseq experimental pipeline. Flow chart outlining the pipeline used for differential 
gene expression analysis. 
 
2.2.10 Gene ontology and pathway analysis 
 
Functional classification of differentially expressed genes involved inputting DESeq2 gene 
lists into the online enrichment analysis tool Enrichr (Chen et al., 2013; Kuleshov et al., 2016). 
Enrichr calculates enrichment scores using statistics based off the Fisher’s exact test, used to 
assess the significance of overlap between inputted gene lists and the chosen gene-set library 
(Chen et al., 2013). Significantly enriched terms are defined as those with an adjusted p-value 
<0.05. Gene lists were initially compared to 472 pathway terms in the 
“WikiPathways_2019_Human” library with a gene coverage of 6201 genes, before further 
enrichment analysis of gene ontology terms utilising libraries: “GO_Biological_Process_2018” 
(5103 terms, 14433 gene coverage), “GO_Molecular_Function_2018” (1151 terms, 11459 
gene coverage) and “GO_Cellular_Component_2018” (446 terms, 8655 gene coverage). 
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2.2.11 Biomark™ HD Real-Time PCR system 
 
Validation of RNAseq data was done using the Biomark™ HD RT-PCR system which detects 
gene expression levels using high throughput microfluidic technology. Three 48.48 Dynamic 
Array™ integrated fluidic circuits (IFC) were used with TaqMan® primers to assess gene 
expression in vastus medialis biopsies, taken from a cohort of MHN (n=36) and MHS (n=36, 
MHSh (18), MHShc (18)) individuals (before and after halothane-treatment, total of 72 
samples). The sample selection for the MHS phenotype was based on the IVCT halothane 
response which required at least 0.2g contracture at 2 Vol% halothane. Each phenotype had a 
1:1 ratio of males to females. 10X assay mixture and sample pre-mix for 17 assays (including 
three housekeeping) were prepared (Table 2.2), with each assay performed in duplicate.  
Each 10X assay consisted of 2.5 µl 20X TaqMan® gene expression assay (Applied 
Biosystems) and 2.5 µl 2X Assay Loading Reagent (Fluidigm, PN 85000736). The final 
concentration (at 10X) for each primer was 9 μM and 2 μM for the probe. Each sample pre-mix 
was made up of 2.5µl TaqMan® Universal PCR Master Mix (2X) (Applied Biosystems, PN 
4304437),  0.25 µl 20X GE Sample Loading Reagent (Fluidigm, PN 85000746) and 2.25 µl 
pre-amplified cDNA, making a total of 5µl volume in each inlet.  The IFC controller MX was 
used to prime 48.48 Dynamic Arrays™ IFC Chips (Fluidigm) with control line fluid by running 
the Prime (113x) script.  
Once primed, 5 µL of each assay and sample mix was then transferred into the 
appropriate inlets of the primed chip and reloaded into the IFC controller MX to run the Load 
Mix (113x) script. Once the script finished, the chips were then placed in the Biomark™ 
instrument to run the RT-PCR protocol starting with 95 °C for 10  minutes followed by 40 
cycles at 95 °C for 15 seconds and 60 °C for one minute. The data was imported into the 
Fluidigm Real-Time PCR Analysis Software and the differences in gene expression (pre – post 
halothane) were normalised against three housekeeping genes (B2M, TBP and RPLP0) and 
converted into log2FC using the ΔΔCt method (Vandesompele 2002, Livak 2001). The 
comparison of datasets between Biomark™ RT-PCR and RNAseq data was achieved by linear 
regression analysis to identify correlations. 
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2.2.12 QuantiStudioTM 7 Real-Time PCR system 
 
The investigation of five OXPHOS genes were selected (Table 2.2) based off the differential 
gene expression analysis at baseline (MHN vs MHS) using RNA-seq data. These genes were 
investigated using the QuantiStudio TM 7  RT-PCR sytem set up on multiple 384-well plates. 
TaqMan® primers were used for assays and genes of interest were normalised against three 
housekeeping genes: TBP, B2M and RPLP0 (Table 2.2) (Vandesompele et al., 2002). Each 
assay was conducted in triplicate, using a sample population of MHN (n=36) and MHS (n=36, 
MHSh (18), MHShc (18)) individuals. The sample selection for the MHS phenotype was based 
on the IVCT halothane response which required at least 0.2g contracture at 2 Vol% halothane. 
Each phenotype had a 1:1 ratio of males to females. Each reaction contained a total volume of 
10 µl, consisting of 0.5 µl 20X TaqMan® gene expression assay, 5 µl 2X TaqMan® gene 
expression master mix, 2 µl cDNA and 2.5 µl RNase-free water. The standard thermocycling 
program consisted of a 95 °C denaturation for 10 min, followed by 40 cycles of 95 °C for 15 
seconds and 60°C for 60 seconds. The CT values from each triplicate assay were averaged for 
each sample and gene expression was expressed as log2FC using the ΔΔCt method (Livak and 
Schmittgen, 2001). Normality of the datasets were assessed using the Shapiro-Wilk test. 
Differences between phenotypes were analysed using Mann-Whitney U tests and median tests 
due to non-parametric distributions. 
 
 
 
 
 
 
 
 
 
 
56 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.2. Genes selection for RT-PCR. TaqMan® gene primers selected for Biomark™ HD RT-PCR 
and QuantiStudio™ 7  RT-PCR systems with corresponding Applied Biosystems assay IDs.  
Gene symbol Applied Biosystems Assay ID
B2M Hs00187842_m1
Housekeeping genes RPLP0 Hs00420895_gH
TBP Hs00427620_m1
INSIG1 Hs01650979_m1
NR4A2 Hs01118813_m1
DNAJA1 Hs00266011_m1
SOCS1 Hs00864158_g1
TNFRSF10D Hs00388742_m1
IRF1 Hs00971965_m1
PPP1R10 Hs00160391_m1
HSPA1A Hs00359163_s1
CNOT11 Hs00213916_m1
VMA21 Hs01595025_m1
SNX3 Hs00601001_m1
NDFIP1 Hs00228968_m1
PYURF Hs00430939_g1
UBE2N Hs03046007_gH
ATP5MD (USMG5) Hs00910071_g1
MALSU1 Hs00370770_m1
NDUFC2 Hs00190012_m1
COQ6 Hs05050186_s1
MPC2 Hs00967250_m1
(QuantiStudio™ RT-PCR) 
OXPHOS genes
(Biomark™ RT-PCR) Genes 
for RNAseq validation
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2.2.13 GeneHancer 
 
The bioinformatic database GeneHancer was utilised to identify regulatory enhancer elements 
for genes of interest. Genehancer is a database containing information on human enhancers and 
their inferred target genes, accessed in the framework of GeneCards (Fishilevich et al., 2017). 
Data on enhancer elements and genomic locations are compiled from four different information 
sources (ENCODE, VISTA, FANTOM and Ensembl). Candidate enhancers with confidence 
scores supported by multiple evidence sources are classed as elite enhancers. The enhancers 
which have gene-enhancer associations reported from multiple evidence sources are also 
flagged with elite association scores. Enhancers that achieve both criteria, are classed as 
‘double elite enhancers’ and those associated with the genes of interest were investigated 
further in this study (Fishilevich et al., 2017).  
 
2.2.14 GTEx consortium 
 
The eQTLs associated with genes of interest were explored using the publicly available tissue-
specific eQTL data on the GTEx consortium, generated from 706 skeletal muscle samples 
(Consortium, 2013). Each gene of interest was used as a search term to identify genomic 
regions containing SNPs associated with modifying gene expression. These genomic regions 
were then compared with the double elite enchancers identified from GeneHancer to observe 
whether there was overlap.  
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2.3 RESULTS 
 
2.3.1 Microarray: Snap frozen vs Re-oxygenated muscle comparison 
 
Gene expression profiles from snap frozen and re-oxygenated muscle were compared using 
two Affymetrix Clariom S microarray chips to decide which sample type was the most 
appropriate to act as control in the RNAseq experiment. The expression levels of 21448 genes 
were investigated and a total of 798 genes were found to be differentially expressed at over 2-
fold difference (3.72% of all gene probe sets). Within this gene set, 447 genes were expressed 
at a higher level in re-oxygenated muscle and 351 genes had reduced expression in comparison 
to snap frozen muscle. An overview of global gene expression differences can be viewed in 
Figure 2.8.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8. Microarray data - Scatter plot presenting global gene expression signals (log2FC) 
between re-oxygenated muscle and snap frozen muscle. Genes found to be expressed at ≥2 fold-
change greater in re-oxygenated muscle are highlighted in red (447) whilst negatively expressed genes 
at ≤-2 fold-change are highlighted in blue (351).  
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Both upregulated and downregulated gene sets were subsequently grouped to identify 
the proportion of coding and non-coding genes (Figure 2.9). The TAC 4.0.2 software assigns 
each transcript with a locus type and each gene is assigned a locus type based on the locus 
types from individual transcripts. If more than one locus type is reported, then the locus type 
is assigned as “multiple complex”. Upregulated and downregulated gene sets showed 94 
(21.03%) and 51 (14.53%) protein-coding transcripts respectively, whilst non-coding and 
unassigned genes occupied ~14-16% of each set. Many genes (>60%) were classified as 
‘multiple complex’ indicating more than one locus type. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9.  Microarray data - Grouping of differentially expressed genes in re-oxygenated 
muscle. Pie chart illustrations summarizing the gene groupings: Multiple complex (blue), coding (red), 
non-coding (purple) and unassigned (green). The proportion of each group within A) upregulated and 
B) downregulated gene sets in re-oxygenated muscle are represented as a percentage.  
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Exploration of the most differentially expressed genes revealed seven out of 447 genes 
were upregulated in re-oxygenated muscle at over 10-fold-change in comparison to snap frozen 
muscle (OTUD1, FOS, EGR1, JUNB, FOSB, ZFP36 and LOC100130705). In contrast, the 
smaller cohort of 351 genes more highly expressed in snap frozen biopsies only had two genes 
expressed at over 10-fold difference (HBB, HBG2) (Figure 2.10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10. Microarray data - Bar charts illustrating differences in gene expression between re-
oxygenated and snap frozen muscle. The average gene expression signals are presented for the seven 
most upregulated (> 10 fold-change) and 2 most downregulated (< -10 fold-change) genes in re-
oxygenated muscle (n=10, blue) vs snap frozen muscle (n=10, red). 
A more detailed summary of all genes expressed between >2-10 fold-change difference in re-
oxygenated muscle is displayed in Table 2.3. 
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Table 2.3. Microarray data - Differentially expressed genes in re-oxygenated muscle vs snap frozen muscle. List of upregulated and downregulated genes 
(>2-10-fold change) in re-oxygenated muscle (n=10) , split into divided according to the degree of fold-change difference in comparison to snap frozen muscle 
(n=10).
Fold difference / % 
total genes
OTUD1 - OTU Deubiquitinase 1 HBB - Hemoglobin Subunit Beta
FOS - Fos Proto-Oncogene, AP-1 Transcription Factor Subunit HBG2 - Hemoglobin Subunit Gamma 2IL7R
>10 / 0.04% EGR1 - Early Growth Response 1
JUNB - JunB Proto-Oncogene, AP-1 Transcription Factor Subunit
FOSB - FosB Proto-Oncogene, AP-1 Transcription Factor Subunit
ZFP36 - ZFP36 Ring Finger Protein
LOC100130705  – Histone Deacetylase 6 also known as HDAC6GADD45B
IER2 - Immediate Early Response 2 HBA2 - Hemoglobin Subunit Alpha 2
MYC - V-Myc Avian Myelocytomatosis Viral Oncogene Homolog HBA1 - Hemoglobin Subunit Alpha 1
>6 / 0.07% IL6 - Interleukin 6
SLC2A14 - Solute Carrier Family 2 Member 14
KLF4 - Kruppel Like Factor 4
KIAA1683 - KIAA1683
ADAMTS1 - ADAM Metallopeptidase With Thrombospondin Type 1 Motif 1
SLC2A3 - Solute Carrier Family 2 Member 3
>5 / 0.11% CYR61 - Cysteine Rich Angiogenic Inducer 61
JUN - Jun Proto-Oncogene, AP-1 Transcription Factor Subunit
CCL2 - C-C Motif Chemokine Ligand 2
DUSP1 - Dual Specificity Phosphatase 1
IRF1 - Interferon Regulatory Factor 1
ATF3 - Activating Transcription Factor 3 RBM26 - RNA Binding Motif Protein 26
NR4A3 - Nuclear Receptor Subfamily 4 Group A Member 3 DBF4 - DBF4 Zinc Finger
BTG2 - BTG Anti-Proliferation Factor 2 ALAS2 - 5'-Aminolevulinate Synthase 2
>4 / 0.18% C9orf84 - Chromosome 9 Open Reading Frame 84 SLCO4C1 - Solute Carrier Organic Anion Transporter Family Member 4C1
SHC4 - SHC Adaptor Protein 4 SMIM8 - Small Integral Membrane Protein 8
C10orf13 - Fibroblast Growth Factor Binding Protein 3, also known as FGFBP3
MAP2K1 - Mitogen-Activated Protein Kinase Kinase 1
OR5T1 - Olfactory Receptor Family 5 Subfamily T Member 1
>2 / 3.72% 419 additional genes 342 additional genes
Downregulated in re-oxygenated muscleUpregulated in re-oxygenated muscle
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 Subsequent functional grouping of genes upregulated in re-oxygenated muscle was 
performed using bioinformatic tool Enrichr (described in section 2.2.10) which showed 
significant enrichment of four molecular function terms involved in TF activity and DNA 
binding. Four enriched pathway terms were also upregulated, but these terms were unrelated 
to each other and deemed to be of low physiological relevance. In contrast, no significant gene 
ontology (GO) terms in the ‘biological process’ and ‘cellular component’ categories were 
found. No significant pathway and ontology terms were found using the list of genes 
downregulated in re-oxygenated muscle (Table 2.4). 
 Overall, the results showed a 3.72% difference in global expression (>2 fold-change) 
between the two sample types. Re-oxygenated muscle showed significant upregulation in genes 
involved with TF activity and binding which may be a natural shift in gene expression due to 
time under ex vivo conditions. This feature of ex vivo degradation was likely to be present in 
post IVCT samples selected for the subsequent RNAseq experiment and on that basis, re-
oxygenated muscle was chosen as the more appropriate control type to minimise experimental 
noise. 
63 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.4. Microarray data - Gene ontology and enriched pathway terms (Snap frozen vs re-oxygenated muscle). Gene ontology analyses of microarray 
data highlighting significantly enriched biological process, molecular function, cellular component, and pathway terms using both upregulated and 
downregulated genes lists from the snap frozen vs re-oxygenated muscle comparison.  Gene ontology terms with >0.05 adjusted p-value were omitted from the 
table.  
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2.3.2 RNAseq: MHN vs MHS (baseline) 
 
RNAseq analysis of differential gene expression was first conducted at baseline comparing 
MHS and MHN phenotypes without IVCT treatment. References to the ‘MHS’ phenotype in 
this section refers to both MHSh and MHShc samples combined. Differentially expressed genes 
were defined as those with a significant adjusted p-value of <0.1, generated by DESeq2. 
Baseline comparisons generated a cohort of 822 differentially expressed genes (false discovery 
rate (FDR) 10%), of which 38 transcripts were novel. Compared to MHN controls, the MHS 
group showed increased gene expression in 203 genes and decreased gene expression in 619 
genes. The effect size of upregulated genes ranged from 0.22 to 5.17 log2FC, whereas the 
larger list of downregulated genes showed a smaller range in effect size (-0.19 to -2.06 log2FC).  
To extract biological information from this data, pathway analysis was carried out on 
each gene list using Enrichr (described in section 2.2.10). Amongst the top 10 pathway terms 
downregulated in MHS samples, five terms were significantly enriched (adjusted p-value 
<0.05), three of which were related to mitochondria. These being ‘Electron transport chain 
WP111’, ‘Oxidative phosphorylation WP623’ and ‘Mitochondrial complex I assembly model 
OXPHOS system WP4324’. Pathways enriched from upregulated genes featured a range of 
terms with no central theme, which makes interpretation difficult (Table 2.5).  
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Table 2.5. Pathway enrichment analysis for MHN vs MHS (baseline). This table contains a list of the top 10 upregulated (orange) and downregulated (blue) 
pathway terms generated by Enrichr are displayed in combined score order (log of p-value from Fisher’s exact test multiplied by z score of deviation from 
expected rank). The 196 genes upregulated, and 591 genes downregulated in the MHN vs MHS baseline comparison were used as input. Significantly enriched 
pathway terms (adjusted p-value < 0.05) are highlighted in grey. 
 
Index Upregulated pathway terms P-value Adjusted p-value Odds Ratio Combined score
1 Overview of nanoparticle effects WP3287 3.09E-05 7.29E-03 21.48 223.09
2 Photodynamic therapy-induced NF-kB survival signaling WP3617 3.69E-04 4.36E-02 11.66 92.18
3 TLR4 Signaling and Tolerance WP3851 2.54E-03 1.99E-01 10.93 65.35
4 Deregulation of Rab and Rab Effector Genes in Bladder Cancer WP2291 1.05E-02 5.49E-01 12.76 58.15
5 TNF alpha Signaling Pathway WP231 2.91E-04 4.58E-02 6.65 54.19
6 Cells and Molecules involved in local acute inflammatory response WP4493 1.18E-02 5.57E-01 12 53.3
7 VEGFA-VEGFR2 Signaling Pathway WP3888 2.23E-05 1.05E-02 4.76 50.95
8 let-7 inhibition of ES cell reprogramming WP3299 5.74E-02 8.74E-01 17.01 48.61
9 DDX1 as a regulatory component of the Drosha microprocessor WP2942 6.66E-02 9.25E-01 14.58 39.49
10 EV release from cardiac cells and their functional effects WP3297 6.66E-02 8.99E-01 14.58 39.49
Index Downregulated pathway terms P-value Adjusted p-value Odds Ratio Combined score
1 Electron Transport Chain (OXPHOS system in mitochondria) WP111 1.14E-26 5.40E-24 11.17 667.26
2 Oxidative phosphorylation WP623 3.67E-20 8.66E-18 12.97 580.53
3 Nonalcoholic fatty liver disease WP4396 2.71E-19 4.26E-17 7.2 308.04
4 Mitochondrial complex I assembly model OXPHOS system WP4324 6.76E-08 7.97E-06 7.25 119.73
5 Proteasome Degradation WP183 8.11E-05 7.66E-03 4.91 46.27
6 Fatty Acid Beta Oxidation WP143 3.03E-03 2.05E-01 4.98 28.86
7 Heme Biosynthesis WP561 2.73E-02 1.00E+00 7.52 27.07
8 Selenium Metabolism and Selenoproteins WP28 2.23E-03 1.75E-01 4.41 26.96
9 Selenium Micronutrient Network WP15 3.90E-03 2.30E-01 3.15 17.46
10 Triacylglyceride Synthesis WP325 3.28E-02 1.00E+00 4.23 14.46
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Following pathway analysis, functional classification was performed using GO libraries 
on Enrichr (described in section 2.2.10). Analysis of downregulated genes from the MHN vs 
MHS (baseline) comparison, revealed 10 significantly downregulated biological processes, all 
of which were involved in mitochondria and the ETS (Table 2.6). Further GO analysis of 
molecular function yielded similar results to biological processes and enriched cellular 
component terms were also based largely in mitochondria. On the other hand, analysis of 
upregulated genes showed no significant gene ontology terms. All gene ontology results for 
the MHN vs MHS baseline comparison are available in the appendices (see Appendix 1). 
 
 
 
 
 
 
 
 
 
Table 2.6. Top 10 downregulated biological processes in the MHN vs MHS baseline comparison. 
Top 10 GO terms for downregulated biological processes comparing MHS controls against MHN 
controls at baseline. GO terms are displayed in combined score order (log of p-value from Fisher’s exact 
test multiplied by z score of deviation from expected rank). 
 
Multiple GO terms corresponded to mitochondrial complex I assembly, and 
information on the genes involved were subsequently extracted from the DESeq2 gene list for 
further investigation. A total of 18 complex I-encoding genes were found downregulated in 
MHS muscle with an effect size ranging from -0.52 to -0.82 log2FC (Table 2.7).  
 
GO Biological process term Overlap P-value
Adjusted P-
value
Odds 
Ratio
Combined 
Score
mitochondrial ATP synthesis coupled electron transport (GO:0042775) 26/85 9.84E-20 5.02E-16 10.35 453.03
respiratory electron transport chain (GO:0022904) 27/94 1.21E-19 3.10E-16 9.72 423.37
NADH dehydrogenase complex assembly (GO:0010257) 18/64 2.32E-13 2.97E-10 9.52 276.87
mitochondrial respiratory chain complex I biogenesis (GO:0097031) 18/64 2.32E-13 2.37E-10 9.52 276.87
mitochondrial respiratory chain complex I assembly (GO:0032981) 18/64 2.32E-13 1.98E-10 9.52 276.87
mitochondrial respiratory chain complex assembly (GO:0033108) 23/97 6.36E-15 1.08E-11 8.02 262.31
mitochondrial electron transport, NADH to ubiquinone (GO:0006120) 14/46 3.34E-11 2.43E-08 10.30 248.46
mitochondrial electron transport, ubiquinol to cytochrome c (GO:0006122) 06/14 1.59E-06 5.08E-04 14.50 193.62
mitochondrial translational elongation (GO:0070125) 18/87 6.60E-11 4.21E-08 7.00 164.13
mitochondrial translational termination (GO:0070126) 18/89 9.84E-11 5.58E-08 6.84 157.70
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Table 2.7. Differentially expressed genes associated with complex I in the MHN vs MHS (baseline) comparison. The list of differentially expressed genes 
encoding proteins associated with mitochondrial complex I, generated from DESeq2 comparing MHN (n=4) and MHS (n=8) controls at baseline, displayed in 
order of adjusted p-value. Gene names are annotated using superscript letters based on function, a. Encodes accessory subunit of the mitochondrial membrane 
respiratory chain NADH dehydrogenase, b. Encodes a core subunit for mitochondrial complex I, and c. Encodes a mitochondrial complex I assembly protein 
that interacts with complex I subunits.
ID log2FC lfcSE Adjusted p-value hgnc_symbol Gene name
ENSG00000151366 -0.72 0.18 3.53E-02 NDUFC2 NADH:Ubiquinone Oxidoreductase Subunit C2
a
ENSG00000259112 -0.75 0.20 5.30E-02 NDUFC2-KCTD14 NDUFC2-KCTD14 Readthrough (NDUFC2  paralog)
a
ENSG00000174886 -0.82 0.24 6.27E-02 NDUFA11 NADH:Ubiquinone Oxidoreductase Subunit A11
a
ENSG00000165264 -0.60 0.18 6.63E-02 NDUFB6 NADH:Ubiquinone Oxidoreductase Subunit B6
a
ENSG00000004779 -0.66 0.21 7.53E-02 NDUFAB1 NADH:Ubiquinone Oxidoreductase Subunit AB1
a
ENSG00000189043 -0.53 0.17 7.71E-02 NDUFA4 NDUFA4 Mitochondrial Complex Associated
a
ENSG00000110717 -0.81 0.27 8.20E-02 NDUFS8 NADH:Ubiquinone Oxidoreductase Core Subunit S8
b
ENSG00000178057 -0.73 0.24 8.21E-02 NDUFAF3 NADH:Ubiquinone Oxidoreductase Complex Assembly Factor 3
c
ENSG00000186010 -0.73 0.24 8.21E-02 NDUFA13 NADH:Ubiquinone Oxidoreductase Subunit A13
a
ENSG00000131495 -0.74 0.25 8.48E-02 NDUFA2 NADH:Ubiquinone Oxidoreductase Subunit A2
a
ENSG00000213619 -0.72 0.25 8.50E-02 NDUFS3 NADH:Ubiquinone Oxidoreductase Core Subunit S3
b
ENSG00000139180 -0.52 0.18 8.56E-02 NDUFA9 NADH:Ubiquinone Oxidoreductase Subunit A9
a
ENSG00000267855 -0.67 0.23 8.71E-02 NDUFA7 NADH:Ubiquinone Oxidoreductase Subunit A7
a
ENSG00000115286 -0.67 0.23 8.83E-02 NDUFS7 NADH:Ubiquinone Oxidoreductase Core Subunit S7
b
ENSG00000167792 -0.62 0.22 8.98E-02 NDUFV1 NADH:Ubiquinone Oxidoreductase Core Subunit V1
b
ENSG00000224877 -0.68 0.24 8.98E-02 NDUFAF8 NADH:Ubiquinone Oxidoreductase Complex Assembly Factor 8
c
ENSG00000099795 -0.73 0.26 9.00E-02 NDUFB7 NADH:Ubiquinone Oxidoreductase Subunit B7
a
ENSG00000185633 -0.69 0.25 9.73E-02 NDUFA4L2 NDUFA4 Mitochondrial Complex Associated Like 2
a
68 
 
 
2.3.3 RNAseq: MHN vs MHSh (baseline) 
 
Following the MHN vs MHS comparison, differential gene expression at baseline was 
performed with the MHS phenotype split into subgroups MHSh and MHShc. Comparisons 
showed that MHSh vs MHN muscle featured a large set of 1654 differentially expressed genes 
(FDR 10%), 73 of which were novel. This may be partly due to the variability in individuals 
chosen to represent the MHSh phenotype in terms of biopsy age (12-39) and RYR1 genetics 
(one individual with no RYR1 variant and one compound heterozygous) (Table 2.1).  
A large proportion of genes were downregulated in MHSh (1281/1654, 74.5%), with an 
effect size ranging from -0.25 to -2.37 log2FC. Genes upregulated in MHSh made up the 
remaining 25.5% of the set (373/1654) with an effect size between 0.3 to 4.09 log2FC. Pathway 
analysis results showed two pathway terms ‘mRNA Processing WP411’ and ‘Translation 
Factors WP107’ upregulated in MHSh and nine pathways downregulated in MHSh including 
the three mitochondria-related terms previously found in the previous MHN vs MHS 
comparison (see Appendix 2). Similarly, GO analyses showed that the MHSh phenotype had 
significant downregulation of biological processes, molecular function, and cellular component 
terms heavily involved with mitochondria and OXPHOS (see Appendix 3). In contrast, 
functional grouping of upregulated genes presented with several GO terms involved with 
mRNA splicing and processing, the most significant being ‘RNA splicing, via 
transesterification reactions with bulged adenosine as nucleophile (GO:0000377)’, ‘mRNA 
splicing, via spliceosome (GO:0000398)’ and ‘mRNA processing (GO:0006397)’. 
 
2.3.4 RNAseq: MHN vs MHShc (baseline) 
 
Compared to the differences between MHN vs MHSh at baseline, the MHShc vs MHN 
comparison only presented with 68 differentially expressed genes (FDR 10%), nine of which 
were novel. Out of 68 genes, there were 42 genes upregulated in MHShc, covering an effect 
size range between 0.54 to 5.79 log2FC. In contrast, 26 genes were found downregulated in 
MHShc, expressed in the range of -0.47 to -2.80 log2FC. Pathway analysis revealed eight terms 
significantly upregulated in MHShc, majority of which are involved with fatty acid metabolism: 
‘SREBF and miR33 in cholesterol and lipid homeostasis WP2011’, ‘Adipogenesis WP236’, 
‘Transcription factor regulation in adipogenesis WP3599’ and ‘Eicosanoid Synthesis WP167’ 
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(see Appendix 4). In contrast, several energy metabolism-related pathways were 
downregulated in MHShc such as ‘Oxidative phosphorylation WP623’, ‘Electron Transport 
Chain (OXPHOS system in mitochondria) WP111’ and ‘Glycolysis and Gluconeogenesis 
WP534’. These however were not statistically significant, likely due to the small number of 
genes used for analysis. In contrast to pathway analysis, no significant GO terms were found 
using both upregulated and downregulated gene sets (see Appendix 5). 
 
2.3.5 MA plot and volcano plot 
 
Global gene expression changes were visualised using MA plots and volcano plots, illustrating 
the differences described in section 2.3.3 and 2.3.4. MA plots present gene expression changes 
between two conditions as two-dimensional scatter plots in terms of log2FC (M) on the y-axis 
and the mean of normalised gene expression counts (A) on the x-axis. The MA plot for MHSh 
against MHN show a large sum of differentially expressed genes with the majority in the range 
of  -1 and 1 log2FC. In contrast, the plot for MHShc against MHN show a much smaller number 
of differentially expressed genes but are expressed at a greater range in effect size (Figure 
2.11).  
Likewise, this can also be seen in the volcano plots (Figure 2.12) in addition to the 
overall distribution of p-values across all genes. Despite having many more statistically 
significant genes in the MHN vs MHSh comparison, the majority of these genes (1653/1654) 
had adjusted p-values between 0.1 and 0.05. In contrast, the MHN vs MHShc volcano plot 
showed that the majority of differentially expressed genes (42/68) had lower p-values (adjusted 
p-value <0.05) which reflect more significant changes in gene expression. 
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Figure 2.11. MA plots visualising gene expression changes between MH phenotypes. Log2FC (y-
axis) is plot against mean of normalised gene expression counts (x-axis). Plots A) and B) feature the 
same MHN vs MHSh comparison but plot B) has shrunken log2FC, which removes the noise from genes 
with low counts (Zhu et al., 2019). Plots C) and D) feature the MHN vs MHShc comparison but plot D) 
also has shrunken log2FC.  Genes which are differentially expressed adjusted p-value < 0.1 are 
highlighted in red. The triangles indicate genes which are expressed at a log2FC that exceeds the y-axis 
limits. 
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Figure 2.12. Volcano plots visualising p-value and fold-change distribution across genes. Log2FC 
(x-axis) is plot against the -log10(adjusted p-value) (y-axis). Plot A) Features data from the MHN vs 
MHSh comparison and plot B) features data from the MHN vs MHShc comparison. The threshold for 
statistical significance was adjusted p-value <0.1 which corresponds to a -log10(adjusted p-value) of 
>1, indicated by the horizontal blue line. All statistically significant genes above this threshold are 
highlighted in red. An addition red line has been added at -log10(adjusted p-value) 1.3 which reflects 
an adjusted p-value of 0.05.  
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2.3.6 RNAseq: Effects of halothane treatment on gene expression 
 
Analysis of gene expression pre vs post halothane IVCT, showed that MHN muscle was the 
most heavily influenced. A total of 2905 genes (212 novel) were differentially expressed in this 
phenotype after IVCT halothane exposure. Among these genes, 1350 were upregulated (0.22 
to 7.27 log2FC) and 1555 genes were downregulated (-0.22 to -3.32 log2FC). In comparison 
to MHN, the MHS phenotype showed much less gene expression change with only 325 
differentially expressed genes (66 novel) after halothane exposure. References to the ‘MHS’ 
phenotype in this section refers to both MHSh and MHShc samples combined. In this gene set, 
248 genes were upregulated, with an effect size between 0.31 and 5.20 log2FC whilst 77 genes 
were downregulated between -0.24 and -3.83 log2FC.  
Pathway analysis on the MHN (pre vs post halothane) gene set showed significant 
downregulation of five OXPHOS-related terms after halothane exposure (Table 2.8). However, 
this same observation was not seen in the MHS phenotype where no pathway terms were found 
significantly downregulated. Analysis of upregulated pathways in both MHN and MHS gene 
sets generated a wide range of signalling and regulation pathways terms with no area of focus 
making interpretation difficult (Table 2.9).  
GO analyses on the MHN phenotype also revealed significant downregulation of many 
mitochondria and OXPHOS-related terms in biological process, molecular function, and 
cellular component (see Appendix 6). Once again, these observations were not apparent in the 
MHS pre vs post halothane response, aside from one biological process term ‘mitochondrial 
electron transport, NADH to ubiquinone (GO:0006120)’ (see Appendix 7). GO analysis of 
upregulated genes in both MHN and MHS phenotypes were similar to the results observed in 
the pathway analysis (see Appendix 6, 7).
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Table 2.8. Top 10 downregulated pathway terms pre vs post IVCT (halothane). A list of the top 10 downregulated pathway terms generated from Enrichr 
comparing the pre vs post effects of halothane on both phenotypes (MHN and MHS). Terms are displayed in combined score order (log of p-value from Fisher’s 
exact test multiplied by z score of deviation from expected rank). Significantly enriched pathway terms (adjusted p-value < 0.05) are highlighted in grey.
Index Name P-value Adjusted p-value Odds Ratio Combined score
1 miR-517 relationship with ARCN1 and USP1 WP3596 1.76E-02 1 56.34 227.51
2 Robo4 and VEGF Signaling Pathways Crosstalk WP3943 2.11E-02 1 46.95 181.12
3 Hfe effect on hepcidin production WP3924 2.46E-02 1 40.24 149.11
4 Type 2 papillary renal cell carcinoma WP4241 6.48E-03 1 16.57 83.5
5 Gene regulatory network modelling somitogenesis WP2854 3.84E-02 1 25.61 83.49
6 Osteoblast Signaling WP322 4.86E-02 1 20.12 60.85
7 Osteoclast Signaling WP12 5.53E-02 1 17.61 50.96
8 ID signaling pathway WP53 5.53E-02 1 17.61 50.96
9 ACE Inhibitor Pathway WP554 5.87E-02 1 16.57 46.98
10 NOTCH1 regulation of human endothelial cell calcification WP3413 5.87E-02 1 16.57 46.98
MHS (pre vs post halothane)
Index Name P-value Adjusted p-value Odds Ratio Combined score
1 Electron Transport Chain (OXPHOS system in mitochondria) WP111 1.03E-25 4.85E-23 6.21 357.39
2 Cytoplasmic Ribosomal Proteins WP477 1.25E-20 2.95E-18 5.94 272.14
3 Oxidative phosphorylation WP623 6.89E-18 1.08E-15 6.72 265.64
4 Nonalcoholic fatty liver disease WP4396 1.96E-16 2.31E-14 4.04 146.04
5 Mitochondrial complex I assembly model OXPHOS system WP4324 3.62E-08 3.42E-06 4.47 76.6
6 Heme Biosynthesis WP561 2.50E-03 1.69E-01 6.18 37.04
7 miRNA Biogenesis WP2338 6.29E-03 2.70E-01 6.95 35.25
8 Cerebral Organic Acidurias, including diseases WP4519 1.04E-02 3.78E-01 5.96 27.2
9 Target Of Rapamycin (TOR) Signaling WP1471 7.98E-04 6.28E-02 3.48 24.8
10 IL-9 Signaling Pathway WP22 5.69E-03 2.68E-01 4.09 21.15
MHN (pre vs post halothane)
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Table 2.9. Top 10 upregulated pathway terms pre vs post IVCT (halothane). A list of the top 10 upregulated pathway terms generated from Enrichr 
comparing the pre vs post effects of caffeine on both phenotypes (MHN and MHS). Terms are displayed in combined score order (log of p-value from Fisher’s 
exact test multiplied by z score of deviation from expected rank). Significantly enriched pathway terms (adjusted p-value < 0.05) are highlighted in grey. 
 
Index Name P-value Adjusted p-value Odds Ratio Combined score
1 Photodynamic therapy-induced NF-kB survival signaling WP3617 7.56E-10 1.79E-07 6.88 144.48
2 mRNA Processing WP411 2.75E-14 1.30E-11 4.46 139.23
3 Cells and Molecules involved in local acute inflammatory response WP4493 3.25E-06 2.19E-04 7.55 95.45
4 Photodynamic therapy-induced unfolded protein response WP3613 2.70E-06 2.12E-04 5.94 76.24
5 Spinal Cord Injury WP2431 1.27E-08 2.00E-06 3.54 64.31
6 Hepatitis C and Hepatocellular Carcinoma WP3646 1.06E-06 1.25E-04 4.59 63.09
7 Overview of nanoparticle effects WP3287 9.29E-05 2.31E-03 5.91 54.91
8 Prion disease pathway WP3995 2.10E-05 7.62E-04 4.86 52.4
9 Hypertrophy Model WP516 1.35E-04 3.04E-03 5.62 50.05
10 Aryl Hydrocarbon Receptor WP2586 1.74E-05 7.47E-04 4.19 45.89
MHN (pre vs post halothane)
Index Name P-value Adjusted p-value Odds Ratio Combined score
1 Platelet-mediated interactions with vascular and circulating cells WP4462 1.50E-05 2.36E-03 25.58 284.03
2 miRNAs involvement in the immune response in sepsis WP4329 1.03E-06 4.84E-04 17.63 243.08
3 EV release from cardiac cells and their functional effects WP3297 1.72E-03 3.11E-02 31.06 197.78
4 Photodynamic therapy-induced NF-kB survival signaling WP3617 1.62E-05 1.91E-03 15.53 171.28
5 Role Altered Glycolysation of MUC1 in Tumour Microenvironment WP4480 2.90E-03 4.90E-02 24.15 141.1
6
Oligodendrocyte Specification and differentiation(including remyelination), leading to 
Myelin Components for CNS WP4304
1.58E-04 8.26E-03 14.49 126.89
7 Bone Morphogenic Protein (BMP) Signalling and Regulation WP1425 5.23E-03 7.05E-02 18.12 95.17
8 Type II interferon signaling (IFNG) WP619 3.61E-04 1.42E-02 11.75 93.14
9 IL1 and megakaryocytes in obesity WP2865 1.35E-03 3.02E-02 13.59 89.83
10 TNF alpha Signaling Pathway WP231 2.26E-05 2.13E-03 8.27 88.49
MHS (pre vs post halothane)
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2.3.7 RNAseq: Effects of caffeine treatment on gene expression 
 
The gene expression change in response to caffeine resembled the pattern observed in response 
to halothane, with most differentially expressed genes occurring in the MHN phenotype. A 
total of 1554 genes (159 novel) differentially expressed, 943 genes upregulated (0.16 to 7.90 
log2FC) and 611 genes downregulated (-0.22 to -4.38 log2FC). The MHS gene set after 
caffeine exposure featured a much smaller gene set with 583 genes (95 novel). Out of 583 
genes 451 were upregulated (0.26 to 5.71 log2FC) and 132 genes were downregulated (-0.23 
to -4.00 log2FC) after caffeine exposure.  
Pathway analysis on the MHN (pre vs post caffeine) gene set showed significant 
downregulation in the ‘Electron Transport Chain (OXPHOS system in mitochondria) WP111’ 
and ‘Oxidative phosphorylation WP623’ pathway terms which were also featured in the MHN 
pre vs post halothane comparison. Likewise, no pathways were significantly downregulated in 
the MHS (pre vs post caffeine) phenotype. Upregulated gene sets from both MHN and MHS 
pre vs post caffeine comparisons generated a wide range of signalling and regulatory pathways 
terms which were difficult to interpret like the effects seen with halothane (see Appendix 8). 
Results from GO analysis also resembled those observed in the pre vs post halothane response, 
with many mitochondria and OXPHOS-related terms downregulated in MHN samples 
following caffeine exposure. These observations were not seen in MHS samples. All 
upregulated gene ontology terms in both phenotypes consisted of a wide range of biological 
functions similar to the pathway analysis (see Appendix 9,10). 
 
2.3.8 Similarities in halothane and caffeine response between MHS phenotypes 
 
Cross comparison of pre vs post IVCT gene lists highlighted differentially expressed genes 
shared between multiple phenotypes (see Appendix 11). DESeq2 was used to generate 
additional pre vs post halothane and caffeine gene lists with the MHS phenotype split into 
MHSh and MHShc subsets. The MHSh phenotype had 230 genes differentially expressed in 
response to halothane and 449 genes in response in caffeine. A similar number of genes were 
differentially expressed in MHShc samples with 256 and 363 genes differentially expressed 
post-halothane and caffeine, respectively. All MHSh and MHShc responses to both halothane 
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and caffeine were compared to identify similarities in gene expression and a total of 89 genes 
were shared between all treatment responses (Figure 2.13).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13. Cross comparison of gene expression changes in response to halothane and caffeine. 
Differentially expressed gene lists for both MHSh and MHShc phenotypes are displayed as a Venn 
diagram showing the overlap between treatment responses. The gene lists for each segment can be 
found in Appendix 11. This image was generated using InteractiVenn (Heberle et al., 2015). 
 
This set of 89 genes was compared against the MHN treatment responses to see if they 
were unique to MHS phenotypes. This comparison revealed that most of these genes were also 
differentially expressed in the MHN phenotype after halothane and caffeine treatments, 
indicative of a gene set associated with normal physiological response. Only three out of 89 
genes (GIMAP8, MT-TM and PECAM1) were unique to the MHS responses, all of which were 
downregulated after halothane and caffeine exposure.  
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2.3.9 Principal component analysis 
 
Relationships between each sample were examined and visualised using a PCA plot (Figure 
2.14). The gene expression count data for all 36 samples were plotted and most of the untreated 
control samples cluster on the right side of the plot whilst post-IVCT samples cluster on the 
left. There is no obvious outlier based off visual assessment but there appears to be a greater 
variability in the baseline pre-IVCT samples in all phenotypes, based off the loose clustering 
seen. Both the post-IVCT halothane and post-IVCT caffeine clusters overlap containing a 
mixture of all three phenotypes indicating a close relationship between samples. This suggests 
that both halothane and caffeine exposure have similar effects on gene expression across all 
phenotypes. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.14. Principal component analysis plot examining relationships between human MH 
samples. The variance between samples is represented by a percentage (%) on PC1 (x-axis) and PC2 
(y-axis). All 36 samples are plotted with PC1 against PC2 and their respective phenotype (MHN: Red, 
MHSh: Green, MHShc: Blue) and treatment groups (untreated: circle, caffeine: triangle, halothane: 
square).  
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2.3.10 RNAseq validation (Biomark™ RT-PCR) 
 
The data generated from RNAseq was validated using genes selected from the MHN and MHS 
(MHSh and MHShc combined) pre vs post halothane comparison. A cohort of paired pre vs post 
halothane samples from MHN (n=36) and MHS (n=36) individuals were used to assess the 
directional changes in gene expression. A selection of 14 genes with adjusted p-value <0.05 
were chosen based on their up or downregulation in specific phenotypes, outlined in Table 
2.10.  
 
 
 
 
 
 
 
 
 
 
Table 2.10. Genes selected for RNAseq validation with rationale.  
The changes in gene expression were quantified using Biomark™ RT-PCR, with each 
gene assay ran in duplicate (described in section 2.2.11). The differences in log2FC from RT-
PCR were calculated and compared to the log2FC results generated from DESeq2 analyses and 
visualised using bar charts (Figure 2.15). Visual inspection of bar charts shows good general 
correlation in most genes selected aside from NR4A2 in the MHS samples. RNASeq results 
show that NR4A2 was significantly upregulated in only MHN samples, but RT-PCR data 
contradict these findings showing similar levels of upregulation in both phenotypes. 
Furthermore, genes found to be downregulated in RNAseq results (CNOT11, VMA21, SNX3. 
NDFIP1, PYURF, UBE2N) showed very little gene expression change in RT-PCR.  
No. Gene Full name Rationale
1 NR4A2 Nuclear Receptor Subfamily 4 Group A Member 2
Genes found upregulated solely in the MHN 
(pre vs post halothane) comparison and not in 
the MHS (pre vs post halothane) comparison
2 INSIG1 Insulin Induced Gene 1
3 DNAJA1 DnaJ Heat Shock Protein Family (Hsp40) Member A1
4 SOCS1 Suppressor of cytokine signaling 1
5 TNFRSF10D TNF Receptor Superfamily Member 10d
6 IRF1 Interferon Regulatory Factor 1
7 PPP1R10 Protein Phosphatase 1 Regulatory Subunit 10
8 HSPA1A Heat Shock Protein Family A (Hsp70) Member 1A
9 CNOT11 CCR4-NOT Transcription Complex Subunit 4
10 VMA21 Vacuolar ATPase Assembly Factor
11 SNX3 Sorting Nexin 3
12 NDFIP1 Nedd4 Family Interacting Protein 1
13 PYURF PIGY Upstream Reading Frame
14 UBE2N Ubiquitin Conjugating Enzyme E2 N
Genes found downregulated solely in the MHN 
(pre vs post halothane) comparison and not 
found in the MHS (pre vs post halothane) 
comparison
Genes upregulated in both MHN and MHS (pre 
vs post halothane) comparisons
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Figure 2.15. RNAseq validation. The gene expression changes comparing the mean log2FC (with 
standard deviation) from RT-PCR to the log2FC generated from DESeq2. Presented as bar charts for 
the A) MHN (n=36) phenotype and B) the MHS (n=36) phenotype.  
A) 
B) 
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  Following visual inspection of bar charts, the correlation between RNAseq and RT-
PCR data was assessed using linear regression analyses. The outcome of this showed strong 
positive correlation in both MHN (R2 = 0.96, p<0.0001) and MHS (R2 = 0.52, p=0.0037) 
phenotypes. The log2FC results from RNAseq and RT-PCR were plotted against each other 
and visualised on a scatter graph (Figure 2.16). Visual inspection of the scatter graph reinforces 
that the MHS NR4A2 result appears to be an outlier in the overall trend. Despite this outlier, 
this experiment was successful in validating the RNAseq data overall. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.16. Scatter graph and linear regression analyses for RNAseq validation. The log2FC 
results from RNAseq and RT-PCR are plotted against each other, featuring both the MHN (blue) and 
MHS (red) phenotypes.  
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2.3.11 Genes of interest (Mitochondria-related) 
 
Given the prominent feature of OXPHOS/mitochondria-related genes in multiple RNAseq 
comparisons, further investigation was conducted at the baseline level using five genes 
(ATP5MD (also known as USMG5), MALSU1, NDUFC2, COQ6 and MPC2) selected from the 
MHN vs MHS (MHSh + MHShc) baseline comparison (described in section 2.3.2). RNAseq 
results show that all five genes were downregulated in the MHS phenotype when compared to 
MHN, and this was reassessed by QuantiStudio™ 7 RT-PCR, in a larger sample size (described 
in section 2.2.6). The expression levels of these genes were quantified, and relative FC data are 
displayed as boxplots (Figure 2.17).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.17. Baseline MHN vs MHS comparison in five genes of interest. Box plots comparing 
relative gene expression (FC) between MHN (n=36) and MHS (n=36) phenotypes. Significant Mann-
Whitney U tests (p <0.05) are annotated with an asterisk and significant independent sample median 
tests (p <0.05) are annotated with #. 
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The gene expression FC data generated was not normally distributed (assessed by 
Shapiro-Wilk test, p>0.05) and was therefore analysed using non-parametric independent 
sample Mann-Whitney U (comparing distributions) and median tests. All five genes of interest 
were downregulated in the MHS phenotype, but only ATP5MD (p=0.022) and COQ6 
(p=0.049) showed a statistically significant difference in distribution (Figure 2.18) and only 
NDUFC2 showed a statistically significant reduction in median (p=0.01). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.18.  Comparison of gene expression fold change data distribution. Bar charts illustrating 
overall distribution of FC data for A) ATP5MD and B) COQ6 in both MHN (n=36) and MHS (n=36) 
phenotypes.   
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2.3.12 Gene expression enhancers and eQTLs 
 
Regulatory elements for ATP5MD, NDUFC2 and COQ6 were identified using information 
available on GeneHancer and the GTEx consortium (Consortium, 2013; Fishilevich et al., 
2017). The three genes of interest  USMG5 (ATP5MD), NDUFC2 and COQ6 were supplied to 
the GTEx consortium as search terms under the tissue filter ‘Muscle -Skeletal’. This search 
identified regions containing SNPs considered to be cis-eQTLs for each gene of interest.  
A total of 184 SNPs were found for USMG5 (ATP5MD) in the region between chr10: 
102831425-104339678, where 22 other protein-coding genes reside. GeneHancer identified 10 
enhancer elements associated with ATP5MD, of which one is a double elite enhancer 
(GH10J103394) containing 249 TF binding sites, located at chr10: 103394884-103398147. 
The GTEx consortium shows there are two SNPs within this double elite enhancer flagged as 
significant cis-eQTLs (Table 2.11).  
220 SNPs for NDUFC2 have been found in the region chr11: 78018473-78389198 
where eight other protein-coding genes reside. GeneHancer shows 25 enhancer elements 
associated with NDUFC2 and one double elite enhancer (GH11J078077) within this region 
containing 407 TF binding sites, located at chr11: 78077847-78082082. The GTEx consortium 
highlights 6 SNPs within this enhancer as cis-eQTLs (Table 2.11).  
581 SNPs for COQ6 reside at chr14: 73788853-74220793 along with seven other 
protein-coding genes. 14 enhancers were associated with COQ6 with one double enhancer 
(GH14J073949) within this region containing 263 TF binding sites, located at chr14: 
73949296-73951373. Seven SNPs within this enhancer are flagged as cis-eQTLs (Table 2.11). 
The GTEx database contained no information on trans-eQTLs being found for any of these 
genes. 
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Table 2.11. A summary of cis-eQTL SNPs identified within enhancer regions.  
 
TFs known to interact with each double enhancer were cross compared with the MHN 
vs MHS baseline gene list to identify shared observations. This comparison identified 171 TFs 
shared between all three enhancers and six TFs (ATF3, CHD2, CTBP1, ESRRA, NFKBIZ, 
TEAD4) were shared between all four datasets (Figure 2.19). In the MHN vs MHS baseline 
comparison the genes encoding ATF3, CHD2 and NFKBIZ are upregulated in MHS 
individuals at 2.26, 0.62 and 1.35 log2FC, respectively. In contrast, CTBP1, ESRRA and 
TEAD4 are downregulated in MHS samples at -0.53, -0.64 and -0.90 log2FC, respectively. 
These six TFs all bind to the double elite enhancers identified in each gene of interest and their 
activities are potentially responsible for the differential gene expression of NDUFC2, COQ6 
and ATP5MD.  
 
 
 
 
Gene Variant ID (cis-eQTL) SNP ID
ATP5MD chr10_103395309_C_A_b38 rs11191676 
chr10_103395888_T_C_b38 rs2292807
NDUFC2 	chr11_78078508_T_C_b38 rs636141
	chr11_78078585_A_G_b38 rs595133
	chr11_78079607_T_C_b38 rs534418
chr11_78079817_C_G_b38 rs499799
chr11_78080263_T_A_b38 rs637124
chr11_78080403_G_C_b38 rs607199
COQ6 chr14_73949296_G_A_b38 rs62006128
chr14_73949536_A_T_b38 rs7400918
chr14_73949700_TTTCTC_T_b38 rs148549829
chr14_73949897_T_C_b38 rs11621743
chr14_73950242_G_C_b38 rs17552038
chr14_73950852_T_G_b38 rs112218167
chr14_73951095_G_C_b38 rs8013496
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Figure 2.19. Cross comparison of transcription factors associated with enhancer regulatory 
elements. The TFs associated with each double enhancer for NDUFC2, ATP5MD and COQ6 (red) were 
cross compared with the MHN vs MHS baseline gene list (Blue). This image was generated using 
InteractiVenn (Heberle et al., 2015). 
 
Follow up work using this information would involve genotyping a large cohort of MHN 
and MHS individuals for the SNPs found within the enhancers of each gene of interest (Table 
2.11). Alternatively, identifying tag-SNPs spanning each eQTL region of interest using 
information from linkage disequilibrium (LD) data can also be achieved using computational 
methods to confirm whether any contribute to the MHS susceptibility. 
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2.4 DISCUSSION 
 
The aim of this study was to identify potential MH modifier loci using bioinformatic tools and 
differential gene expression data between MH phenotypes, both at baseline and after IVCT. As 
outlined in the methods, the IVCT is a lengthy procedure which utilises muscle biopsies over 
a period of ~30 minutes after surgical excision. The length of time the sample spends outside 
the human body can potentially cause changes in gene expression, resulting from external 
stressors such as temperature, oxygen availability and lack of blood supply. To address this 
concern, a comparison of gene expression was conducted prior to sequencing using snap frozen 
and re-oxygenated muscle. This experiment explored possible alterations in gene expression 
caused by ex vivo stressors prior to IVCT. This information was then used to inform which 
muscle sample was the most appropriate choice to act as control for the subsequent RNAseq 
experiment. 
  The gene expression profiles comparing re-oxygenated muscle to snap frozen muscle 
revealed a significant 10 fold-change upregulation in several genes, three of which (FOS, 
FOSB, JUNB) were known as AP-1 TF subunits. Other members of this group found highly 
expressed include JUN upregulated in re-oxygenated muscle at >5 fold-change and ATF3 at 
>4 fold-change. This group of TFs is known to modulate gene expression with diverse 
functional properties, associated with cell proliferation, differentiation, apoptosis and 
oncogenesis (Shaulian and Karin, 2002). The roles of AP-1 TFs in skeletal muscle are complex, 
as their function can be dependent on specific subunit compositions (Chinenov and Kerppola, 
2001).  
Structurally, AP-1 TFs are heterodimers formed by a combination of proteins from the 
FOS (FOS, FOSB, FRA-1, FRA-2), JUN (JUN, JUNB and JUND), ATF and MAF protein 
families which are widely expressed in a variety of cell types (Garces de Los Fayos Alonso et 
al., 2018). JUN proteins can form homodimers with other JUN proteins as well as heterodimers 
with FOS proteins, whereas FOS proteins can only form heterodimers in order to bind DNA 
(Halazonetis et al., 1988; O'Shea et al., 1992). Following dimerization, they act as TFs which 
bind to regulatory sites called TPA-responsive elements and cAMP response elements in 
promoter and enhancer regions of target genes (Chinenov and Kerppola, 2001).  
A study investigating mRNA expression in human skeletal muscle found that almost 
all members of the JUN and FOS gene family (aside from FRA-2) were significantly 
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upregulated after 30 minutes of exercise, ranging from 1.5 to 20 fold-change (Puntschart et al., 
1998). Likewise, a similar observation was made when mRNA and protein levels in the JUN 
and FOS family were overexpressed in skeletal muscle after denervation, which has also been 
linked with the induction of apoptosis during times of cellular stress (Weis, 1994; Shaulian and 
Karin, 2001). These findings from literature support the notion that the JUN and FOS genes 
were likely upregulated due to the sample stress and degradation from ex vivo conditions. Gene 
expression of FOS and JUN was much lower in snap frozen muscle since they were frozen and 
kept at -80 °C shortly after surgery. As a result, the gene expression profile from snap frozen 
muscle, is thought to be the most accurate representation of basal gene expression within 
skeletal muscle. However, given that the IVCT is conducted ex vivo, natural degradation of the 
sample cannot be avoided, so re-oxygenated muscle was therefore chosen to serve as the 
RNAseq control to reduce the noise caused by non-IVCT stressors. 
 Initial interrogation of RNAseq data compared differential gene expression at baseline, 
showing a large set of genes downregulated in MHS (MHSh + MHShc) samples, many of which 
were functionally grouped into the OXPHOS system and mitochondria. Baseline analyses with 
MHS phenotype subsets showed surprisingly few differentially expressed genes in MHShc 
individuals in comparison to MHSh, despite the former being responsive to both halothane and 
caffeine. This may be due to the MHSh sample group being more diverse than both MHN and 
MHShc groups with regards to age range. The MHSh sample group age range was between 12-
39 years which was significantly greater than the MHN (13-19 years) and MHShc (11-18 years).  
Several studies have shown that age can have a profound effect on skeletal muscle gene 
expression, showing increased expression of pathways regulating cell growth and immune 
response with age, whilst gene expression for energy metabolism and mitochondrial OXPHOS 
decreases (Zahn et al., 2006; Bua et al., 2006; de Magalhaes et al., 2009). The higher age range 
in MHSh samples may have contributed in the overestimation of baseline differences between 
MHN and MHSh phenotypes. Differentially expressed genes in the MHShc vs MHN 
comparison, although few, have a greater effect size than those seen in MHSh. This may reflect 
the differences in IVCT phenotype with MHShc individuals being associated with stronger 
responses (Robinson et al., 2002). 
Mitochondrial dysfunction is speculated to be a downstream consequence of RyR1 
dysfunction in MH, since MH events result in sustained muscle contractures which depend on 
ATP. Amongst differentially expressed genes at baseline, a large percentage downregulated in 
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MHS were responsible for encoding mitochondrial complex I. Complex I is the first enzyme 
of the electron transport chain (ETC) and its primary function is to oxidize NADH (generated 
by the Krebs cycle) and to transfer these electrons along the ETC reducing ubiquinone to 
ubiquinol. The energy released from this process is then used to transfer protons from the 
mitochondrial matrix into the intermembrane space, contributing to a proton gradient which is 
later used by ATP synthase to synthesize ATP (Sharma et al., 2009). Disruption of complex I 
function therefore negatively impacts OXPHOS resulting in metabolic conditions.  
Complex I is the largest and most complicated component of the ETC, composed of 44 
subunits, 37 of which are encoded by nuclear genes and 7 by mitochondrial genes (Sanchez-
Caballero et al., 2016). Comparison of MHN vs MHS at baseline identified 18 complex I-
encoded nuclear genes downregulated in MHS skeletal muscle. This significant number of 
downregulated genes suggests MHS individuals may have a degree of complex I deficiency. 
The prevalence of adults suffering from mitochondrial disease is estimated at 1 in 8000 
individuals and complex I deficiency is the most common single enzyme deficiency 
responsible for mitochondrial disorders (Schaefer et al., 2008; Rodenburg, 2016). Many of the 
complex I and OXPHOS genes downregulated in MHS muscle, have been associated with 
metabolic conditions such as type 2 diabetes (T2DM) (Sreekumar et al., 2002; Mootha et al., 
2003; Patti et al., 2003; Ling et al., 2007). Downregulation of OXPHOS genes are thought to 
contribute towards mechanisms leading to insulin-resistance, increasing the risk of T2DM 
(Patti and Corvera, 2010). 
A past study found that MHS individuals had elevated plasma insulin levels in 
comparison to controls after intravenous glucose tolerance tests, leading to suggestions of 
impaired Ca2+ handling in pancreatic beta cells (Denborough et al., 1974). Individuals with 
T2DM are also frequently associated with deficiencies in extracellular and intracellular Mg2+ 
which is a known RyR1 inhibitor (Barbagallo and Dominguez, 2015).  RyRs in muscle are 
sensitive to intracellular and luminal Mg2+ which act to inhibit Ca2+ release from the SR by 
competing with intracellular Ca2+ for RyR1 binding sites (Laver et al., 2004). If MH 
susceptibility is indeed linked to mechanisms which cause T2DM, then the associated Mg2+ 
deficits would help explain the hypersensitivity of RyR1 due to lower levels of inhibition. 
A study using complex I (NDUFV1) knock-down C2C12 myoblasts found evidence of 
enhanced skeletal myogenesis and insulin signalling, suggesting a mechanism whereby 
NDUFV1 knock-down reduces NAD+/NADH ratio which inactivates SIRT1 (Hong et al., 
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2014). The protein SIRT1 is a NAD+-dependent histone deacetylase and has been shown to 
regulate skeletal muscle gene expression and differentiation (Fulco et al., 2003). In the model 
proposed by Hong and colleagues, the inactivation of SIRT1 leaves myogenic transcription 
factors such as MyoD acetylated and activated, resulting in myogenic enhancement (Hong et 
al., 2014). This is interesting in the context of MH, as a study on >300 MHS patients found 
that individuals with muscular body types had a significantly higher rate of recrudescence 
(defined as the development of MH signs 2 hours after the initial MH event) (Burkman et al., 
2007). This indicates a possible correlation between complex I, muscle mass and MH 
susceptibility.  
Increased muscle mass is typically correlated with increased mitochondrial biogenesis 
- an adaptation from physical training. Physical training not only promotes mitochondrial 
biogenesis but can also alter the  muscle fibre type distribution in skeletal muscle, a variable 
which was difficult to account for in this study. Studies have shown that the muscle fibre type 
distribution in the quadriceps of untrained individuals is in the range of ~40% type I, ~60% 
type II (Staron et al., 2000). The amount and type of physical training experienced by an 
individual can alter the proportion of type I and type II fibres present within the muscle biopsy 
and this may influence gene expression since they prefer different modes of energy metabolism 
(Wilson et al., 2012). 
Furthermore, certain health conditions such as chronic obstructive pulmonary disease 
(COPD) have also been known to shift muscle fibre type distributions (Debigare et al., 2003; 
Gosker et al., 2007). Studies have found that individuals with COPD had less type I slow-
oxidative fibres in comparison to controls, in addition to a reciprocal increase in type IIB fast-
glycolytic fibres, possibly as a compensation mechanism (Debigare et al., 2003; Gosker et al., 
2007). Detailed information on physical training and medical history was not factored into the 
analysis for this study and may account for some of the variability seen between datasets. If 
OXPHOS deficiency is truly present in MHS muscle, then individuals who possess higher 
proportions of type I slow-oxidative fibres may be more susceptible to myopathic traits and a 
more severe MH phenotype.  
In addition to baseline differences, OXPHOS genes were also found to be 
downregulated in MHN samples after exposure to both halothane and caffeine. Surprisingly, 
halothane and caffeine had a much larger effect on MHN muscle gene expression in 
comparison to MHS. Pathway analysis on MHN gene lists highlighted the downregulation of 
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OXPHOS and ETS pathway terms after both halothane and caffeine exposure, but these 
findings were not observed in the MHS phenotype. The absence of OXPHOS gene 
downregulation in the MHS treatment response may be due to OXPHOS gene expression 
already being reduced at baseline. Many complex I-encoding genes were downregulated in 
MHN and this negative shift in complex I gene expression may reflect a relationship between 
complex I and muscle stimulants. A study on complex I gas-1 mutant Caenorhabditis elegans 
(C.elegans), showed that halothane had an inhibitory effect on complex I-dependent respiration 
whilst complex II-dependent respiration was increased, possibly as a way of compensation 
(Kayser et al., 2004). This observation was also supported in a study involving cardiac 
mitochondria taken from guinea-pigs, showing reversible inhibition of complex I activity using 
halothane, isoflurane and sevoflurane (Hanley et al., 2002).  
Evidence has shown that halothane can induce Ca2+ release from the SR resulting in 
muscle contracture (Palade et al., 1989). This can occur in both wild-type and MHS skeletal 
muscle but the activation of RyR1 is regulated by several cytosolic modulators (Ca2+, ATP, 
Mg2+) (Diaz-Sylvester et al., 2008). As previously mentioned, cytosolic Mg2+ is an important 
inhibitor of RyR1 and the resting Mg2+ concentration in MHN muscle is higher than MHS, 
reducing the sensitivity of RyR1. The downregulation of OXPHOS genes in MHN muscle after 
halothane and caffeine stimulants may also be an adaptation to lower cytosolic ATP levels 
which reduce the sensitivity of RyR1 further and prevent Ca2+ release from the SR. These 
inhibitory mechanisms are possibly weaker in MHS muscle, given the cytosolic Mg2+ deficits 
and passive Ca2+ leak from the SR raising cytosolic Ca2+. 
Comparison of halothane and caffeine responses across MHS phenotypes identified 
only three genes in common (GIMAP8, MT-TM, PECAM1), all of which were downregulated 
after drug exposure. The gene GIMP8 is a member of the GTPase of immunity-associated 
protein (GIMAP) family, which aids the regulation of lymphocyte survival and homeostasis 
(Schwefel et al., 2013). One study has also described a reduction in GIMAP8 expression after 
exercise (McLean et al., 2015). PECAM1 similarly encodes, platelet and endothelial cell 
adhesion molecule 1, a protein which is found on the surface of a range of immune cells  
(Gumina), whilst MT-TM is an RNA gene for the mitochondrially encoded the tRNA for 
methionine (Anderson et al., 1981). The downregulation of these genes may be due to an 
inflammatory response caused by the stress of drug exposure. 
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The comparatively weak effect of halothane and caffeine seen on MHS gene expression 
might be explained by limitations in experimental design. One concern for the RNAseq design 
was whether the length of time exposed to halothane/caffeine was appropriate to detect gene 
expression changes reflective of an MH reaction. The IVCT is a diagnostic test with fixed 
guidelines on drug exposure time and concentrations, limiting the experiment to a singular time 
point and predefined drug concentrations. Optimisation of experimental factors was therefore 
not possible since the IVCT was used as the means of applying drug treatment.  Multiple studies 
have shown that skeletal muscle gene expression can change significantly with time, differing 
in orders of magnitude over a 24-hour period (Neubauer et al., 2014; Liu et al., 2010). On that 
basis, it is possible that the time point used to assess treatment effect in this experiment failed 
to capture changes which reflect the hypermetabolic response of interest.  
Ideally, this experimental design could be refined by using cultured myotubes to help 
optimise for experimental factors. The first advantage to culturing myotubes, is the ability to 
overcome the limitations with the muscle biopsy control samples (ex vivo stressors and 
degradation over time) described in this section. Secondly, instead of using the IVCT to apply 
drug treatment,  drugs can be incorporated into culture media in a plate format to allow more 
flexibility over drug exposure time and drug concentrations. One approach would be to use a 
microplate reader to measure Ca2+ flux in myotubes using a Ca2+-sensitive fluorescent dye. 
With this technique, a dose response experiment can be conducted with a range of halothane 
and caffeine concentrations to identify the concentration which elicits a maximum response, 
indicated by Ca2+ flux. Using this information, the ideal drug concentration can then be applied 
to myotubes at several time points spanning 0 to 24-hours. RNA can then be extracted from 
myotubes at each time point and prepared for RNAseq. This setup design should provide the 
maximal drug response in myotubes and allow the assessment of gene expression change over 
time in all MH phenotypes. Furthermore, myotubes cultured for such experiments should 
ideally be sourced from individuals who are of similar age, fitness level and RYR1 variant to 
reduce variability associated with those factors.  
Due to the concerns regarding the efficacy of drug treatments, follow up work from 
RNAseq data was done on baseline MHN and MHS comparisons only, using the QuantiStudio 
RT-PCR system. Five genes of interest were selected from baseline MHN vs MHS 
comparisons, three directly involved with the ETC (USMG5, NDUFC2 and COQ6) and two 
involved in closely related external processes (MPC2 and MALSU1). All five genes were found 
to be downregulated in MHS samples based on the results from RNAseq, but this was not 
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entirely consistent with the follow up RT-PCR. Only three of the five mitochondria-related 
genes showed statistically significant downregulation (USMG5, NDUFC2 and COQ6). 
Directional changes in gene expression were consistent between RNAseq and RT-PCR, but it 
appeared as though these differences were overestimated in the RNAseq data. The MHS 
individuals selected for RNAseq had strong IVCT responses (majority >0.5g contracture at 2 
Vol% halothane) as opposed to the much more lenient criteria (>0.2g contracture at 2 Vol% 
halothane) used for RT-PCR. The more stringent criteria was adopted for RNAseq to maximize 
the chance of identifying differential gene expression between phenotypes and this could not 
be applied to RT-PCR due to limitations in sample population. On that basis, the RT-PCR 
findings are a more accurate representation of the overall MHS population, as the overtly strong 
IVCT responses selected for RNAseq may have exaggerated the baseline findings.   
Consequently, the two genes MPC2 and MALSU1 which were not significantly 
downregulated using RT-PCR, also had the smallest effect sizes out of the five genes selected. 
This may reflect a need to consider a FC threshold in future when considering genes of interest. 
The gene expression difference between MHS and MHN samples at baseline were less than -1 
log2FC in all five genes selected. These effect sizes may be too small for RT-PCR detection if 
there is indeed an overestimation of baseline differences as previously discussed. This 
observation appears to be supported by the data generated on the Biomark RT-PCR system 
used for RNAseq validation. The six genes assessed for their downregulation in MHN samples 
after halothane exposure (CNOT11, VMA21, SNX3, NDFIP1, PYURF, UBE2N) also had less 
than -1 log2FC effect size from RNAseq data and this corresponded to very little gene 
expression on the Biomark system. In contrast, the genes assessed for their upregulation after 
halothane treatment (NR4A2, INSIG1, DNAJA1, SOCS1, TNFRSF10D, IRF1, PPP1R10 and 
HSPA1A) had larger effect sizes (majority >2 log2FC) and these differences resembled those 
detected on the Biomark. In hindsight, it would have been more appropriate to follow up genes 
of interest showing > 1 log2FC effect size to account for overestimations in the RNAseq data. 
With regards to biological function, MPC2 encodes mitochondrial pyruvate carrier 2, 
responsible for importing pyruvate across the inner mitochondrial membrane. Deficiency in 
MPC2 has been shown to result in elevated blood glucose levels as a result of reduced glucose-
stimulated insulin secretion (Vigueira et al., 2014). In contrast, MALSU1 (mitochondrial 
assembly of ribosomal large subunit 1), is required for assembly and stability of the large 
ribosomal subunit (Rorbach et al., 2012). These two genes did not appear to be downregulated 
in the wider MHS sample population assessed by RT-PCR which may indicate that 
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bioenergetic defect in MHS muscle is caused by damage to ETC components as opposed to 
deficiencies in external factors such as substrate transport or mitochondrial ribosome 
formation. 
USMG5 (ATP5MD) encodes the diabetes-associated protein in insulin-sensitive tissue 
(DAPIT) and was first described as a novel protein downregulated in the insulin-sensitive 
tissues found in diabetic rats (Paivarinne and Kainulainen, 2001). It is associated with ATP 
synthase (complex V) and is thought to have a role in maintaining complex V population in 
mitochondria (Meyer et al., 2007; Ohsakaya et al., 2011). Histological reports have shown 
increased localisation of DAPIT in cells with high aerobic metabolism, favouring oxidative 
fibres in skeletal muscle (Kontro et al., 2012). Mutations in USMG5 are associated with 
complex V deficiency, reduced ATP production and Leigh’s syndrome (Barca et al., 2018). 
Leigh’s syndrome is a condition which can be caused by mutations in all mitochondrial 
complexes, characterised by progressive loss of mental capacity and motor function, often 
resulting in death 2-3 years after disease onset (Ruhoy and Saneto, 2014). 
The complex I-encoding NDUFC2 has been associated with stroke, diabetes and 
cardiovascular disease (Rubattu et al., 2016; Raffa et al., 2017; Madonna et al., 2019). It has 
been shown that NDUFC2 deficiency can result in a variety of mitochondrial defects such as 
reduced ATP production, reduced mitochondrial membrane potential, ultra-structural 
impairments and increased reactive oxygen species (ROS) production (Rubattu et al., 2016; 
Raffa et al., 2017; Raffa et al., 2019; Madonna et al., 2019). Mitochondria are a main source 
of ROS, generated primarily from complex I, complex III and the more recently suggested 
complex II (Murphy, 2009b; Quinlan et al., 2012). ROS are important signalling molecules for 
organelle crosstalk, and dysregulation can lead to mitochondrial dysfunction and induction of 
apoptosis through excessive oxidative damage. The reduced expression of complex I subunits 
may lead to higher levels of oxidative stress in MHS muscle, resulting in functional defects. 
These findings suggest inherent bioenergetic defect in MHS muscle, which may contribute to 
some of the muscle-related symptoms (cramps, weakness etc) described in MHS patients.  
Coenzyme Q6 monooxygenase (CoQ6) encoded by COQ6 is an essential component 
to the ETC and takes part in the production of coenzyme Q10 (CoQ10). CoQ10 is responsible 
for several functions which include acting as an antioxidant, a cofactor for mitochondrial 
dehydrogenases and an apoptotic regulator. Mutations in COQ6 cause CoQ10 deficiency, often 
associated with steroid-resistant nephrotic syndrome (SRNS), deafness and a range of muscle-
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related manifestations such as hypotonia, dystonia, myopathy, exercise intolerance and 
elevated CK levels (Heeringa et al., 2011; Salviati et al., 2017). The bioenergetic consequences 
of CoQ10 deficiency appears to be complex as severe deficiency has been associated with 
reduced ATP production and normal ROS production, whilst minor CoQ10 deficiency has been 
observed with high ROS production and no change to ATP levels (Quinzii and Hirano, 2010). 
Consequences to reduced CoQ6 expression include increased apoptosis and mitochondrial 
depolarisation, both of which were observed in CoQ6 knockdown cells carrying pathogenic 
mutations (Salviati et al., 2017).  
Exploration of regulatory elements for ATP5MD, NDUFC2 and COQ6 showed that 
many common TFs regulate the gene expression for all three genes. Among this selection, the 
genes encoding six of these TFs (ATF3, CHD2, NFKBIZ, CTBP1, ESRRA and TEAD4) were 
also found differentially expressed in the MHS phenotype at baseline.  Gene expression levels 
of ATF3, CHD2 and NFKBIZ were upregulated in MHS skeletal muscle whilst CTBP1, ESRRA 
and TEAD4 were downregulated in comparison to MHN. Dysregulation of these TFs in MHS 
muscle may contribute to the MH phenotype by modifying OXPHOS gene expression resulting 
in functional consequences. 
Activating transcription factor 3 (ATF3), encoded by ATF3, is a member of the 
ATF/CREB family of TFs and is upregulated in response to a range of stressors including: 
exercise, ER-stress, oxidative stress and hypoxia (Hai et al., 1999; Hai and Hartman, 2001). 
Exercise-induced ATF3 expression in skeletal muscle has shown to regulate the mRNA 
expression of inflammatory chemokines and cytokine, performing a homeostatic function for 
recovery (Fernandez-Verdejo et al., 2017). The increase of ATF3 expression in MHS skeletal 
muscle indicates a state of elevated cellular stress at baseline. This is further supported by the 
increased gene expression of CHD2, encoding chromodomain helicase DNA-binding domain 
2 (CHD2), which has been shown to localise at sites of DNA damage and promotes repair 
(Luijsterburg et al., 2016). One source of increased cellular stress could be increased ROS 
production as previously mentioned, given the number of OXPHOS-related genes 
downregulated in MHS muscle. 
Furthermore, studies have shown that CTBP1, encoding the c-terminal binding protein 
(CTBP1), can function as a metabolic sensor through interactions with NAD+/NADH and helps 
maintain mitochondrial activity (Fjeld et al., 2003). Mitochondrial elongation, swelling, 
reduced ATP levels and reduced oxygen consumption has been observed in CTBP1 knock-out 
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HeLa cells (Kim and Youn, 2009). Likewise, downregulation of ESRRA in skeletal muscle, 
encoding estrogen-related receptor-α (ERRα), has also been shown to impair muscle 
regeneration and mitochondrial biogenesis (LaBarge et al., 2014). Many of these features have 
been reported in MH studies which supports a link between mitochondrial abnormality and 
differential gene expression (Lavorato et al., 2016; Durham et al., 2008; Yuen et al., 2012; 
Giulivi et al., 2011).  
In summary, transcriptome comparisons between MHN and MHS skeletal muscle, has 
highlighted a downregulation of OXPHOS-related gene expression at baseline in MHS 
individuals. RNAseq resulted were successfully validated using the Biomark RT-PCR system, 
and three OXPHOS genes of interest, ATP5MD, NDUFC2 and COQ6 were followed up using 
bioinformatic resources. Many common TFs were found to regulate all three genes, six of 
which were also differentially expressed at baseline between MHN and MHS samples. Since 
these OXPHOS genes and their TFs appear to be associated with the MHS phenotype, the 
regulatory mechanisms of these genes have become an area of interest. It is possible that 
variants within the enhancer regions of ATP5MD, NDUFC2 and COQ6 interfere with TF 
binding properties which modify transcriptional activity, causing variation in MH phenotypes.  
One approach to further this investigation would be to study the eQTLs identified for 
ATP5MD, NDUFC2 and COQ6, by SNP genotyping a large cohort of MHN and MHS 
individuals. A focal point for genotyping could be the SNPs identified in each enhancer for the 
three genes of interest, or alternatively a broader tag-SNP genotyping approach could be 
adopted across the eQTL region of interest. A tag-SNP is a representative SNP in a region of 
the genome in high LD that represents a haplotype. Programs containing tag-SNP algorithms 
can be used to select tag-SNPs from haplotype blocks containing SNPs in high LD across the 
candidate loci (Halperin et al., 2005; Sicotte et al., 2011; Ao et al., 2005). This makes it possible 
to investigate genetic variation and association between phenotypes without genotyping every 
SNP in the region. Successful identification of these SNPs in MHS individuals, will provide 
evidence of these loci contributing towards the MH phenotype and provide new insights into 
the pathophysiology surrounding MH.  
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3 ASSESSMENT OF MITOCHONDRIAL FUNCTION IN MALIGNANT 
HYPERTHERMIA-SUSCEPTIBLE INDIVIDUALS 
3.1      INTRODUCTION 
 
MHS individuals, in the absence of anaesthetic triggers, do not have obvious clinical 
phenotypes but there have been reports of some experiencing muscle-related traits, such as 
exercise intolerance, muscle weakness, cramping and exercise-induced rhabdomyolysis 
(Timmins et al., 2015; Wappler et al., 2001; Litman et al., 2018). These features are often 
observed in MH-associated congenital myopathies such as central core disease and multi-
minicore disease, which have impaired oxidative metabolism (Jungbluth, 2007; Robinson et 
al., 2006). Mitochondria are the primary drivers of cellular metabolism and their involvement 
in MH susceptibility was speculated prior to the discovery of any genetic factors. Over fifty 
years ago, researchers hypothesised that MH triggering events lead to mitochondrial 
uncoupling, which contribute to the increase in body temperature, CO2 production and lactate 
formation observed in MH reactions (Wilson et al., 1966; Gatz and Jones, 1969). However, the 
literature surrounding mitochondrial dysfunction in MH has been conflicting, with differing 
observations reported in both human and animal MH models. 
In 1975, Isaacs & Heffron used electron microscopy to examine four human MHS 
muscle biopsies, taken from the quadriceps, and each sample had sub-populations of swollen 
mitochondria with damaged cristae (Isaacs and Heffron, 1975). These observations were 
supported in a more recent study by Lavorato et al., who were investigating chronic alterations 
in MHS skeletal muscle ultrastructure (Lavorato et al., 2016). In that study, they observed a 
higher frequency of mitochondrial abnormalities within MHS skeletal muscle, referring to sub-
populations of round, swollen mitochondria, with reduced matrix density and variable 
distributions of cristae (Lavorato et al., 2016). These reports of structural abnormality within 
MHS mitochondria suggest some form of chronic muscle damage associated with MH 
susceptibility which may be difficult to detect clinically.  
Two studies reported normal OXPHOS and respiratory control in human MHS 
mitochondria, but a higher sensitivity to Ca2+-induced uncoupling was observed (Britt et al., 
1973; Cheah et al., 1989). These findings appear to contradict the recent study by Thompson 
and colleagues, who reported evidence of impaired OXPHOS and ATP production after bouts 
of training in MHS individuals, indicating a functional defect in MHS mitochondria 
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(Thompson et al., 2017). It was also noted that skeletal muscle homogenates from MHS 
humans and MHS pigs had higher rates of fatty acid production which may indicate a defect in 
mitochondrial lipid metabolism (Cheah et al., 1989; Fletcher et al., 1991a; Fletcher et al., 
1991b; Fletcher et al., 1990). 
Early observations on MHS mitochondria were based primarily on skeletal muscle 
taken from MHS pigs. In contrast to MHS humans, MH susceptibility in pigs is autosomal 
recessive and they are predisposed to an overt sensitivity towards stress (Fujii et al., 1991; 
Fletcher et al., 1993). Although rare, heat-stress induced MH reactions have been reported in 
humans which may reflect a degree of similarity between species in the absence of anaesthesia 
(Gronert et al., 1980; Groom et al., 2011; Nishio et al., 2009; Carsana, 2013). MHS pigs have 
been reported to have respiratory states over three times higher than MHN pigs, alongside 
reduced Ca2+ accumulation in MHS mitochondria (Britt et al., 1975). This study contradicted 
other reports which have shown either no significant difference or reduced mitochondrial 
function in MHS mitochondria in comparison to MHN pigs (Denborough et al., 1973; 
Eikelenboom and van den Bergh, 1973; Gronert and Heffron, 1979). These conflicting claims 
are likely due to differences in methodology, but one consistent observation shared between all 
studies was the halothane-induced inhibition of mitochondrial respiration (Britt et al., 1975; 
Britt et al., 1973; Gronert and Heffron, 1979).  
Research on RYR1 knock-in mouse models of MH have also reported various degrees 
of mitochondrial abnormality depending on the Ryr1 variant. On a structural level, 
mitochondrial deformity has been observed in the skeletal muscle from the Y522S-RYR1 and 
T4826I-RYR1 mouse models which is an indication of damage (Durham et al., 2008; 
Boncompagni et al., 2009; Yuen et al., 2012). These reports often denote a loss of cristae 
organization and mitochondrial swelling which suggests there may be metabolic dysfunction 
and altered OXPHOS in muscles from both MHS mice (Durham et al., 2008; Boncompagni et 
al., 2009; Yuen et al., 2012) and humans (Isaacs and Heffron, 1975; Lavorato et al., 2016). 
Other notable observations found in MHS mice include reduced oxygen consumption rates in 
T4826I-RYR1 knock-ins (Yuen et al., 2012), increased oxidative stress in Y522S-RYR1 
knock-ins (Durham et al., 2008) and evidence of R163C-RYR1 mutants having both those 
features with reduced mitochondrial protein expression (Giulivi et al., 2011).  
The purpose of this study was to investigate mitochondrial function in skeletal muscle 
biopsies taken from human MHS individuals. This was achieved by using high-resolution 
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respirometry to measure oxygen consumption rates in permeabilised muscle fibres. 
Experiments were designed and carried out to address the following research questions:  
 
• Is there evidence of altered mitochondrial content between MHN and MHS 
skeletal muscle? 
• Does mitochondrial function differ between MHN and MHS skeletal muscle at 
baseline? 
• How does exposure to IVCT halothane alter mitochondrial function in both MH 
phenotypes?  
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3.2        METHODS 
 
3.2.1 Patients 
 
Patients samples were collected from individuals who were referred for IVCT on suspicion of 
their susceptibility to MH. Most index case patients had been found not to harbour a pathogenic 
variant in RYR1 and CACNA1S (www.emhg.org, 2020) prior to attending. Family members 
were either from families where no pathogenic variant had been found or who had been found 
not to carry a familial variant. Patients gave written informed consent to the study that was 
approved by Leeds (East) Research Ethics Committee (reference 10/H1306/70). Patients were 
diagnosed using the IVCT as either MHSh, MHShc or MHN according to the protocol of the 
EMHG (Hopkins et al., 2015).  
3.2.2 Muscle samples 
 
Diagnostic muscle biopsies and IVCTs were conducted by Ms Catherine Daly (Laboratory 
Manager of the MH Unit) and Dr Dorota Miller (Postdoctoral Researcher at the MH Unit), 
according to the protocol of the EMHG (Hopkins et al., 2015). In brief, six muscle fascicles 
(typical dimensions 25 mm x 4 mm x 3mm) were excised from vastus medialis under femoral 
nerve block and immediately placed in oxygenated Krebs-Ringer solution (118.1 mM NaCl, 
3.4 mM KCl, 0.8 mM MgSO4, 1.2 mM KH2PO4, 11.1 mM Glucose, 25.0 mM NaHCO3, 2.5 
mM CaCl2, pH 7.4) at room temperature and taken to the MH laboratory. There, the samples 
were kept at room temperature in the Krebs-Ringer solution, which was gassed continuously 
with carbogen (95% O2, 5% CO2), until being used for the IVCT tests.  
This study required both a muscle fascicle that had not been used for the diagnostic 
challenge tests (baseline) and a fascicle that had been used in the static halothane test 
(halothane-exposed). At the end of the halothane test procedure both the halothane-exposed 
and baseline samples were each placed into 1 ml of ice-cold biopsy preservation buffer, BIOPS 
(2.77 mM CaK2EGTA, 7.23 mM K2EGTA, 5.77 mM Na2ATP, 6.56 mM MgCl2·6H2O, 20 
mM taurine, 15 mM Na2Phosphocreatine, 20 mM imidazole, 0.5 mM dithiothreitol, and 50 
mM MES hydrate, pH 7.1, adjusted with 5 N KOH at 0 °C). The samples were then placed in 
a petri dish with ice cold BIOPS and separated using forceps to obtain small muscle fibre 
bundles containing approximately 4-5 fibres each.  
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These samples then underwent chemical permeabilization in BIOPS containing saponin 
(50 μg·ml-1) for 30 min, before being washed with 1 ml respiration medium, Mir05 (0.5 mM 
EGTA, 3 mM MgCl2·6H2O, 60 mM lactobionic acid, 20 mM taurine, 10 mM KH2PO4, 20 mM 
HEPES adjusted to pH 7.1 with KOH at 37 °C, 110 mM D-sucrose, and 1 g·L-1 essentially 
fatty acid free BSA) to remove residual saponin. The sample was then taken out of solution 
and blot-dried for 5 seconds before being weighed and loaded into the respirometer chambers 
(5-10 mg in each chamber) containing 2 ml of Mir05. The time between biopsy collection and 
assay time was approximately 90 – 120 minutes. This sample preparation procedure was 
adapted from previously described protocols (Kuznetsov et al., 2008; Pesta and Gnaiger, 2012; 
Chang et al., 2019). 
 
3.2.3 High Resolution Respirometry  
 
Oxygen consumption over time was measured using Oroboros respiratory analysers (Oroboros 
Instruments, Innsbruk, Austria) at 2 second intervals with polarographic oxygen sensors and 
expressed as mass-specific oxygen flux (pmol/s*mg). The analyser was calibrated daily in air 
saturated solution before experimentation. Assays were initiated by injecting oxygen into each 
chamber to raise the oxygen concentration to >400 nmol/mL prior to starting a substrate-
uncoupler-inhibitor titration (SUIT) protocol. Re-oxygenation of the chambers was performed 
to maintain oxygen concentration between 200-500 nmol/mL to prevent limitation due to 
oxygen diffusion (Kuznetsov et al., 2008) each assay was performed at 37 °C, with chamber 
stirrers set at 750 rpm.  
 
3.2.4 Substrate-uncoupler-inhibitor titration protocol 
 
An adapted SUIT protocol (Figure 3.1) was used to investigate the OXPHOS capacity of 
individual complexes and respiratory states (Kuznetsov et al., 2008; Pesta and Gnaiger, 2012; 
Chang et al., 2019). The procedure was initiated with the addition of 5 μM blebbistatin (BLEB) 
to prevent spontaneous contraction of muscle fibres (Perry et al., 2012; Perry et al., 2011). 
Glutamate (10 mM), malate (0.5 mM) and pyruvate (5 mM) were then applied to facilitate 
measurements of the complex I respiration in the absence of ADP (LEAK). ADP (2.5 mM) is 
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then added next to allow the measurement of maximal complex I-supported OXPHOS 
(CI(OXPHOS)). At this point, the outer mitochondrial membrane integrity was assessed by the 
addition of 10 μM cytochrome c. An increased respiration rate after addition of cytochrome c 
indicates outer mitochondrial membrane damage: samples that showed an increased respiration 
rate after cytochrome c of >10% were excluded from data analysis. 
Once membrane integrity has been assessed, the maximal activity of complex II is 
stimulated with the addition of succinate (10 mM). The oxygen flux at this stage 
(CI+CII(OXPHOS)) reflects the combined activities of complex I and complex II together and is 
also regarded as the maximum OXPHOS capacity in the coupled state. Next, step-wise 
additions of carbonyl cyanide 4-(trifluoromethoxy)-phenylhydrazone (FCCP) (0.5 μM) are 
made until there is no further increase in oxygen flux. This step-wise addition of FCCP 
uncouples the ETS by collapsing the proton gradient between the intermembrane space and the 
mitochondrial matrix providing the maximum ETS capacity (CI+CII(ETS)). Then, after 
uncoupling the system, electron flow through complex I is inhibited using rotenone (0.5 μM), 
providing maximum complex II activity alone (CII(ETS)). Finally, antimycin A is introduced to 
inhibit complex III. Complex III activity is technically contributing to all data points aside from 
the Complex IV assay. However, its activity is not measured directly in this protocol as it 
obtains electrons downstream of complex I and II. Residual oxygen flux (ROX) present after 
the addition of antimycin A is a result of non-mitochondrial respiration which is then subtracted 
from each respiratory state reading before analysis.  
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Figure 3.1. High resolution respirometry trace. This trace shows the rate of oxygen flux (red line) over time after sequential titration of substrates and 
inhibitors, expressed as pmol/s*mg. An overview of the SUIT protocol and CIV assay can be seen, with each vertical line representing the timepoint at which 
substrates/inhibitors were added. The blue line represents oxygen levels within the chamber (nmol/ml). The horizontal black lines which overlay the red line 
plateaus indicate the position of data points, Residual oxygen flux (ROX) present after the addition of antimycin A reflects non-mitochondrial respiration.
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3.2.5 Complex IV Assay 
 
Measurement of mass-specific complex IV oxygen flux was used as an alternative proxy 
marker for estimations of mitochondrial content. Ascorbate (2 mM) and N,N,N′,N′-
tetramethyl-p-phenylenediamine (TMPD) (0.5 mM) was applied to each sample at the end of 
the standard SUIT protocol. The measurement of complex IV flux is taken at the peak of the 
corresponding trace and residual chemical background is finally removed from this value by 
applying sodium azide (10 mM) to the sample (Larsen et al., 2012).  
 
3.2.6 Data handling and analysis 
 
Raw data output is in the form of oxygen flux per muscle mass (pmol/s*mg) which includes 
the confounding effects of both mitochondrial quality and quantity. The data in this study were 
internally normalised to the common reference state, CI+CII(ETS) (maximum uncoupled 
respiration). Normalised oxygen flux per mass is presented as flux control ratios (FCR) which 
highlight differences in mitochondrial function, as a proportion of the reference state, which is 
independent of mitochondrial content.  
Oxygen flux readings recorded from each sample trace were exported from proprietary 
software DatLab5 (Oroboros Instruments, Innsbruk, Austria) into Microsoft Excel before 
analysis using IBM SPSS statistics v21. Pairwise comparisons were performed using a 
combination of Wilcoxon signed-rank tests to assess the effects of halothane-exposure and 
Mann-Whitney U tests to assess differences between baseline controls. Mann-Whitney U tests 
were also used to compare the magnitude of FCR differences (pre vs post halothane) between 
MH phenotypes (MHN vs MHS). Further analysis using MHS subgroups involved a Kruskal-
Wallis test and post hoc Dunn’s procedure to identify differences between patients classified 
as MHN, MHSh and MHShc. Data were summarised as boxplots using GraphPad Prism 8.  
 
 
 
 
104 
 
3.3    RESULTS  
 
3.3.1 Patient characteristics 
 
A summary of patient characteristics is presented in Table 3.1. We included 59 individuals 
(MHN n=36, MHS n=23) from 52 families: the maximum number from any family was two 
individuals. 18 of the 23 MHS individuals were subsequently found to carry at least one variant 
in the RYR1 gene, of which only the c.1021G>A mutation has been functionally characterised 
(www.emhg.org, 2020). None of the patients had clinical or histopathological features 
suggestive of a mitochondrial myopathy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.1. Summary of patient characteristics contributing to the respirometry study. The RYR1 
variants are annotated for their likely pathogenicity using the criteria of Miller et al as: a. Unlikely 
pathogenic; b. Potentially pathogenic; c. Likely pathogenic; d. pathogenic (Miller et al., 2018).  
105 
 
The contracture strengths of each MHS individual are summarised in Table 3.2. The threshold 
for positive IVCT halothane response is 0.2g at 2 Vol% halothane and a positive caffeine 
response was 0.2g at 2 mM caffeine.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.2. In vitro contracture test responses for all MHS samples used in respirometry. 
Contracture responses at 2 Vol% halothane and 2 mM caffeine for all 23 MHS patient samples used for 
high resolution respirometry.  The MHN patients all had 0 g responses at 2 Vol% halothane and 2 mM 
caffeine.  
Patient 
number
IVCT 
classification
Contracture at 
2% halothane (g)
Contracture at 
2mM caffeine (g)
1 MHSh 0.6 0
2 MHSh 0.4 0
3 MHSh 1.05 0
4 MHSh 0.3 0
5 MHSh 0.35 0
6 MHSh 0.2 0
7 MHSh 0.2 0
8 MHSh 0.3 0
9 MHSh 0.2 0.05
10 MHSh 0.3 0
11 MHSh 0.2 0.1
12 MHSh 0.2 0.1
13 MHShc 0.7 0.2
14 MHShc 0.7 2
15 MHShc 1.8 1
16 MHShc 1.05 0.5
17 MHShc 0.9 0.2
18 MHShc 1.05 0.75
19 MHShc 2.55 0.9
20 MHShc 0.4 0.25
21 MHShc 1.6 0.4
22 MHShc 0.9 0.2
23 MHShc 0.45 0.3
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3.3.2 Mass-specific oxygen flux comparisons 
 
Oxygen flux per milligram of muscle was compared between MHN and MHS samples, with 
and without exposure to halothane (Figure 3.2). Baseline comparison of samples without 
halothane exposure showed no differences between the two phenotypes aside from CIV(MAX). 
A statistically significant increase in mass-specific CIV(MAX) was observed in the MHS 
phenotype (p=0.021) which suggests that MHS samples had greater mitochondrial content in 
comparison to MHN. The effects of halothane were assessed using pairwise comparisons 
within phenotype, which showed that oxygen flux was significantly elevated in MHS samples 
after halothane exposure in several respiratory states: CI(OXPHOS), CI+CII(OXPHOS), CI+CII(ETS) 
and CII(ETS). This change in oxygen flux was not observed in MHN samples, showing no 
significant alteration after exposure to halothane.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. High resolution respirometry of permeabilised vastus medialis biopsies from MHN 
and MHS individuals. Boxplots show median, IQR and min-max range for MHN (n= 36) and MHS 
(n=23) individuals in control and halothane-exposed samples. Statistically significant pairwise 
comparisons (p<0.05) are labelled with an asterisk (refer to table 3.3 for exact p-values). 
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3.3.3 Flux control ratios (normalised oxygen flux) 
 
Mass-specific oxygen flux was normalised to a common reference state (control CI+CII(ETS)) 
to generate FCR, which provides a measure of mitochondrial function as a proportion of the 
max ETS capacity. This removes the confounding effects of mitochondrial content differences 
between samples and gives a more accurate representation of inherent function (Figure 3.3). 
Comparisons of FCR at baseline revealed that CI+CII(OXPHOS) and CII(ETS) were significantly 
lower in MHS samples when compared to MHN (p=0.033 and 0.005, respectively), suggesting 
functional deficiency. Normalised CIV(MAX) showed no significant differences between MHS 
and MHN controls indicating similar functional capacity of complex IV. The pairwise 
comparisons of FCR between control and halothane-exposed samples support the findings seen 
in the mass-specific dataset, with statistically significant findings in several of the same 
respiratory states (Table 3.3). However, one exception was found in MHN CII(ETS) which 
increased after halothane-exposure (p=0.041).  
 
 
 
 
 
 
 
 
 
 
Figure 3.3. Boxplot comparison of flux control ratios from MHN and MHS individuals. FCR are 
generated by internally normalizing oxygen flux per muscle mass to the non-halothane-exposed control 
CI+CII(ETS) (indicated by the horizontal dashed line). Boxplots show median, IQR and min-max range 
for MHN (n=36) and MHS (n=23) individuals in control and halothane-exposed samples. Statistically 
significant pairwise comparisons (p<0.05) are labelled with an asterisk (refer to table 3.3 for exact p-
values). 
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Table 3.3.  Summary of all statistical comparisons for each data set (Human respirometry). An 
overview of the specific p-values for each pairwise comparison between and within phenotype for the 
mass-specific oxygen flux (pmol/s*mg) and FCR readings are displayed. The p-values for FCR 
differences between MHS subgroups are also included with post hoc statistics for each comparison. 
MHN MHS
LEAK   0.944 0.429
CI(OXPHOS) 0.593 0.012
CI+CII(OXPHOS) 0.789 0.005
CI+CII(ETS) 0.157 0.003
CII(ETS)   0.057 0.001
CIV(MAX)  0.718 0.101
MHN MHS
LEAK   0.753 0.362
CI(OXPHOS) 0.48 0.007
CI+CII(OXPHOS) 0.47 0.003
CI+CII(ETS)
CII(ETS)   0.041 0.001
CIV(MAX)  0.307 0.052
Oxygen consumption rate (pmol/s*mg)
MHN vs MHS
Control vs halothane-exposure   
 (p-value)
Respiratory 
State Control comparisons (p-value)
0.113
0.071
0.05
0.376
0.021
0.074
0.534
0.033
0.005
0.913
Flux control ratio (FCR)
MHN vs MHS
Control vs halothane-exposure  
 (p-value)
0.732
Respiratory 
State Control comparisons (p-value)
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3.3.4 FCR changes within subdivided MHS phenotypes 
 
To assess whether halothane effects differed within the MHS sub-phenotypes (MHSh and 
MHShc), FCR data was used for further analysis. Prior to splitting the MHS phenotype into 
subgroups, the magnitude of change before and after halothane exposure (FCR difference) was 
calculated and compared between MHN and MHS phenotypes (MHSh + MHShc) (Figure 3.4). 
Mann-Whitney U tests were used to compare FCR differences in six respiratory states and a 
statistically significant difference was found in CI+CII(OXPHOS) (p=0.045) and CI+CII(ETS) 
(p=0.03).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Boxplots comparing FCR difference (in response to halothane) between MHN and 
MHS phenotypes. The magnitude of change in FCRs (before and after IVCT halothane exposure) are 
compared between MHN (n = 36) and MHS samples (n = 23). Data is displayed as boxplots, which 
show median, IQR and min-max response range for each phenotype. Comparisons labelled with an 
asterisk show statistically significant comparisons (p<0.05).  
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Next, FCR differences were calculated and compared between MHN and MHS samples 
subdivided into MHSh and MHShc subgroups (Figure 3.5) – there were no patients in this study 
categorized as MHSc. Results from the Kruskal-Wallis test showed that CI+CII(OXPHOS) 
responses differed significantly between MH phenotypes after halothane exposure (p=0.043). 
Post hoc analysis showed that FCR differences in CI+CII(OXPHOS) were significantly different 
between MHN and MHShc phenotypes (p=0.036). The differences in response between MHN 
and MHS groups is largely attributable to responses from the MHShc subgroup because 
significant differences in response between the MHN and MHSh groups were not found. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Boxplots comparing FCR difference (in response to halothane) between MHN, MHSh 
and MHShc phenotypes. MHN samples (n = 36) were plotted with MHS samples (n = 23) - further 
split into MHSh (n = 12) and MHShc (n = 11) subgroups. Boxplots show median, IQR and min-max 
response range for each phenotype. Comparisons labelled with an asterisk show statistically significant 
post hoc pairwise comparisons (p<0.05).
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3.4 DISCUSSION 
 
The aim of this study was to provide insight into the relationship between mitochondrial 
function and MH susceptibility using human skeletal muscle as opposed to MH animal models. 
Mass-specific oxygen consumption rates (pmol/s*mg) was first compared between MH 
phenotypes at the baseline level before halothane treatment. This comparison showed that the 
mass-specific oxygen consumption rates was not significantly different between MHN and 
MHS samples, aside from the CIV(MAX) state, which was significantly elevated in the MHS 
phenotype. This observation suggests that there was increased mitochondrial content in the 
MHS sample population, which was somewhat surprising since other MH studies have reported 
either no significant difference or the opposite effect in MHS muscle (Lavorato et al., 2016; 
Boncompagni et al., 2009; Giulivi et al., 2011; Barrientos et al., 2012).  
The report by Lavorato et al. observed human MHN and MHS muscle composition 
using electron microscopy and they reported slightly less mitochondrial content in MHS 
samples, but this was not found to be statistically significant (Lavorato et al., 2016). Other 
reports commenting on this feature were based on muscle from the Y522S-RYR1, T4826I-
RYR1 and R163C-RYR1 knock-in mouse models, all of which presented evidence of reduced 
mitochondrial content (Boncompagni et al., 2009; Giulivi et al., 2011; Barrientos et al., 2012). 
Despite the CIV(MAX) oxygen consumption rates data suggesting increased mitochondrial 
content in human MHS samples, it is difficult to claim that this observation is representative 
of the overall MHS population due to the variable nature of human skeletal muscle. 
Mitochondrial content and OXPHOS capacity in humans can be significantly altered based on 
muscle fibre type distribution and different types of physical training. The vastus medialis 
biopsies used for IVCT, are a part of the quadriceps muscle group, which typically have a fibre 
type distribution around ~40% slow-twitch type I and ~60% fast-twitch type II (Staron et al., 
2000; Edgerton et al., 1975). Slow-twitch oxidative muscle fibres are rich in mitochondria and 
can be developed from sustained exercises with increased time under tension. Both variables 
were not accounted for in this experimental design which in hindsight could be improved by 
incorporating data from an exercise questionnaire to group individuals into levels of fitness for 
sub-analysis. 
The use of alternative mitochondrial biomarkers such as citrate synthase and 
mitochondrial DNA (mtDNA) were considered but the complex IV assay was ultimately 
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chosen for several reasons. The complex IV assay can be easily prepared and applied 
immediately after the SUIT protocol, which allows an assessment of mitochondrial content on 
the same exact sample to avoiding issues with sample degradation. Its usage was also supported 
by the study conducted by Larsen et al. which compared commonly used mitochondrial 
biomarkers to the gold standard transmission electron microscopy (TEM) (Larsen et al., 2012). 
The outcome of that study showed that the complex IV assay (TMPD + Ascorbate) had strong 
correlations with the mitochondrial content measurements made by TEM, serving as a good 
functional biomarker. This contrasts with their findings comparing mtDNA with TEM, which 
showed poor correlation between the two assays (Larsen et al., 2012). The use of mtDNA as a 
marker for mitochondrial content is very common and the lack of correlation observed in that 
study was surprising. However, there have been reports of mtDNA not increasing significantly 
after training despite other biomarkers increasing, which seem to support this claim 
(Menshikova et al., 2005; Pesta et al., 2011). Furthermore, mtDNA copy number can vary 
considerably between individuals which also adds additional variability to its usage (Wiesner 
et al., 1992). 
To identify functional differences between MHN and MHS mitochondria specifically, 
mass-specific oxygen consumption rates were normalised against a common respiratory state 
(CI+CII(ETS)) within each sample to generate FCR data, which is corrected for mitochondrial 
content. Baseline comparison of FCR between phenotypes, showed significantly reduced 
CI+CII(OXPHOS) and CII(ETS) FCRs in MHS samples - indicating a functional deficit. The 
reduction of CI+CII(OXPHOS) FCR reflects a lower OXPHOS capacity and implies that there is 
uncoupling of MHS mitochondria in addition to complex II deficiency (reduced CII(ETS) ) under 
normal untriggered conditions. As previously mentioned, MHS individuals do not typically 
present with a phenotype in the absence of MH triggers, but some individuals in past reports 
have shown signs of myopathy such as exercise intolerance, weakness and cramping (Timmins 
et al., 2015; Wappler et al., 2001; Litman et al., 2018). It is possible that the baseline 
deficiencies detected here in MHS mitochondria are a downstream consequence of RyR 
dysfunction, which contribute to some of those issues.  
A lower OXPHOS capacity and MHS mitochondrial uncoupling likely limits the rate 
of ATP production and is potentially due to the mitochondrial swelling and structural 
abnormalities reported in both human (Lavorato et al., 2016; Isaacs and Heffron, 1975) and 
MH animal models (Durham et al., 2008; Boncompagni et al., 2009; Yuen et al., 2012). The 
structural damage seen in MHS mitochondria is speculated to be the result of oxidative damage 
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accumulated over time which is promoted by the chronically elevated [Ca2+]rest present in MHS 
muscle (Lopez et al., 1985; Lopez et al., 1986; Lopez et al., 2018; Giulivi et al., 2011; Yuen et 
al., 2012). Studies have shown that mitochondria, Ca2+ and ROS interact closely to regulate 
cellular processes and increases in [Ca2+] is known to stimulate mitochondrial activity which 
in turn increases the rates of ROS production through the ETS (Gorlach et al., 2015).  
The main sites of ROS production in mitochondria are complex I and III but some 
reports have also shown significant ROS generation at complex II under special circumstances 
(Guzy et al., 2008; Quinlan et al., 2012; Zorov et al., 2014). Studies on MH RYR1 knock-in 
mouse models have reported an increase in ROS production and it is possible that this feature 
also translates into human MHS muscle (Durham et al., 2008; Giulivi et al., 2011). ROS have 
traditionally been associated with negative consequences (contributing to oxidative stress, 
pathogenesis and cell death) but research has now shown that ROS also contributes to the 
regulation of normal physiological processes, at the appropriate concentrations (Barbieri and 
Sestili, 2012). Oxidative stress in mitochondria is usually regulated by antioxidative 
mechanisms involving superoxide dismutases (SOD) that act to convert superoxide into H2O2, 
which in turn is further decomposed by glutathione peroxidase (Turrens, 2003). Elevations in 
mitochondrial ROS and Ca2+ have also been shown to trigger the activation of mitochondrial 
uncoupling proteins and the MPTP, which may account for the mitochondrial uncoupling 
observed in MHS samples (Mailloux and Harper, 2011; Briston et al., 2017). The inability of 
antioxidative mechanisms to compensate for increased ROS production can lead to 
pathogenesis in skeletal muscle and may warrant further research in the context of MH. 
With regards to complex-specific deficiency, the lack of difference observed in 
complex I between MH phenotypes at baseline indicates that complex II is the major 
component responsible for the reduced OXPHOS capacity observed in MHS muscle. Complex 
II, also known as succinate dehydrogenase, is encoded entirely by nuclear genes and functions 
in both OXPHOS and the Kreb’s cycle (Bezawork-Geleta et al., 2017). There has not been any 
previous literature connecting complex II involvement with MH susceptibility and this is the 
first study to provide evidence of its deficiency in MHS muscle. Collectively these findings 
suggest a potential compensation mechanism, in which human MHS muscle upregulates 
mitochondrial numbers to counteract deficiencies in mitochondrial function, hence similar 
baseline oxygen flux per unit of muscle mass.  
114 
 
Literature surrounding mitochondrial function in MH is conflicting, but the overall 
concept of mitochondrial deficiency in MHS muscle is supported by several other studies 
having also shown functional deficiencies (Gronert and Heffron, 1979; Barrientos et al., 2012; 
Yuen et al., 2012; Rouviere et al., 2012; Thompson et al., 2017). One study of interest was the 
recent publication by Thompson et al. who also studied MH in humans. In this study they 
reported significant reductions in aerobic and anaerobic capacity in MHS individuals after 
bouts of exercise which they suspect is the reason for MHS-related exercise intolerance 
(Thompson et al., 2017). Despite evidence of OXPHOS deficiency being reported across 
multiple studies, some of the features detailed in our human study conflict with the those 
generated using the MH mouse models.  
One example of this comparison is the Giulivi et al. study using R163C-RYR1 knock-
in mice (Giulivi et al., 2011). R163C-RYR1 knock-in mice were shown to have reduced 
mitochondrial content, reduced oxygen uptake using malate-glutamate and succinate, in 
addition to reduced complex I, III and IV activity when compared to wild-type mice (Giulivi 
et al., 2011). These aspects conflict with the data from this present human study on several 
accounts, having shown evidence suggesting higher mitochondrial content, deficiency in 
succinate-facilitated oxygen flux and deficiency in only complex II. These conflicting 
observations may reflect  a combination of interspecies variation between human and mice, 
and technical differences in methodology.  
The present study utilised permeabilised muscle fibres extracted from the vastus 
medialis whilst Giulivi et al. used isolated mitochondria in their assessment of mitochondrial 
function and content. A limitation of using isolated mitochondria is that it does not allow 
interaction between organelles within the cell. Studies have identified tethers between 
mitochondria and the SR creating close contact sites called mitochondria-associated 
membranes (MAMs) (Eisner et al., 2013). The passive Ca2+ leak from mutant RYR1 in MHS 
muscle would expose mitochondrial subpopulations to higher concentrations of Ca2+ which 
may alter mitochondrial Ca2+ intake through MCU channels. This interaction can be important 
for the  accurate reflection of mitochondrial function in MH since its pathology is caused by 
Ca2+ dysregulation. The use of muscle fibres permeabilised with saponin is advantageous in 
this regard, as it allows the assessment of mitochondrial function with cellular components 
intact and maintains the crosstalk ability between organelles (Saks et al., 1998).  
115 
 
In addition to sample type, another significant difference in protocol is the temperature 
used between studies. The oxygen uptake assay in the Giulivi et al. mouse study was conducted 
at 22 °C, whereas this present study was performed at 37 °C (Giulivi et al., 2011). A study by 
Lemieux et al. used high resolution respirometry to assess mitochondrial respiratory control 
across a temperature range (4 °C - 40 °C) using permeabilised mouse myocardial fibres and 
showed significant alterations in OXPHOS capacity at different temperatures (Lemieux et al., 
2017). This factor, together with sample type and interspecies variation, can change 
mitochondrial bioenergetics and should be taken into consideration before drawing 
comparisons. 
Following baseline observations, the effect of halothane on mitochondrial function was 
assessed by analysing oxygen consumption rates and FCR data before and after halothane 
exposure between phenotypes. Results showed that halothane exposure triggered an increase 
in oxygen consumption in the MHS phenotype – indicative of a hypermetabolic response. This 
response to halothane is thought to be due to an increase in Ca2+ uptake in MHS mitochondria 
following Ca2+ efflux from the SR, through activated RyR1 channels. Increases in 
mitochondrial [Ca2+] is known upregulate oxidative metabolism by stimulating dehydrogenase 
enzymes, increasing the rates of NADH and ATP production (Griffiths and Rutter, 2009; 
McCormack and Denton, 1979; Denton, 2009). An overload of Ca2+ in mitochondria is known 
to induce the opening of the MPTP and activate apoptotic mechanisms - a potential cause of 
the rhabdomyolysis and cell death which occur in a fulminant MH reaction. In contrast, MHN 
samples were largely unaltered by halothane exposure, aside from the CII(ETS) FCR result which 
was also elevated. This increase in CII(ETS) was unexpected but suggests that there is a non-
RyR1 mediated halothane effect on mitochondria.  
Several reports studying the effects of halothane have noted an interaction which causes 
the inhibition of complex I activity in mitochondria. In the context of MH, complex I activity 
was shown to be reduced by halothane exposure in MHS swine (Britt et al., 1975; Gronert and 
Heffron, 1979), but this effect was also demonstrated in research outside of MH, showing that 
the two traits are not dependent. Hanley et al. studied the effects of anaesthetics on porcine 
heart mitochondria and demonstrated reversible dose-dependent inhibition of complex I after 
exposure to isoflurane, sevoflurane, and halothane – the latter of which had the strongest effect 
(Hanley et al., 2002). This observation was supported by research on the complex I mutant gas-
1 C.elegans model which also presented with evidence of decreased complex I function and 
increased sensitivity to inhalation anaesthetics (Falk et al., 2006; Kayser et al., 2004). 
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Surprisingly, this halothane-induced complex I inhibition was also not observed in this study 
in either phenotype. This disparity may be due differences in methodology, as previously 
explained, in addition to the limitations in this protocol. In this present study, there was a time 
delay between halothane exposure and oxygen consumption measurements (~90 - 120 minutes) 
due to sample preparation and transport. Since the halothane-induced complex I inhibition is 
reversible (Hanley et al., 2002), it is possible that complex I function was given enough time 
to recover before the assay was conducted.   
The magnitude of FCR change, before and after halothane exposure, was compared 
between MH phenotypes and the maximum OXPHOS (CI+CII(OXPHOS)) and ETS (CI+CII(ETS)) 
capacities were significantly upregulated in MHS samples. Within this dataset, sub-analysis of 
the MHS phenotype was performed to identify any differences between MHSh and  MHShc 
samples. There was a significant difference in maximum OXPHOS capacity between MHShc 
and MHN phenotypes, but this was absent in MHSh comparisons, indicating a heightened 
sensitivity in MHShc samples. This was not surprising as the MHShc classification has been 
associated with stronger phenotypes based on IVCT contracture data (Robinson et al., 2002) 
and this was supported by the results of this present study.  The MHSh classification in contrast 
is often associated with weaker phenotypes and the FCR changes were coincidently not 
significantly different from MHN responses after halothane exposure.  
The only study which has reported a conflicting pattern in MHSh and MHShc responses 
was a recent study on Canadian MHS individuals which identified a higher index of calcium-
related changes in muscle cells cultured from MHSh individuals in comparison to MHShc 
(Figueroa et al., 2019). This discrepancy might be explained by their use of cultured myotubes 
as opposed to the adult muscle fibres used in this present study. The reason behind why some 
MHS individuals have increased sensitivity to caffeine is unknown and the differences between 
MHSh and MHShc skeletal muscle is unclear from a physiological viewpoint. The RyR1 
architecture is known to have a putative binding site for caffeine next to the Ca2+ binding site 
in the central domain (des Georges et al., 2016). Caffeine is a potent activator of RyR1, and its 
binding causes a conformational change which significantly increases RyR1 sensitivity to Ca2+ 
activation (Murayama et al., 2018). One possible explanation may be that certain MH-
associated RYR1 mutations interfere with the caffeine binding sites on RyR1 which 
consequently raises its affinity and sensitivity to caffeine.  
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Despite identifying differences in mitochondrial function after halothane exposure, a 
potential confounding factor needs to be taken into consideration when interpreting results. The 
issue stems from the method of halothane administration through the IVCT, which is a complex 
test encompassing several other interventions. Samples that undergo IVCT are held at an 
approximate physiological length and tension before being electrically stimulated prior to 
halothane exposure. This adjustment of sample length and exposure to electric stimulus were 
not applied to the baseline control samples due to limitations of the IVCT rig not allowing 
multiple tests to occur simultaneously. Ideally the experiment could have been improved by 
applying these additional treatments to all baseline samples in the absence of halothane to rule 
out any effects not related to halothane exposure. Alternatively, it may have been possible to 
avoid all IVCT-related confounding factors if halothane were applied directly into the 
respirometry chambers by dissolving it into a solvent. 
In conclusion, the results from this study have demonstrated evidence of impaired 
mitochondrial function in permeabilised human MHS skeletal muscle at baseline. These 
findings may be a contributor towards some of the myopathic symptoms (exercise intolerance, 
cramping, weakness) reported by MHS individuals in absence of MH triggering agents. This 
feature is believed to be a downstream consequence of oxidative stress facilitated by the 
chronic elevation of cytoplasmic Ca2+ described in MHS muscle. Furthermore, exposure to 2 
Vol% halothane also significantly increased OXPHOS and ETS capacity in MHS muscle 
which is indicative of a hypermetabolic response associated with the MH phenotype.  
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4 DIFFERENTIAL GENE EXPRESSION BETWEEN WILD-TYPE 
AND RYR1 KNOCK-IN MICE  
 
4.1 INTRODUCTION 
 
Many studies on MH have adopted the use of RYR1 knock-in mouse models which offer 
several advantages with regards to experimental design. Firstly, skeletal muscle is easily 
attainable from knock-in mice as they can be captive bred for experimentation. This breeding 
process can control for genetic variability and other factors which significantly alter muscle 
function, such as muscle fibre distribution and muscle mass which vary considerably in humans 
due to lifestyle. Other advantages of using mouse models include a greater degree of control 
over variables such as age and sex, which can be investigated within experimental designs. In 
the last two decades, four RYR1 knock-in mouse models have been developed based on 
variants of interest (Y522S-RYR1, R163C-RYR1, T4826I-RYR1, G2435R-RYR1), to further 
our understanding of MH pathophysiology (Chelu et al., 2006; Yang et al., 2006; Yuen et al., 
2012; Lopez et al., 2018). Ryr1 variants associated with MH, can occur across all regions of 
the gene but research in knock-in mouse models of MH has focussed on variants within the N-
terminal, C-terminal and central regions of the RYR1 protein (Lopez et al., 2018).  
The first murine model of MH developed was the Y522S-RYR1, corresponding to an 
Ryr1 mutation of tyrosine to serine at position 522 of N-terminal region (Chelu et al., 2006). 
This mutation was identified in three individuals of a French family, following the death of a 
proband due to an MH crisis (Quane et al., 1994). Functional characterisation of this model 
showed Y522S-RYR1 HET mice to have increased sensitivity to temperature, voltage, and 
caffeine exposure, resulting in rhabdomyolysis and temperature-induced death (Chelu et al., 
2006). A mild bleeding phenotype was also observed in Y522S-RYR1 HET mice, with 
bleeding scores two-three times greater than wild-type (WT) mice, attributed to alterations in 
smooth muscle Ca2+ homeostasis (Lopez et al., 2016). Additional phenotypic traits include a 
range of mitochondrial defects with regards to damage, structure and oxidative/nitrosative 
stress - to be explored further in chapter 5 (Durham et al., 2008; Boncompagni et al., 2009; 
Michelucci et al., 2017; Canato et al., 2019).  
The second murine model of MH (R163C-RYR1) was reported in the same year, 
carrying another mutation found in the N-terminal region of RYR1 (Yang et al., 2006). The 
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R163C-RYR1 HET mice were found to undergo fulminant MH reactions in response to 
halothane and high ambient temperatures. Characterised by increased rectal temperatures, 
increased respiratory rate, metabolic acidosis, and acute rigor mortis upon death (Yang et al., 
2006). Whole cell patch clamp studies found that DHPR channel activity was also altered due 
to the R163C-RYR1 variant, and this was speculated to contribute towards MH episodes 
(Bannister et al., 2010). Cultured myotubes from this model demonstrated several aspects of 
Ca2+ dysregulation featuring elevated intracellular Ca2+ (Feng et al., 2011; Yang et al., 2006), 
enhanced Ca2+ entry rates (Cherednichenko et al., 2008) and slower decay of Ca2+ transients in 
response to membrane depolarisation (Esteve et al., 2010). Furthermore, mitochondrial defects 
were also observed in R163C-RYR1 mice with reduced OXPHOS and increased oxidative 
stress, similar to that seen in the Y522S-RYR1 model (Giulivi et al., 2011; Durham et al., 
2008).  
In contrast to the first two knock-in murine models, the third RYR1-knock in mouse 
model (T4826I-RYR1) was developed carrying a variant in C-terminal region of RYR1 (Yuen 
et al., 2012). This mutation resides between the S4-S5 cytoplasmic linker of RYR1 and was 
associated with MH after being first described in a New Zealand Maori pedigree (Brown et al., 
2000). Both heterozygous (HET) and homozygous (HOM) mice with this mutation were fully 
viable, whilst HOM mice from the first two models showed developmental defects and did not 
survive past the embryonic stage (Yuen et al., 2012; Chelu et al., 2006; Yang et al., 2006). 
Consistent with the other MH mouse models, T4826I-RYR1 mice have elevated intracellular 
Ca2+, evidence of mitochondrial defect and fulminant MH reactions in response to high 
temperatures and anaesthetic treatment (Barrientos et al., 2012; Yuen et al., 2012). 
Interestingly, mice with this mutation also exhibit a gene-dose and sex-dependent susceptibility 
to MH, which may be a feature of Ryr1 variants within the C-terminal region (Yuen et al., 
2012). 
Among the several hundred human RYR1 mutations associated with MH, the missense 
point mutation c.7300G>A on exon 44, is the most common cause of human MH within the 
UK (Carpenter et al., 2009b; Miller et al., 2018; Robinson et al., 2002). This mutation causes 
a p.Gly2434Arg amino acid change and resides in the central region of RYR1. It is present in 
approximately 16% of MHS families in the UK and despite its prevalence, is associated with a 
weak clinical phenotype based off IVCT contracture data (Carpenter et al., 2009b; Miller et al., 
2018). Due to its significance in the UK MHS population, a fourth RYR1 knock-in mouse 
model (G2435R-RYR1) equivalent to the human RYR1 c.7300G>A mutation was created, 
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representing the only MH mouse model with a variant in central region (Lopez et al., 2018). 
Consistent with previously reported RYR1 knock-in mice models, G2435R-RYR1 HET and 
HOM mice were functionally characterised showing elevated [Ca2+]rest and increased 
sensitivity to caffeine, halothane, and elevated ambient temperatures (Lopez et al., 2018). 
These features have a gene-dose dependent effect reflected by the differences in [Ca2+]rest 
(mean (SD): HET-156nM (16), HOM-265nM (32)), death times for halothane-induced (mean: 
HET–65.2 minutes, HOM-18 minutes) and temperature-induced MH reactions (mean: HET-
68.6 minutes, HOM-17.9 minutes) (Lopez et al., 2018).  
 To date there has not been an in-depth report on the gene expression profiles for any of 
these RYR1 knock-in mouse models. This information may help explain the functional 
variation observed in MH phenotypes and provide insight into how different Ryr1 variants 
affect skeletal muscle function. This chapter presents the first study of transcriptomic changes 
in the skeletal muscle of G2435R-RYR1 mice both under baseline conditions and after 
treatment with halothane. This will be achieved using RNAseq and bioinformatic resources to 
functionally categorise gene sets. The use of this mouse model allowed more control over 
experimental design which accounts for some of the limitations (age, treatment, fibre 
composition) previously described in the human RNAseq experiment (Chapter 2). In addition, 
T4826I-RYR1 HET mice were also included in this study to see how gene expression differs 
between these two mouse models.  
 
This chapter aims to address the following research questions: 
• What genes are differentially expressed between WT, G2435R-RYR1 and T4826I-
RYR1 knock-in mice at baseline? 
• How does halothane exposure alter gene expression in WT, G2435R-RYR1 and 
T4826I-RYR1 knock-in mice? 
• Which biological functions and pathways are enriched at baseline and in response to 
halothane exposure? 
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4.2 METHODS 
 
4.2.1 Animals 
 
All RYR1 knock-in mice were housed in pathogen-free conditions with free access to food, 
water, and 12-hour light-and-dark cycles. All mice used for transcriptomics were eight weeks 
of age and experiments were undertaken with UK Home Office approval (Licence number 
PB2FB5E94).  
 
4.2.2 RNAseq experimental design 
 
A total of 12 mice were selected for sequencing comprised of four genotypes: WT, G2435R-
RYR1 HET, G2435R-RYR1 HOM and T4826I-RYR1 HET. All RYR1 knock-in mice (n=3 of 
each genotype) were eight weeks of age and male. The purpose of this experiment was to 
explore differential gene expression between the different RYR1 knock-in mouse genotypes 
both at baseline and after exposure to halothane. Paired samples were collected from each 
mouse (before and after halothane exposure) and all WT mice used in next generation 
sequencing were created within the G2435R-RYR1 colony through HET x HET breeding.  
 
4.2.3 Preparation of samples for RNA sequencing 
 
RYR1 knock-in mice were killed by cervical dislocation before both hind limbs were removed 
from each mouse and dissected to expose the Soleus muscles on the surface. One limb was 
designated as the baseline sample (without halothane exposure) and the other limb was 
designated as the halothane-treated sample. The baseline samples for each genotype were kept 
suspended in oxygenated Krebs-Ringer solution for 30 minutes at 37 oC before Soleus muscles 
were removed from the limb and transferred into RNAlater (INVITROGEN) at -80 oC until 
further processing.  
Halothane-treated samples were given the same treatment, with the addition of 2 Vol% 
halothane perfused into the Krebs-Ringer solution for 30 minutes at 37 oC. Both baseline and 
halothane-treated Soleus muscles were homogenised in 1 ml TRIzol© using an IKA T-10 basic 
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ULTRA-TURRAX® homogeniser before RNA was extracted using a chloroform/isopropanol 
extraction method (described in chapter 2, section 2.2.3), followed by an RNA clean up step 
using the RNAeasy microkit (QIAGEN) with on-column DNase treatment, according to 
manufacturer’s instructions. Quality assessment of RNA samples was performed on the Agilent 
4200 Tapestation (described in chapter 2, section 2.2.4) and samples with integrity scores of 
RINe >7.0 were considered acceptable for sequencing.  
 
4.2.4 Truseq® Stranded mRNA library preparation 
 
PolyA selected mRNA libraries were created from the isolated RNA by the Next Generation 
Sequencing Facility at St James’s University Hospital, Leeds. RNA samples were first 
quantified using the Qubit™ RNA BR Assay Kit (Invitrogen™), before being used to create 
libraries using the Truseq Stranded mRNA library preparation kit (Illumina®), according to 
manufacturer’s guidelines. All cDNA libraries were quality checked and quantified by Ms 
Catherine Daly (Laboratory Manager of the MH Unit) using the Agilent D1000 screentape and 
the Quant-iT™ PicoGreen® dsDNA assay. 
 
4.2.5 Illumina® HiSeq® NGS 
 
A total of 24 mRNA-enriched libraries (12 before and 12 after halothane exposure) were 
indexed and compiled into a single pool at equimolar concentrations. This library pool was 
then distributed across two HiSeq 3000 150-bp paired-end lanes, achieving an average of 25M 
reads per sample. A forward and reverse FASTQ file was generated for each sample on each 
lane. Further details on the sequencing technology can be found in chapter 2, section 2.2.8. 
 
4.2.6 Differential gene expression analysis 
 
Raw sequencing data (FASTQ files) were initially processed using the Medical Advanced 
Research Computer (MARC1) - a high-performance computer cluster at the University of 
Leeds. The FASTQ files for each technical replicate across HiSeq lanes were combined and 
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trimmed using “Cutadapt” to remove adapters and bad quality base calls (<10) (Martin, 2011). 
Quality assessment before and after trimming was performed using FastQC 
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/) (Cock et al., 2010). All samples 
were aligned a reference genome (GRCm38.p6) using the STAR aligner and quantified using 
featureCounts (Dobin et al., 2013; Liao et al., 2014). Processed sequencing data was then 
imported into RStudio and analysed using the DESeq2 package for differential gene expression 
(RStudio Team, 2015; Love et al., 2014). DESeq2 generates gene lists with p-values adjusted 
for multiple testing using the BH adjustment (Benjamini and Hochberg, 1995). The default 
setting in DESeq2 uses a cut-off of padj <0.1 for differentially expressed genes, but in this 
study, a more stringent cut-off of padj <0.05 was used to classify statistically significant 
findings. Visualisations of data through MA plots, PCA plots and heatmaps were created using 
the R package “ggplot2” (Wickham, 2016). 
 
4.2.7 Pathway and gene ontology 
 
Differentially expressed gene lists generated from DESeq2 were functionally characterised 
using the online enrichment analysis tool Enrichr (Chen et al., 2013; Kuleshov et al., 2016). 
Enrichr calculates enrichment scores using statistics based off the Fisher’s exact test, used to 
assess the significance of overlap between inputted gene lists and the chosen gene-set library 
(Chen et al., 2013). Gene lists were initially examined for enriched pathway terms by 
comparing the genes to 176 pathway terms in the “WikiPathways_2019_Mouse” database with 
a gene coverage of 4558 genes. Bar chart visualisation of pathway enrichment analysis was 
produced through the Enrichr webtool and modified. Pathway map visualisation was generated 
through MetaCore™ from Thomson Reuters. 
Further enrichment analysis of GO terms involved comparing gene sets to the following gene-
set libraries from Enrichr:  
“GO_Biological_Process_2018” (5103 terms, 14433 gene coverage), 
“GO_Molecular_Function_2018” (1151 terms, 11459 gene coverage), 
“GO_Cellular_Component_2018” (446 terms, 8655 gene coverage).  
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4.3 RESULTS  
 
4.3.1 Differential gene expression at baseline  
 
The transcriptome profiles from each RYR1 knock-in mouse genotype was compared to WT 
to identify genes differentially expressed at baseline (Adjusted p-value <0.05). The WT vs 
G2435R-RYR1 HET comparison showed only one gene, Blvrb (log2FC 0.88), upregulated in 
G2435R-RYR1 HET muscle. In contrast, a much larger set of 393 genes were differentially 
expressed in the WT vs G2435R-RYR1 HOM comparison with 98 genes upregulated (0.19 to 
1.47 log2FC) and 295 downregulated (-0.16 to -7.14 log2FC) in G2435R-RYR1 HOM. 
Likewise, the WT vs T4826I-RYR1 HET comparisons featured 206 differentially expressed 
genes with 82 upregulated (0.24 to 6.96 log2FC) and 124 downregulated (-0.16 to -5.06 
log2FC) in T4826I-RYR1 HET. These three gene sets were cross compared on a Venn diagram 
to identify genes in common (Figure 4.1).  
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Cross comparison of differential gene expression between RYR1 knock-in mice at 
baseline. The WT vs G2435R-RYR1 HET (1 gene, orange), WT vs G2435R-RYR1 HOM (393 genes, 
red) and WT vs T4826I-RYR1 HET (206 genes, blue) gene sets were compared and overlapping genes 
are highlighted with an asterisk.  
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Only Blvrb was found differentially expressed (upregulated) in all three WT vs RYR1 
knock-in comparisons, whilst 16 genes were exclusively shared between the WT vs G2435-
RYR1 HOM and WT vs T4826I-RYR1 HET gene sets (Figure 4.1). The expression levels of 
these 16 genes in both RYR1 knock-in genotypes followed the same directionality in 
comparison to WT, aside from Ide which was upregulated in T4826I-RYR1 HETs (0.59 
log2FC) and downregulated in G2435R-RYR1 HOMs (-0.31 log2FC). Within this short list of 
genes, another noteworthy finding was the gene expression of Ryr1 which was significantly 
reduced in both G2435R-RYR1 HOM (-0.78 log2FC) and T4826I-RYR1 HET (-0.93 log2FC) 
mice in comparison to WT (Table 4.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1. A summary of all data associated with differentially expressed genes found in common 
across multiple RYR1 knock-in genotypes. Genes of interest are displayed in alphabetical order and 
the directionality of change in comparison to WT mice is represented by log2FC values (negative = 
downregulated, positive = upregulated) alongside their respective adjusted p-values (padj).  
 
 
Gene Log2FC padj Log2FC padj Log2FC padj
Abca5 -0.35 1.97E-02 -0.50 8.00E-05
Acadm -0.30 6.43E-03 -0.27 3.01E-02
Adk -0.25 3.98E-02 -0.35 1.63E-03
Blvrb 0.88 3.91E-03 1.47 2.82E-15 0.87 8.63E-05
Decr1 -0.33 1.41E-02 -0.31 3.69E-02
Dlat -0.27 9.87E-03 -0.24 4.77E-02
Ech1 -0.87 1.50E-13 -0.46 1.36E-03
Eif4a2 -0.16 1.46E-02 -0.16 1.68E-02
Eif4g2 -0.17 6.66E-03 -0.16 2.67E-02
Gm13910 -0.42 1.12E-03 -0.37 7.69E-03
Ide -0.31 3.33E-02 0.59 1.08E-07
Lgals4 -1.58 2.09E-09 -0.88 6.02E-03
Lrtm1 -0.45 2.57E-02 -0.60 1.22E-03
Ryr1 -0.78 5.28E-08 -0.93 7.20E-13
Smad3 -0.40 1.41E-02 -0.37 4.98E-02
Srpr -0.28 1.44E-02 -0.29 1.57E-02
Uqcrc2 -0.22 1.51E-02 -0.22 2.07E-02
G2435R-RYR1 HOMG2435R-RYR1 HET T4826I-RYR1 HET
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4.3.2 MA plots 
 
Global gene expression differences at baseline were visualised using MA plots which display 
the comparisons between G2435R-RYR1 HET, HOM and T4826I-RYR1 HET mice against 
WT mice (Figure 4.2). MA plots present gene expression changes between two conditions as 
two-dimensional scatter plots in terms of log2FC (M) on the y-axis and the mean of normalised 
gene expression counts (A) on the x-axis. The MA plot for G2435R-RYR1 HETs against WT 
show very little difference between genotypes as only one gene was differentially expressed. 
In contrast, both the plots for G2435R-RYR1 HOM and T4826I-RYR1 HETs against WT show 
many differentially expressed genes (adjusted p-value <0.05) but the gene expression in 
T4826I-RYR1 HETs appear more spread out along the y axis indicating greater range in effect 
sizes overall.
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Figure 4.2. MA plots visualising global gene expression changes between RYR1 knock-in mouse 
genotypes. The log2FC were shrunken (Zhu et al., 2019) to remove the noise associated with log2FC 
from low count genes. These shrunken log2FC (y-axis) are plot against mean of normalised gene 
expression counts (x-axis). Plots A), B) and C) reflect the global gene expression changes in the WT vs 
G2435R-RYR1 HET, WT vs G2435R-RYR1 HOM and WT vs T4826I-RYR1 HET comparisons, 
respectively. Genes which are differentially expressed adjusted p-value < 0.05 are highlighted in red. 
The triangles indicate genes which are expressed at a log2 fold change that exceeds the y-axis limits. 
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4.3.3 Pathway enrichment analysis 
 
The lists of differentially expressed genes (adjusted p-value < 0.05) from the WT vs G2435R-
RYR1 HOM and WT vs T4826I-RYR1 HET comparisons were divided into up/downregulated 
subgroups and used as inputs for pathway enrichment analysis through Enrichr. The WT vs 
G2435R-RYR1 HET comparison was not used as there was only one differentially expressed 
gene. The top 10 upregulated pathways output for WT vs G2435R-RYR1 HOM only contained 
one statistically significant term (adjusted p-value < 0.05) ‘MAPK signalling pathway WP493’ 
upregulated in G2435R-RYR1 HOM muscle (see Appendix 12). Likewise, there was also a 
lack of observations in the WT vs T4826I-RYR1 HET comparison, which had no significantly 
upregulated pathways (see Appendix 13). 
In contrast, many downregulated genes in the WT vs G2435R-RYR1 HOM comparison 
were successfully grouped, featuring seven significantly enriched pathway terms, all of which 
were related to cellular energy production (Figure 4.3). In particular, the top four 
downregulated pathways: ‘Fatty Acid Beta Oxidation WP1269’, ‘Mitochondrial LC-Fatty Acid 
Beta-Oxidation WP401’, ‘Fatty Acid Biosynthesis WP336’ and ‘Fatty acid oxidation WP2318’ 
were all involved with fatty acid oxidation. Likewise, a similar feature was also found in the 
WT vs T4826I-RYR1 HET comparison. The top three significantly downregulated pathways 
were all related to fatty acid oxidation, but only ‘Fatty acid oxidation WP2318’ was statistically 
significant (Figure 4.3). 
 
 
 
 
 
 
 
 
 
129 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Bar chart visualisation of pathway analysis generated by Enrichr. The top 10 
downregulated pathways are shown for the WT vs G2435R-RYR1 HOM (red) and WT vs T4826I-
RYR1 HET (orange) comparisons, in combined score order (log of p-value from Fisher’s exact test 
multiplied by z score of deviation from expected rank). Significantly downregulated genes generated 
from DESeq2 analysis were used as input. Coloured bars represent statistically significant terms 
(adjusted p-value < 0.05). 
 
Following pathway enrichment analysis, a fatty acid β-oxidation pathway map was then created 
to visualise the genes found downregulated in both G2435R-RYR1 HOM and T4826I-RYR1 
HET genotypes (Figure 4.4). 
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Figure 4.4. Schematic diagram of the mitochondrial fatty acid β-oxidation pathway.  This diagram 
was generated using MetaCore™ and provides an overview of the proteins involved with fatty acid β-
oxidation within mitochondria. Proteins encoded by genes found under the pathway term 
‘Mitochondrial LC-Fatty Acid Beta-Oxidation WP401’ by Enrichr are highlighted by coloured circles 
(red = downregulated in G2435R-RYR1 HOM, orange = downregulated in T4826I-RYR1 HET).  
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4.3.4 Gene ontology analysis  
 
Up and downregulated genes (adjusted p-value < 0.05) were functionally grouped based on 
biological processes, molecular function, and cellular component ontology terms. Most of the 
statistically significant observations came from using the downregulated gene set in the WT vs 
G2435R-RYR1 HOM comparison. The top 10 downregulated biological processes in G2435R-
RYR1 HOM mice were all involved in either fatty acid oxidation or fatty acid transport into 
mitochondria (Table 4.1) and only one molecular function term ‘Acetyl-CoA C-acyltransferase 
activity (GO:0003988)’ was significantly downregulated.  
Many genes encoding proteins localised in the mitochondria also appear to be 
downregulated in G2435R-RYR1 HOM, as ‘Mitochondrion (GO:0005739)’, ‘Mitochondrial 
matrix (GO:0005759)’ and ‘Mitochondrial inner membrane (GO:0005743)’ were among the 
top three enriched cellular component terms. The ‘Mitochondrion (GO:0005739)’ contained 
the highest number of differentially expressed genes, including some genes of interest 
‘Ndufs1’, ‘Ndufs2’, ‘Sdha’ and ‘Uqcrc2’ which encode for mitochondrial complexes I, II and 
III of the electron transport chain (Table 4.1). Analysis of upregulated genes for the WT vs 
G2435R-RYR1 HOM comparison showed no significant enrichment of biological process or 
molecular function terms, and the only statistically significant finding was in the cellular 
component terms: ‘Cytoskeleton (GO:0005856)’, ‘Cell cortex part (GO:0044448)’, ‘Secretory 
granule lumen (GO:0034774)’, ‘Caveola (GO:0005901)’, ‘Focal adhesion (GO:0005925)’(see 
Appendix 14).  
In comparison, the same analysis using downregulated genes in the WT vs T4826I-
RYR1 HET gene set shared several of the same biological process terms surrounding fatty acid 
metabolism, but these were not found to be statistically significant (see Appendix 15). The only 
shared observation between the two WT vs G2435R-RYR1 HOM and the WT vs T4826I-
RYR1 HET comparisons was an enrichment of genes in the cellular component terms 
‘Mitochondrion (GO:0005739)’ and ‘Mitochondrial matrix (GO:0005759)’.  
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Gene Ontology analyses for WT vs G2435R-RYR1 HOM comparison (downregulated) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.2. Gene ontology analyses (downregulated genes) for the WT vs G2435R-RYR1 HOM 
comparison. The significantly downregulated gene list from the WT vs G2435R-RYR1 HOM 
comparison was used as input for Enrichr and the top 10 terms for biological process, molecular function 
and cellular component are presented, in p-value ascending order. Continued on next page. 
Downregulated Adjusted p-value Genes
1. Fatty acid beta-oxidation (GO:0006635) 8.84E-08
Abcd3, Acad11, Acadl, Acadm, Acadvl, Acat1, 
Decr1, Etfa, Etfdh, Hadha, Hadhb, Hsd17b4  
2. Fatty acid catabolic process (GO:0009062) 1.05E-05
Abcd3, Acad11, Acadl, Acadm, Acadvl, Acat1, 
Decr1, Hadha, Hadhb, Hsd17b4, Mut  
3. Fatty acid oxidation (GO:0019395) 1.50E-05
Abcd3, Acad11, Acadl, Acadm, Acadvl, Acat1, 
Decr1, Hadha, Hadhb, Hsd17b4  
4. Fatty acid beta-oxidation using acyl-CoA 
dehydrogenase (GO:0033539)
8.25E-05 Acad11, Acadl, Acadm, Acadvl, Etfa, Etfdh   
5. Long-chain fatty acid transport 
(GO:0015909)
2.62E-03 Acacb, Acsl1, Cd36, Cpt1b, Cpt2, Prkaa2     
6. Mitochondrial transmembrane transport 
(GO:1990542)
9.58E-03 Acacb, Afg3l2, Cpt1b, Cpt2, Prkaa2, Timm29   
7. Fatty acid transmembrane transport 
(GO:1902001)
1.17E-02 Acacb, Cpt1b, Cpt2, Prkaa2  
8. Carnitine shuttle (GO:0006853) 1.33E-02 Acacb, Cpt1b, Cpt2, Prkaa2  
9. Regulation of fatty acid oxidation 
(GO:0046320)
1.97E-02 Acadl, Acadvl, Lonp2, Mlycd
10. Regulation of acyl-CoA biosynthetic 
process (GO:0050812)
2.19E-02 Dlat, Dld, Pdha1, Pdpr 
1. Acetyl-CoA C-acyltransferase activity 
(GO:0003988)
4.30E-02 Acat1, Hadha, Hadhb
2. 3-hydroxyacyl-CoA dehydrogenase activity 
(GO:0003857)
7.84E-02 Hadha, Hadhb, Hsd17b4
3. Acyl-CoA dehydrogenase activity 
(GO:0003995)
8.27E-02 Acad11, Acadl, Acadm, Acadvl
4. Aminoacyl-tRNA ligase activity 
(GO:0004812)
9.50E-02 Eprs, Iars, Iars2, Lars, Tarsl2  
5. Nucleoside-triphosphatase activity 
(GO:0017111)
1.02E-01
Abcd3, Ddx6, Dnajc27, Eif4a2, Gfm1, Hspa9, 
Hspd1, Kif1b, Kif16b, Kif21a, Myh8, Mut, 
Rab10, Rhou, Rragd, Tsr1, Vwa8   
6. Adenylate cyclase binding (GO:0008179) 1.23E-01 Adcy2, Akap6, Cap2
7. RNA binding (GO:0003723) 1.53E-01
Adk, Akap1, Atxn2, Cd, Cefl1, Cluh, Ddx21, 
Ddx6, Eif4A2, Eif4G2, Eprs, Fastkd2, G2Bp2, 
Gfm1, Gpatch1, Hadhb, Hdlbp, Hspa9, Hspd1, 
Immt, Larp18, Lrpprc, Map3K20, Map4, 
Mrps12, Msi2, Mtif2, Mtdh, Nap1L4, Otud4, 
Polr2B, Ptcd3, Rrp12, Sf3B2, Smad3, Uso1, 
Tsr1 
8. Voltage-gated cation channel activity 
(GO:0022843)
1.57E-01
Cacna1s, Cacna2d1, Itgav, Kcnq5, Kcnma1, 
Lrrc38, Ryr1      
9. Flavin adenine dinucleotide binding 
(GO:0050660)
1.67E-01 Acad11, Acadl, Etfa, Etfdh, Oxnad1   
10. Protein transporter activity (GO:0008565) 2.02E-01 Cse1l, Ipo7, Kpna3, Kpna6, Uso1, Vps35 
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Downregulated Adjusted p value Genes
1. Mitochondrion (GO:0005739) 3.09E-11
Acacb, Acadl, Acadm, Acadvl, Acat1, Acsl1, 
Afg3l2, Akap1, Alas1, Bcl2l13, Coq3, Cpt1b, 
Cpt2, Cs, Decr1, Dlat, Dld, Dnaja3, Ech1, Etfa, 
Fastkd2, Gfm1, Hadha, Hadhb, Hsdl2, Hspa9, 
Hspd1, Iars2, Ide, Immt, Lrpprc, Mlycd, Mrs2, 
Msrb3, Mtif2, Mut, Ndufs1, Ndufs2, Ogdh, 
Oxnad1, Pdha1, Pdpr, Pptc7, Ptcd3, Sdha, 
Slc25a12, Taco1, Timm44, Uqcrc2, Vps35, 
Vwa8, Yme1l1                       
2. Mitochondrial matrix (GO:0005759) 9.04E-10
Acadl, Acadm, Acadvl, Acat1, Alas1, Coq3, Cs, 
Decr1, Dlat, Dld, Dnaja3, Etfa, Etfdh,   Gfm1, 
Hspa9, Hspd1, Iars2, Mlycd, Mut, Ndufs1, 
Ndufs2, Nsun4, Ogdh, Pdha1, Pdpr, Timm44        
3. Mitochondrial inner membrane 
(GO:0005743)
4.89E-03
Acad11, Abcb7, Afg3l2, Cpt2, Hadha, Hadhb, 
Hspd1, Immt, Mrps12, Mrs2, Ptcd2, Sdha, 
Slc25a12, Timm29, Timm44, Uqcrc2, Yme1l1
4. Microbody (GO:0042579) 9.86E-03
Abcd3, Acad11, Ech1, Hsd17b4, Hsdl2, Ide, 
Lonp2, Mlycd 
5. Peroxisome (GO:0005777) 1.23E-02
Abcd3, Acad11, Ech1, Hsd17b4, Hsdl2, Ide, 
Lonp2, Mlycd 
6. Peroxisomal matrix (GO:0005782) 3.53E-02 Abcd3, Hsd17b4, Ide, Lonp2, Mlycd
7. Microbody lumen (GO:0031907) 4.11E-02 Abcd3, Hsd17b4, Ide, Lonp2, Mlycd
8. Endoplasmic reticulum subcompartment 
(GO:0098827)
6.90E-02 Rab10, Rab3gap1, Ryr1 
9. Endoplasmic reticulum tubular network 
(GO:0071782)
1.11E-01 Rab10, Rab3gap1, Stim1 
10. Early endosome (GO:0005769) 1.30E-01
Hspd1, Igf2r, Kif16b, Lmtkz, Mmgt1, Snx12, 
Snx27, Tbc1d16, Vps33a, Vps35   
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4.3.5 Differential gene expression in response to halothane  
 
No differentially expressed genes were identified in WT mice after halothane exposure and 
only one, zero and 23 genes were differentially expressed in G2435R-RYR1 HET, HOM and 
T4826I-RYR1 HET genotypes, respectively. The single gene differentially expressed in 
G2435R-RYR1 HET was Gm46620, a non-characterised long non-coding RNA gene and is 
thought to be of low physiological significance. Out of the 23 genes differentially expressed in 
T4826I-RYR1 HETs, 21 were downregulated with an effect size between -0.20 and -3.65 
log2FC. Genes of interest within this list include Pygm (-0.36 log2FC), Pgm1 (-0.33 log2FC) 
and Atp2a1 (-0.26 log2FC) implicated in metabolic deficiencies and Ca2+ dysregulation. The 
minor effects of halothane exposure within all four RYR1 genotypes suggest that the halothane 
treatment was not effective and failed to trigger a physiologically relevant response. 
 
4.3.6 Relationships between samples 
 
The relationships between samples were examined and visualised using a PCA plot (Figure 
4.5). The gene expression count data for all 24 samples was plotted together and the highest 
degrees of variability occurs between the T4826I-RYR1 HET and G2435R-RYR1 HOM 
sample genotypes as shown by the distant clustering on the horizontal PC1 axis. The WT and 
G2435R-RYR1 HET samples in comparison are loosely clustered together in the centre, 
showing similar global gene expression, as expected from the results previously described. 
Likewise, the halothane-treated samples within each genotype are clustered with the baseline 
control samples showing a close relationship. Variability on the vertical PC2 axis is the greatest 
within the G2435R-RYR1 HOM genotype as two samples does not seem to cluster effectively. 
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Figure 4.5. Principle component analysis plot examining the relationships between all mouse 
samples. The variance between samples is represented by a percentage (%) on PC1 (x-axis) and PC2 
(y-axis). All 24 mouse samples are plotted with PC1 against PC2 and their respective genotype (WT: 
Red, G2435R-RYR1 HET: Green, G2435R-RYR1 HET: Blue and G2435R-RYR1 HET: Purple) and 
treatment groups (untreated: circle, halothane: triangle).  
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 A sample-sample distance heatmap (Figure 4.6) was also used as an alternative 
visualisation for the overall gene expression differences between samples. Using the 
dendrogram we can see clustering of all WT and G2435R-RYR1 HET samples showing a close 
relationship between these two genotypes. In contrast, the T4826I-RYR1 HET samples formed 
their own distinct cluster in the top left whilst all G2435R-RYR1 HOM samples clustered to 
the bottom right which support the notion that these two genotypes have more divergent 
transcriptome profiles in comparison to G2435R-RYR1 HETs and WT mice. Halothane-
treated samples clustered together with their respective untreated counterparts highlighting the 
lack of effect from the halothane treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6. Expression heatmap of sample-to-sample distances. The distances between each sample 
were calculated using variance-stabilising transformation of count data for overall gene expression. All 
24 mouse samples are plotted against each other to form relationship clusters represented by the 
dendrograms at the top and left side of the heatmap. The intensity of the coloured squares reflects the 
degree of similarity between two samples, ranging from dark blue to pale yellow. 
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4.4 DISCUSSION 
 
This study aimed to provide an insight into how muscle physiology between RYR1 knock-in 
mice differs from WT, by investigating differential gene expression at baseline and after 
halothane exposure. The comparison of transcriptomes, in the absence of MH triggering agents, 
showed that WT and G2435R-RYR1 HET mice have very similar gene expression profiles, 
differing in the expression of only one gene (Blvrb). In contrast, G2435R-RYR1 HOM and 
T4826I-RYR1 HET mice had greater variability in gene expression, featuring 393 and 206 
differentially expressed genes respectively, in comparison to WT. These results show that 
different RYR1 genotypes can impact skeletal muscle gene expression in a variant and gene-
dose dependent manner, which may account for the variability associated with the MH 
phenotype.   
Studies reporting MH genotype-phenotype correlations have shown that individuals 
with the human G2435R-RYR1 mutation (G2434R) have weaker phenotypes in comparison to 
those with the T4826I-RYR1 mutation, who tend to have greater IVCT contracture responses 
to both caffeine and halothane (Carpenter et al., 2009b). Visual inspection of gene expression 
data through the MA plot, PCA plot and heatmap showed that global gene expression between 
WT and G2435R-RYR1 HET mice were almost indistinguishable, which supports the notion 
of G2435R-RYR1 being a weak mutation. Mice with HOM expression of the G2435R-RYR1 
mutation had more divergent gene expression profiles in comparison to the HET equivalent, 
which may reflect a more severe phenotype. Functional characterisation of this mouse model 
by Lopez et al., found that HOM mice had increased phenotype severity over HET mice, based 
on their responses during MH reactions (Lopez et al., 2018). On that basis, it is possible that 
greater differences in baseline gene expression may contribute to an increased severity of the 
MH phenotype. 
Although rare, a few cases of human MH have been reported with autosomal recessive 
inheritance of RYR1 mutations (Lynch et al., 1997; Rueffert et al., 2001; Monnier et al., 2002; 
Wolak et al., 2014). One of the first studies described an MHS proband carrying two mutant 
alleles of the RYR1 Cys35Arg mutation, arising from consanguineous parents, both of whom 
were MHS (Lynch et al., 1997). In this study a large pedigree of 18 individuals were 
investigated, in which two were found to be recessive carriers. IVCT muscle contracture 
strengths in response to 2 mM caffeine were significantly higher in these two individuals, but 
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responses to halothane were indistinguishable from MHS family members carrying one 
mutation (Lynch et al., 1997). This was similar to the observations made in another MHS 
pedigree where individuals with recessive inheritance of the RYR1 Arg614Cys mutation, had 
stronger IVCT contracture strengths in response to both drugs (Rueffert et al., 2001). These 
findings present some evidence of increased IVCT phenotype severity in relation to RYR1 
gene-dose but due to low sample size and limited data from human cases, definitive conclusions 
on this feature cannot be made.  
To identify genes in common across comparisons (WT vs G2435R-RYR1 HET, WT 
vs G2435R-RYR1 HOM and WT vs T4826I-RYR1 HET), each list of differentially expressed 
genes was contrasted against one another to reveal 17 genes that were differentially expressed 
in more than one comparison. Among these genes, Blvrb was the only transcript upregulated 
in all three RYR1 knock-ins tested. Blvrb encodes for the enzyme biliverdin reductase B 
(BLVRB), which has a role in heme metabolism and redox regulation (Paukovich et al., 2018; 
Shalloe et al., 1996). A recent study showed that induced pluripotent stem cells infected with 
lentiviruses expressing BLVRB, have enhanced redox activity and reduced ROS accumulation 
(Wu et al., 2016). The increase in Blvrb gene expression observed in this study may reflect a 
cytoprotective response to help reduce ROS accumulation in these MH mice, as increased 
oxidative stress has been reported in multiple RYR1 knock-in mouse models (Durham et al., 
2008; Boncompagni et al., 2009; Canato et al., 2019; Giulivi et al., 2011). With regards to the 
G2435R-RYR1 mouse model specifically, a colleague within the Leeds MH Unit, Dr Xiaochen 
Liu, has recently found evidence of elevated ROS production and altered redox regulation 
within this mouse line which supports this hypothesis (Chang et al., 2020)(discussed in more 
detail in chapter 5, section 5.4). 
Functional annotation of gene lists found that most downregulated genes in both 
G2435R-RYR1 HOM and T4826I-RYR1 HET mice encoded proteins localised within 
mitochondria. Many of these genes were responsible for regulating fatty acid metabolism 
which is an important source of energy in skeletal muscle. Free fatty acids (FFA) are 
metabolised by first undergoing β-oxidation to generate acetyl coenzyme A (CoA), which is a 
substrate for the Krebs cycle in the mitochondrial matrix (Turner et al., 2014). Impairment of 
fatty acid oxidation and transport leads to an accumulation of FFA in skeletal muscle causing 
lipotoxicity - associated with insulin resistance, oxidative stress, and mitochondrial dysfunction 
(Turner et al., 2014; Wajner and Amaral, 2015; Vishwanath, 2016). Based on the gene 
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expression profiles generated, a deficiency in fatty acid β-oxidation may be present in the 
G2435R-RYR1 HOM and T4826I-RYR1 HET mouse genotypes (Figure 4.7).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7. Schematic diagram of the fatty acid β-oxidation pathway. Genes encoding enzymes 
within the pathway, were found downregulated in G2435R-RYR1 HOM (highlighted by the red box) 
and T4826I-RYR1 HET mice (highlighted by the orange box). The genes Acadm, Acadl and Acadvl 
encode for medium-chain, long-chain, and very long-chain acyl-CoA dehydrogenase respectively 
(MCAD, LCAD and VLCAD), which target fatty acids of various lengths. These enzymes catalyse the 
first step of fatty acid β-oxidation which involves the dehydrogenation of acyl-CoA to trans-2,3-enoyl-
CoA (Houten et al., 2016). Echs1 encodes the short-chain enoyl-CoA hydratase, which catalyses the 
second step, generating 3-hydroxyacyl-CoA through hydration (Kanazawa et al., 1993). This is 
subsequently followed by dehydrogenation to form 3-ketoacyl-CoA, catalysed by 3-hydroxyacyl-CoA 
dehydrogenase (encoded by Hadha). Finally, 2-ketoacyl-CoA thiolase (encoded by Hadhb) cleaves the 
3-ketoacyl-CoA to form an acetyl-CoA and a shortened acyl-CoA (Houten et al., 2016). This image 
was taken and modified from Wikimedia Commons, made available under the terms of the Creative 
Commons Attribution-Share Alike 3.0 Unported (https://creativecommons.org/licenses/by-
sa/3.0/deed.en). 
 
140 
 
Several genes encoding enzymes within the fatty acid β-oxidation pathway were 
downregulated in G2435R-RYR1 HOM mice whilst only two were differentially expressed in 
T4826I-RYR1 HET mice. Furthermore, carnitine palmitoyltransferases 1b (CPT1B) and 2 
(CPT2) (encoded by Cpt1b and Cpt2 respectively), which facilitate the transport of fatty acids 
into mitochondria through the carnithine cycle, were downregulated in G2435R-RYR1 HOM 
mice only (Longo et al., 2006). These differences between genotype suggest that fatty acid 
metabolism in G2435R-RYR1 HOM mice is more severely impaired in comparison to T4826I-
RYR1 HET mice.  
In humans, mutations in many of the genes discussed (Acadm, Acadvl, Hadha, Hadhb, 
Cpt2 and Echs1) cause enzyme deficiencies which are associated with fatty acid oxidation 
disorders (FAOD) (Merritt et al., 2018). FAOD can be asymptomatic or rapidly fatal and often 
manifest during infancy, with an autosomal recessive mode of inheritance. Examples of FAOD 
related to genes of interest include: MCAD deficiency (mutations in Acadm), VLCAD 
deficiency (mutations in Acadvl), Long-chain 3-hydroxy acyl-CoA dehydrogenase deficiency 
(mutations in Hadha), trifunctional protein deficiency (mutations in Hadha and/or Hadhb), 
CPT2 deficiency (mutations in Cpt2) and Leigh syndrome (mutations in Echs1) (Zschocke et 
al., 2001; Strauss et al., 1995; IJlst et al., 1994; Brackett et al., 1995; Naiki et al., 2014; Elpeleg 
et al., 2001; Sakai et al., 2015). Common clinical symptoms associated with these FAOD 
include hypoketotic hypoglycaemia, cardiomyopathy, arrhythmias and conduction defects, 
myopathy, and rhabdomyolysis (Houten et al., 2016; Merritt et al., 2018). 
Connections between FFA and MH pathology were first described in MHS pigs after 
significantly higher levels of FFA and phospholipase activity were found in mitochondria 
(Cheah, 1981; Cheah and Cheah, 1981a; Cheah and Cheah, 1981b). Several years later, 
elevated FFA production in MHS human muscle was linked to increased sensitivity to 
halothane (Fletcher et al., 1991a; Fletcher and Rosenberg, 1986; Fletcher et al., 1991b). It was 
hypothesised that FFA and lipid peroxidation contributed to Ca2+ dysregulation by inducing 
Ca2+ release from the SR, with potential to modulate the MH phenotype (Rosenberg et al., 
2015; Cheah and Cheah, 1981b; Cheah et al., 1989; Duthie et al., 1992). More recently, a study 
also speculated that mice with the R163C-RYR1 mutation associated with MH had reduced 
fatty acid oxidation due to observing a lower expression of enzymes regulating this process 
(Giulivi et al., 2011; Hardie and Pan, 2002). The data generated from this RNAseq experiment 
suggests that fatty acid oxidation may indeed be deficient in MHS muscle and may contribute 
towards the MH phenotype, which warrants further investigation. 
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Follow up work on this study would first involve selecting genes of interest within the 
fatty acid β-oxidation pathway and validating them using RT-PCR to confirm RNAseq 
findings. From there, western blotting should be used to quantify the expression levels of the 
encoded proteins, to see if the downregulation in mRNA corresponds to a downregulation at 
the protein level. This can be further supplemented with functional studies using skeletal 
muscle carrying different MH-associated RYR1 mutations. One approach would be to use the 
Agilent seahorse XF analyser which allows functional testing of mitochondria through cell 
culture plate formats. Mitochondrial function and fatty acid oxidation can be assessed within 
myotubes cultured from different RYR1 knock-in mouse genotypes, using the XF Cell Mito 
Stress test and palmitate-BSA substrate kits developed by Agilent. Any differences found 
between RYR1 genotypes would support the connection between MH and fatty acid oxidation 
suggested by the gene expression data presented. 
Aside from fatty acid oxidation, other genes of interest include mitochondria-related 
genes such as Ndufs1 and Ndufs2 (encoding subunits of complex I), Sdha (encoding subunit A 
of complex II) and Uqcrc2 (encoding a subunit of complex III), all of which were 
downregulated in G2435R-RYR1 HOM mice when compared to WT. The proteins encoded 
by these genes are involved in OXPHOS and their downregulation implies functional 
impairment of skeletal muscle at rest. These genes were not downregulated in G2435R-RYR1 
HET mice, and only Uqcrc2 was downregulated in the T4826I-RYR1 HET genotype. Intact 
myotubes from T4826I-RYR1 HET and HOM mice have been reported with evidence of lower 
oxygen consumption rates and mitochondrial content in comparison to WT (Barrientos et al., 
2012), and this might be related to reduced mitochondrial complex III expression. All RYR1 
knock-in mouse models of MH, except for G2435R-RYR1, have had reports of mitochondrial 
defects (Giulivi et al., 2011; Barrientos et al., 2012; Canato et al., 2019), and these deficiencies 
may correlate with the downregulation of OXPHOS gene expression. This topic of 
mitochondrial dysfunctional within RYR1 knock-in mice will be investigated further in 
Chapter 5 of this thesis.  
With regards to treatment effects, gene expression changes in response to halothane 
exposure were very modest and resulted in surprisingly few changes between genotypes. The 
experimental conditions for this mouse study were designed to be a simplified version of the 
IVCT halothane treatment, with fewer confounding variables. Instead of incremental 
concentrations of halothane, a static concentration of 2 Vol% halothane was used over 30 
minutes. This exposure time was thought to be sufficient for gene expression changes to occur, 
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as many genes were found to be differentially expressed within a similar time frame, in the 
human RNAseq experiment described in chapter 2, section 2.3.6. The electrical stimulation 
usually applied to the muscle sample at the start of the IVCT was also removed so that 
differences in gene expression could be attributed to halothane exposure alone.  
Visual inspection of PCA plots and heatmaps showed that halothane-treated samples 
clustered together with the untreated baseline samples within each genotype, indicating little 
to no treatment effect. Gene expression in WT and G2435R-RYR1 HOM muscle was 
unaffected by halothane exposure and the only gene differentially expressed in G2435R-RYR1 
HET muscle (Gm46620) has not been functionally characterised. In contrast, halothane 
exposure had the most pronounced effect on T4826I-RYR1 HET mouse gene expression with 
several genes downregulated after treatment. Genes of interest in this response include Pygm, 
Pgm1 and Atp2a1 which have been implicated in metabolic deficiencies and Ca2+ regulation 
(McArdle, 1951; Stojkovic et al., 2009; Zhang et al., 1995). 
Pygm encodes myophosphorylase which is an enzyme that catalyses and regulates the 
breakdown of glycogen to glucose-1-phosphate during glycogenolysis (Gautron et al., 1987). 
In humans, mutations within this gene are associated with McArdle disease, which is a 
recessively inherited condition that prevents the breakdown of glycogen in skeletal muscle 
(McArdle, 1951). Individuals with this condition often exhibit symptoms of fatigue, cramping, 
muscle stiffness/weakness and exercise intolerance (Di Mauro, 2007). In cases of sustained 
exercise, more severe symptoms may include myoglobinuria, rhabdomyolysis and acute renal 
failure (Quinlivan et al., 2010). The inability to breakdown glycogen impairs energy production 
during exercise which affects glycolysis directly and OXPHOS indirectly through the lack of 
pyruvate availability.  
Three variants (c.148C>T, c.577G>T and c.1279C>T) in PYGM (human orthologue of 
Pygm) were recently reported in three individuals with exertional heat illness (EHI) (Gardner 
et al., 2020), a condition characterised by the inability to thermoregulate during physical 
activity (American College of Sports et al., 2007). Both EHI and MH have similar 
pathophysiology, presenting with common symptoms such as hyperthermia, tachycardia, 
metabolic and respiratory acidosis, muscle cramps, rhabdomyolysis, multiorgan failure, 
disseminated intravascular coagulation and death (Capacchione et al., 2010). In the study by 
Gardner et al., the individual carrying the PYGM c.148C>T mutation, and two of the three 
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individuals carrying the PYGM c.577G>T mutation were also found to be MHSh, diagnosed 
through the IVCT (Gardner et al., 2020).   
Pgm1 encodes phosphoglucomutase-1 (PGM1), an enzyme with a role in both 
glycolysis and gluconeogenesis, catalysing the transfer of phosphate between the 1- and 6- 
positions of glucose (Putt et al., 1993). Similar to the symptoms of McArdle disease, PGM1 
deficiency in adults has been associated with exercise intolerance, rhabdomyolysis, elevated 
muscle glycogen content, hypoglycaemia and elevated creatine kinase levels (Stojkovic et al., 
2009; Morava, 2014). The reduced expression of both these genes after halothane exposure 
indicates a shift in metabolic regulation which impairs energy production. This would likely 
contribute to the rapid depletion of ATP from involuntary muscle contractures during fulminant 
MH reactions which accelerates cell death. 
In addition to energy production mechanisms, exposure to halothane appears to alter 
the expression of genes regulating intracellular Ca2+ in T4826I-RYR1 HET muscle. The gene 
Atp2a1 encodes SERCA1, which is an enzyme that catalyses the hydrolysis of ATP coupled 
with the translocation of Ca2+ from the cytosol into the SR to replenish Ca2+ stores (Zhang et 
al., 1995). Mutations in Atp2a1 are associated with the autosomal recessive inheritance of 
Brody disease, a skeletal muscle disorder characterised by exercise-induced impairment of 
skeletal muscle relaxation (Brody, 1969). Individuals with Brody disease have reduced 
expression of SERCA1 and the delay in muscle relaxation is attributed to deficiencies in Ca2+ 
uptake into the SR which results in the increase of intracellular Ca2+ levels (Guglielmi et al., 
2013). A variant (c.1613C>T) in ATP2A1 (human orthologue of Atp2a1) was also recently 
reported in an individual with both EHI and MH susceptibility (Gardner et al., 2020). The 
downregulation of Atp2a1 in response to halothane may contribute towards the involuntary 
muscle contractures by further disrupting Ca2+ regulation and during MH reactions.  
These observations suggest that the method of halothane treatment was not appropriate 
to elicit changes in gene expression. This may be due to insufficient halothane exposure time 
or dosage, despite the human RNAseq results (chapter 2, section 2.3.6), used to inform this 
experimental design. The effects of these variables on gene expression are difficult to address 
due to the limitations associated with RNAseq experiments. In an ideal scenario, each mouse 
sample would be treated with multiple different concentrations of halothane over a range of 
timepoints to assess the effects of both exposure time and drug dose on gene expression. 
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However, this experimental design would be extremely costly to perform using RNAseq, as 
many sequencing lanes would be required to achieve appropriate read depth for each sample.  
As previously mentioned in chapter 2, section 2.4, this experiment can be refined by 
first addressing these variables through drug dose response and time course experiments on 
cultured myotubes. A microplate reader can be used to measure Ca2+ flux in myotubes using a 
Ca2+-sensitive fluorescent dye. The halothane dose which results in the maximum response in 
Ca2+ flux can be chosen and applied over a range of timepoints, before RNA is extracted from 
each sample. RT-PCR can then be used to measure gene expression levels at each timepoint, 
and this information can then be used to better inform the RNAseq design. Unlike RNAseq, 
this strategy requires a pre-selection of specific genes to assess through RT-PCR. Since MH is 
a condition associated with Ca2+ dysregulation in skeletal muscle, genes involved with Ca2+ 
homeostasis may be a good target for this process.  
 In summary, the results observed in this study have highlighted differences in baseline 
gene expression between RYR1 knock-in mouse genotypes. Gene expression profiles from 
G2435R-RYR1 HET mice are virtually indistinguishable from WT at baseline. In contrast, the 
G2435R-RYR1 HOM and T4826I-RYR1 HET genotypes showed greater disparity in gene 
expression which may be associated with differences in phenotype severity. Fatty acid 
metabolism should be studied further in the context of MH as many genes involved in this 
pathway were downregulated in RYR1 mutant muscle. This suggests that defects in fatty acid 
oxidation contribute towards the MH phenotype. Further investigations in this area may involve 
RT-PCR validation of RNAseq results, quantification of associated protein expression, and 
functional testing of mitochondria using fatty acid substrates. Genes involved with metabolic 
deficiencies and Ca2+ regulation were downregulated after halothane exposure in T4826I-
RYR1 HET mice only.  This may reflect a genuine lack of gene expression change in the 
G2435R-RYR1 knock-in model or that the halothane treatment applied was ineffective, which 
need to be refined. This can be achieved through a combination of dose-response and time 
course experiments which will help identify optimal conditions required for gene expression 
change.  
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5 BIOENERGETIC DEFECTS IN RYR1 KNOCK-IN MICE 
 
5.1 INTRODUCTION 
 
Evidence of mitochondrial defects have been reported in the first three RYR1 knock-in mouse 
models associated with MH, supporting a link between MH susceptibility and mitochondrial 
dysfunction (Durham et al., 2008; Boncompagni et al., 2009; Michelucci et al., 2017; Canato 
et al., 2019; Giulivi et al., 2011; Barrientos et al., 2012; Yuen et al., 2012). These reports have 
described gross morphological changes in skeletal muscle mitochondria followed by evidence 
of functional deficiencies either through alterations in ROS homeostasis or oxygen 
consumption rates.  
The first description of mitochondrial defect was in the Y522S-RYR1 mouse model 
associated with both MH and central core disease (Durham et al., 2008). Examination of muscle 
fibres from Y522S-RYR1 HET mice showed many damaged mitochondria, characterised by 
abnormal size and shape, swelling, loss of matrix density, disorganisation of cristae and 
external membrane disruption (Durham et al., 2008). These observations were supported by 
Boncompagni et al. who identified signs of mitochondrial damage as early as eight weeks of 
age, in addition to central cores devoid of mitochondria which increased in size with age 
(Boncompagni et al., 2009). Similar structural abnormalities have also been reported in the 
T4826I-RYR1 mouse model, which shows that these features are not exclusive to Ryr1 variants 
associated with central core disease (Yuen et al., 2012). Histological examination of Soleus 
muscles from this model identified abnormal distribution of enlarged mitochondria with deeply 
infolded sarcolemma and increased severity in males, indicating a sex-dependent phenotype 
(Yuen et al., 2012).  
The cause of mitochondrial damage in RYR1 knock-in mice has been attributed to 
oxidative stress with evidence of increased ROS production reported in multiple studies 
(Durham et al., 2008; Boncompagni et al., 2009; Canato et al., 2019). It was proposed that the 
elevated intracellular Ca2+ detected in RYR1 mutant myotubes increases ROS output from 
mitochondria, resulting in cellular damage over time and myopathic traits (Boncompagni et al., 
2009). In support of this hypothesis, a study has shown reduced mitochondrial damage in 
Y522S-RYR1 HET mice after treating their drinking water with antioxidants (Michelucci et 
al., 2017). Furthermore, increased Ca2+ uptake was observed in Y522S-RYR1 mitochondria at 
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rest and after electrical/caffeine stimulation, in addition to reduced ROS accumulation after 
MCU silencing – supporting the connection between ROS production and mitochondrial 
damage (Canato et al., 2019). 
Cellular damage due to oxidative stress causes functional impairment of mitochondria 
which has been demonstrated in both the R163C-RYR1 and T4826I-RYR1 mouse models 
(Giulivi et al., 2011; Boncompagni et al., 2009). Muscle fibres from R163C-RYR1 HET mice 
have been shown to have lower OXPHOS capacity in conjunction with lower expression of 
mitochondrial proteins, believed to be the result of elevated intracellular Ca2+ and increased 
ROS production (Giulivi et al., 2011). Measurements of oxygen consumption in the T4826I-
RYR1 HET and HOM genotypes show a similar pattern with lower oxygen consumption rates 
and reduced mitochondrial number detected in cultured myotubes (Barrientos et al., 2012). 
Following the transcriptomic analysis of G2435R-RYR1 knock-in mice (chapter 4), 
mitochondrial function was investigated using permeabilised muscle fibres. This chapter 
describes the first investigation into mitochondrial dysfunction within the G2435R-RYR1 
mouse model and this was achieved using high resolution respirometry. This technique allows 
oxygen consumption rates to be measured through specific mitochondrial complexes using 
permeabilised muscle fibres, providing the highest level of detail achieved in any MH animal 
study. Three different experiments were conducted, measuring oxygen consumption rates: at 
baseline, after halothane exposure and at different Ca2+ concentrations. HET mice from the 
T4826I-RYR1 mouse model were used as a comparison to assess whether responses have an 
Ryr1 variant-specific effect. The data generated will help to answer the following research 
questions with respect to G2435R-RYR1 knock-in mouse genotypes: 
• Do muscle fibres from RYR1 knock-in mice have different oxygen 
consumption rates to WT at baseline? 
• How does halothane effect oxygen consumption rates within these mouse 
muscle fibres? 
• How does increased [Ca2+] effect oxygen consumption rates within these mouse 
muscle fibres? 
• Do the oxygen consumption rates differ between the two different RYR1 knock-
in mouse models? 
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5.2   METHODS 
 
5.2.1 Animals 
 
Animals were housed in pathogen-free conditions with free access to food, water and 12 hr 
light-and-dark cycles. All experiments were undertaken with UK Home Office approval, 
licence number PB2FB5E94. A mixture of male and female mice (approximately 1:1), between 
the ages of 8-14 weeks old were used for functional respirometry studies.  
 
5.2.2 Muscle sample preparation for respirometry  
 
An adapted SUIT protocol was used to investigate the OXPHOS capacity of individual 
complexes and respiratory states (Kuznetsov et al., 2008; Pesta and Gnaiger, 2012). WT and 
RYR1 knock-in mice (age 8-12 weeks) were killed by cervical dislocation and their Soleus 
muscles were rapidly dissected from their hind limbs and placed into 1 ml of ice-cold biopsy 
preservation buffer, BIOPS (2.77 mM CaK2EGTA, 7.23 mM K2EGTA, 5.77 mM Na2ATP, 
6.56 mM MgCl2·6H2O, 20 mM taurine, 15 mM Na2Phosphocreatine, 20 mM imidazole, 0.5 
mM dithiothreitol (DTT), and 50 mM MES hydrate, pH 7.1, adjusted with 5 N KOH at 0°C) 
immediately after collection for storage and transport.  
Muscle fibre bundles containing approximately 4-5 fibres each were mechanically 
separated from the intact muscles using forceps. These fibre bundles were then exposed to 
chemical permeabilisation in ice cold BIOPS containing saponin (50 μg·ml-1) for 30 minutes, 
before being washed with 1 ml respiration medium, Mir05 (0.5 mM EGTA, 3 mM 
MgCl2·6H2O, 60 mM lactobionic acid, 20 mM taurine, 10 mM KH2PO4, 20 mM HEPES 
adjusted to pH 7.1 with KOH at 37 °C, 110 mM D-sucrose, and 1 g·L-1 essentially fatty acid 
free BSA) to remove residual saponin. Muscle fibre bundles from both legs were then blot-
dried for 5 seconds, weighed and loaded into a respirometer chambers (1-2 mg in each chamber, 
left Soleus chamber A, right Soleus chamber B) containing 2 ml of Mir05. The time between 
biopsy collection and assay was ~90 – 120 min (Chang et al., 2019; Pesta and Gnaiger, 2012). 
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5.2.3 High Resolution Respirometry  
 
Oxygen consumption rates was measured using Oroboros respiratory analysers (Oroboros 
Instruments, Innsbruk, Austria) at two second intervals with polarographic oxygen sensors and 
expressed as mass-specific oxygen flux (pmol/s*mg). The analyser was calibrated daily in air 
saturated solution before experimentation. Assays were initiated by injecting oxygen into each 
chamber to raise the oxygen concentration to >400 nmol/mL prior to starting a SUIT protocol. 
Re-oxygenation of the chambers was performed to maintain oxygen concentration between 
200-500 nmol/mL to prevent limitation due to oxygen diffusion (Pesta and Gnaiger, 2012). 
Each assay was performed at 37 °C, with chamber stirrers set at 750 rpm.  
 
5.2.4 SUIT protocol 
 
An in-depth description of the SUIT protocol is described in chapter 3 section 3.2.4. In brief, 
reagents and inhibitors were sequentially added into the reaction chambers in the order 
displayed (Table 5.1).  
 
 
 
 
 
 
 
 
 
Table 5.1. Summary of the chemical components in the SUIT protocol. The chemical names are 
displayed in the order of application with the respective concentrations applied for each assay. 
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The composition of each respiratory state (in bold) are as follows –  
LEAK: (B, G, M, P)  
CI(OXPHOS): (LEAK + ADP)  
CI+CII(OXPHOS): (LEAK + ADP + CC + S)  
CI+CII(ETS): (LEAK + ADP + CC + S + FCCP)  
CII(ETS): (LEAK + ADP + CC + S + FCCP + R)  
ROX: (LEAK + ADP + CC + S + FCCP + R + AA).  
The ROX state represented residual oxygen consumption outside of mitochondrial function 
and is therefore subtracted from the other states to obtain final readings (Perry et al., 2011; 
Pesta and Gnaiger, 2012; Chang et al., 2019). 
 
5.2.5 Complex IV Assay  
 
Measurement of mass-specific complex IV oxygen flux was used as an alternative proxy 
marker for estimations of mitochondrial content. Ascorbate (2 mM) and TMPD (0.5 mM) were 
applied to each sample at the end of the standard SUIT protocol (Larsen et al., 2012). The 
measurement of CIV(MAX) is taken at the peak of the corresponding trace and residual chemical 
background is finally removed from this value by applying sodium azide (10 mM) to the 
sample. Refer to chapter 3, section 3.2.4, Figure 3.1 for a visual summary of the SUIT and 
complex IV assay protocol. 
 
5.2.6 Halothane treatment 
 
To assess the effects of halothane on oxygen flux, muscle fibre bundles from WT and RYR1-
knock in mice were prepared in the same way as described in section 5.2.2. The muscle fibre 
bundles in chambers A and B were treated as paired samples with samples in chamber A used 
as a control for the samples in chamber B which were exposed to halothane. 1 mM halothane 
was applied as treatment prior to the SUIT protocol, from a stock solution prepared in dimethyl 
sulphoxide (DMSO). In experiments where 1 mM halothane was used, the DMSO 
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concentration was 0.05%. An equal concentration of DMSO 0.05% (without halothane) was 
applied into chamber A to function as control. The SUIT protocol described in section 5.2.4 
was conducted three minutes after the addition of halothane/DMSO. 
 
5.2.7 Calcium assay 
 
Oxygen flux in WT and RYR1 knock-in mice was measured and compared at 0, 100 and 300 
nM concentrations of free Ca2+.  A stock solution of calcium carbonate (CaCO3) was prepared 
in Mir05 and applied to assay chambers using a Hamilton syringe to modify the [Ca2+] in the 
assay medium.  The free [Ca2+] in the assay medium was calculated with the Ca-EGTA 
Calculator v1.3 using constants from Theo Schoenmakers' Chelator (Schoenmakers et al., 
1992). Due to the limitations of the respirometry analyser having only two chambers, the 
assessment of each [Ca2+] was conducted on separate mice and was therefore analysed as 
independent samples rather than paired. The SUIT protocol described in section 5.2.4 was 
conducted three minutes after the addition of CaCO3. 
 
5.2.8 Data handling and analysis (Respirometry) 
 
Data are presented either as oxygen flux per muscle mass (pmol/s*mg) or as FCR normalised 
for mitochondrial content. Oxygen flux readings were exported from specialised software 
DatLab5 (Oroboros Instruments, Innsbruk, Austria) into Microsoft Excel before analysis using 
IBM SPSS statistics v21. Mass-specific oxygen flux and FCR were assessed for normal 
distribution using the Shapiro Wilk test before statistical testing.  
Oxygen consumption rates and FCR data generated from baseline comparisons were 
not normally distributed and analysed using the non-parametric Kruskall-Wallis H test with 
post hoc Dunn’s test. Data collected pre vs post halothane treatment were normally distributed 
and analysed using a two-way mixed analysis of variance (ANOVA). Finally, data from the 
calcium assay was analysed using a two-way ANOVA. P-values generated from pairwise 
comparisons were adjusted for multiple testing using the Bonferroni correction.  
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Figures used to visualise data were created using GraphPad Prism 8. The power 
calculator software G*Power, version 3.1.9.2 was used to calculate sample sizes for each 
experiment (Faul et al., 2007). Post hoc power analysis of preliminary baseline mouse data 
using a total sample size n = 60, achieved 0.97 power, α = 0.05, effect size = 0.58. Sample size 
calculations for halothane and calcium exposure experiments was performed a priori, with the 
aim of achieving 0.8 power, α  = 0.05. An effect size of 0.25 was used, defined as a medium 
size effect, which generated a total sample size n = 48, across four genotypes. 
 
5.3   RESULTS 
 
5.3.1 Baseline comparisons 
 
Baseline oxygen flux was measured from WT (n=16), G2435R-RYR1 HET (n=16), G2435R-
RYR1 HOM (n=16) and T2826I-RYR1 HET (n=12) mice. Results showed that oxygen 
consumption rates significantly differed among RYR1 genotypes in the LEAK (p<0.001), 
CI+CII(ETS) (p=0.024) and CIV(MAX) (p=0.017) states. Post hoc pairwise comparisons (Figure 
5.1) between WT and G2435R-RYR1 HETs showed no significant differences, while the 
G2435R-RYR1 HOMs differed only in CIV(MAX) with significantly lower output than WT 
(p=0.027). This finding suggests that G2435R-RYR1 HOM skeletal muscle fibres may have a 
lower mitochondrial content than WT fibres. T4826I-RYR1 HET knock-ins had lower oxygen 
flux in LEAK (p<0.01 against all genotypes) and a greater ETS capacity (CI+CII(ETS)) 
compared to G2435R-RYR1 HOM mice (p=0.023). 
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Figure 5.1. Mass-specific oxygen flux in permeabilised Soleus muscle across RYR1 mouse 
genotypes. This figure contains data from WT (n = 16, blue), G2435R-RYR1 HET (n = 16, yellow), 
G2435R-RYR1 HOM (n = 16, red) and T4826I-RYR1 HET (n = 12, orange) mice. Boxplots show 
median, IQR and min-max range for each genotype. Statistically significant pairwise comparisons 
(p<0.05) are labelled with an asterisk.
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The confounding variable of mitochondrial content was removed in the mass-specific oxygen 
flux data by normalising to a common reference state, producing FCR (Figure 5.2). FCR 
provide a measure of function as a proportion of ETS capacity, which is independent of 
mitochondrial content. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. Comparison of flux control ratios between RYR1 mouse genotypes. This figure shows 
normalised data from WT (n = 16, blue), G2435R-RYR1 HET (n = 16, yellow), G2435R-RYR1 HOM 
(n =16, red) and T4826I-RYR1 HET (n = 12, orange) mice. FCR are generated by internally normalising 
mass-specific oxygen flux to the CI+CII(ETS) state (indicated by the horizontal dashed line). Boxplots 
show median, IQR and min-max range for each genotype. Statistically significant pairwise comparisons 
(p<0.05) are labelled with an asterisk. 
 
154 
 
Comparison of FCR between RYR1 genotypes differed significantly in the LEAK, 
CI(OXPHOS) and CI+CII(OXPHOS) states (all p<0.001). Pairwise FCR comparisons within the 
LEAK state did not differ from mass-specific oxygen flux after normalisation. However, 
CI(OXPHOS) FCR showed significantly higher values in G2435R-RYR1 HOM compared to WT 
(p=0.014), suggesting a greater reliance on complex I function as it forms a higher proportion 
of the ETS capacity. This was also observed in the CI+CII(OXPHOS) combined state which was 
also significantly higher in G2435R-RYR1 HOM (p=0.004), likely due to the differences in 
complex I. Interestingly, T4826I-RYR1 HET knock-ins showed significantly lower CI(OXPHOS) 
and CI+CII(OXPHOS) FCR in comparison to G2435R-RYR1 HET and HOM knock-ins which 
shows that mitochondrial function can differ depending on the Ryr1 variant present. 
 
5.3.2 Effects of halothane exposure  
 
Oxygen flux was measured with and without exposure to halothane, across all mouse 
genotypes: RYR1 WT (n =15), G2435R-RYR1 HET (n=15), G2435R-RYR1 HOM (n=14), 
T4826I-RYR1 HET (n=10). Two-way mixed ANOVAs were conducted for each respiratory 
state to examine the effects of genotype and halothane on mass-specific oxygen consumption 
rates (pmol/s*mg). Data is presented as mean ± SE, unless otherwise stated. There was no 
statistically significant interaction between genotype and halothane exposure on the oxygen 
consumption rates in any respiratory state. Therefore, analysis of main effects for halothane 
treatment was performed, which indicated a statistically significant difference in CI(OXPHOS), 
CI+CII(OXPHOS) and CI+CII(ETS) (p<0.001, p=0.001 and p<0.001 respectively). Pairwise 
comparisons showed a significant reduction in mean oxygen consumption rates after halothane 
exposure in CI(OXPHOS) (Pre: 129.2±3.8, Post: 67.8±2.9), CI+CII(OXPHOS) (Pre: 207.4±5.9, Post: 
182.6±5.2) and CI+CII(ETS) (Pre: 285.7±8.9, Post: 238.5±7.3). 
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FCR data showed similar observations with a statistically significant reduction after 
halothane exposure in CI(OXPHOS) (Pre: 0.458±0.01, Post: 0.246±0.014, p<0.001) and 
CI+CII(OXPHOS) (Pre: 0.730±0.06, Post: 0.662±0.026, p=0.009). Additionally, a significant 
interaction effect between genotype, halothane and FCR was also observed in CI(OXPHOS) 
(p=0.037). This interaction was followed up by assessing the simple main effects of halothane 
exposure by performing a one-way ANOVA pre and post treatment. The results showed no 
significant difference in CI(OXPHOS) FCR between genotypes pre halothane exposure (p=0.248) 
but a statistically significant difference was observed post halothane exposure (p=0.004).  
Pairwise comparisons between genotypes showed that the mean CI(OXPHOS) FCR in 
T4826I-RYR1 HETs post halothane (0.143±0.06) was significantly lower than all other 
genotypes (WT: 0.259±0.07, p=0.039, G2435R-RYR1 HET: 0.294±0.14, p=0.004 and 
G2435R-RYR1 HOM: 0.287±0.11, p=0.007). Pairwise comparisons between the remaining 
three genotypes showed no significant differences in mean CI(OXPHOS) FCR after halothane 
exposure. The reduction of CI(OXPHOS) FCR across all genotypes after halothane exposure 
reflects a normal drug response, but the significantly lower FCR in T4826I-RYR1 HETs 
suggest that this genotype has heightened sensitivity to halothane. A visual summary of all 
differences pre vs post halothane can be seen in Figure 5.3, and all raw data is summarised in 
Table 5.2. 
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Figure 5.3. Magnitude of responses to halothane exposure across RYR1 knock-in mouse 
genotypes. The effects of halothane exposure on A) oxygen consumption rates (pmol/s*mg) and B) 
FCR (converted to a %) in each respiratory state is illustrated using a bar chart, presenting means ± SE. 
These plots include data from all samples across the following genotypes: RYR1 WT (n =15, blue), 
G2435R-RYR1 HET (n=15, yellow), G2435R-RYR1 HOM (n=14, red), T4826I-RYR1 HET (n=10, 
orange).
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Table 5.2. The effects of halothane exposure on oxygen flux across RYR1 mouse genotypes. A summary of raw oxygen consumption rates and FCR data, 
is displayed for each genotype (pre vs post halothane exposure), presented as means ± SD. 
Control SD Post halothane SD Control SD Post halothane SD Control SD Post halothane SD Control SD Post halothane SD
LEAK 20.6 6.7 19.3 6.9 22.1 8.6 19.2 7.7 19.9 6.8 20.1 10.8 12.7 3.6 10.2 3.5
CI(OXPHOS) 138.9 26.5 76.3 22.0 129.5 34.5 76.5 24.9 129.9 18.7 77.3 19.3 118.6 28.2 41.3 16.7
CI+CII(OXPHOS) 216.4 35.7 202.7 37.0 201.0 60.2 181.0 44.7 199.9 31.7 170.8 30.9 212.4 34.9 175.7 34.5
CI+CII(ETS) 297.6 50.5 270.0 49.6 281.4 89.9 245.0 65.2 281.1 53.2 224.7 42.3 282.8 48.4 214.4 50.0
CII(ETS) 123.3 18.4 122.2 22.1 126.6 37.8 124.1 38.1 121.6 19.1 113.5 18.0 125.4 27.0 131.8 25.6
CIV(MAX) 370.3 86.4 385.6 104.3 352.2 119.5 352.2 108.9 326.1 52.9 290.5 52.5 354.8 94.3 310.3 99.7
Control SD Post halothane SD Control SD Post halothane SD Control SD Post halothane SD Control SD Post halothane SD
LEAK 0.07 0.03 0.07 0.03 0.09 0.04 0.07 0.04 0.07 0.03 0.07 0.04 0.04 0.01 0.04 0.01
CI(OXPHOS) 0.47 0.05 0.26 0.07 0.48 0.11 0.29 0.14 0.47 0.06 0.29 0.11 0.42 0.06 0.14 0.06
CI+CII(OXPHOS) 0.73 0.05 0.70 0.17 0.72 0.04 0.70 0.26 0.72 0.05 0.62 0.15 0.75 0.05 0.63 0.13
CII(ETS) 0.42 0.08 0.43 0.12 0.46 0.08 0.48 0.21 0.44 0.04 0.41 0.08 0.44 0.04 0.47 0.10
CIV(MAX) 1.25 0.26 1.35 0.47 1.25 0.25 1.33 0.55 1.18 0.19 1.07 0.27 1.26 0.31 1.11 0.35
FCR ± SD FCR ± SD
Respiratory 
states (OCR)
OCR (pmol/s*mg) ± SD OCR (pmol/s*mg)  ± SD OCR (pmol/s*mg)  ± SD OCR (pmol/s*mg)  ± SD
G2435R-RYR1 HOM T4826I-RYR1 HET
Respiratory 
states (FCR)
WT G2435R-RYR1 HET
FCR ± SD FCR ± SD
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5.3.3 Effects of calcium concentration on oxygen flux 
 
Three different [Ca2+] of 0, 100 and 300 nM were selected for the Ca2+ assay to encompass the 
range in [Ca2+]rest (mean ± SD) reported in WT (123 ± 3 nM), G2435R-RYR1 HET (156 ± 16 
nM), G2435R-RYR1 HOM (265 ± 32 nM) and T4826I-RYR1 HET (278 ± 21 nM) skeletal 
muscle (Barrientos et al., 2012; Lopez et al., 2018). The effects of Ca2+ on oxygen consumption 
rates and FCR at those concentrations, were assessed across four RYR1 mouse genotypes (WT 
(0 nM: n = 16; 100 nM: n = 12; 300 nM: n =12); G2435R-RYR1 HET (0 nM: n = 16; 100 nM: 
n = 16; 300 nM: n =16); G2435R-RYR1 HOM (0 nM: n = 16; 100 nM: n = 16; 300 nM: n =16) 
and T4826I-RYR1 HET (0 nM: n = 12; 100 nM: n = 16; 300 nM: n =16)).  
All data is presented as mean ± SD unless otherwise stated. Starting with mass-specific 
oxygen consumption rates, results showed that there was a statistically significant interaction 
effect between [Ca2+], genotype and oxygen consumption rates in the LEAK state (p=0.03). 
Subsequent analysis using one-way ANOVAs showed that LEAK oxygen consumption rates 
were significantly affected by [Ca2+] in the G2435R-RYR1 HET and HOM genotypes (p<0.001 
and p=0.001 respectively).  
Post hoc pairwise comparisons (Table 5.3) revealed that LEAK oxygen consumption 
rates in G2435R-RYR1 HETs were reduced at 100 nM and 300 nM [Ca2+], in comparison to 0 
nM (p<0.001 and p<0.001, respectively). In the G2435R-RYR1 HOM genotype, the LEAK 
oxygen consumption rates at 100 nM was significantly lower than WT (p=0.001), but the 
comparison between 0 and 300 nM [Ca2+] was not significantly different. Comparisons 
between 100nM and 300 nM [Ca2+] was also not significantly different in any genotype. 
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Table 5.3. Raw data for LEAK oxygen consumption rates in the Ca2+ assay. Raw oxygen 
consumption rates data is presented as means (SD) for each genotype across all [Ca2+]. Pairwise 
comparisons are also displayed with p-values adjusted with Bonferroni correction (p<0.05 is 
significant). 
 
In contrast, no statistically significant interaction effect between [Ca2+], genotype and 
oxygen consumption rates were observed in CI(OXPHOS), CI+CII(OXPHOS), CI+CII(ETS), CII(ETS) 
and CIV(MAX). On that basis, data from each genotype was combined and one-way ANOVAs 
were used to see how different respiratory states were affected by [Ca2+]. The results of this 
showed that CI(OXPHOS) and CII(ETS) were significantly different between different [Ca
2+] 
(p<0.001 and p=0.002). The mean CI(OXPHOS) oxygen consumption rates at 0, 100 and 300 nM 
[Ca2+] were 141.6 ± 30.0, 119.1 ± 34.9 and 109.4 ± 39.8, respectively. Pairwise comparisons 
showed that CI(OXPHOS) oxygen consumption rates at 100 and 300 nM [Ca
2+] was significantly 
lower than at 0 nM [Ca2+] (p=0.004 and p<0.001). The mean CII(ETS) oxygen consumption rates 
at 0, 100 and 300 nM [Ca2+] were 117.4 ± 29.7, 102.8 ± 26.5 and 101.9 ± 26.3, respectively. 
Pairwise comparisons showed that CII(ETS) oxygen consumption rates at 100 and 300 nM [Ca
2+] 
were significantly lower than at 0 nM [Ca2+] (p=0.012 and p=0.003).  
Following the analysis of oxygen consumption rates data, the same procedure was 
performed using FCR data, to address the confounding factor of mitochondrial content. Results 
showed that the interaction effect previously found in the LEAK state was not statistically 
significant after normalisation. However, when data across all genotypes were combined, a 
statistically significant main effect for [Ca2+] in the LEAK state was found (p=0.005). Pairwise 
comparisons showed that the mean LEAK FCR at 100 nM [Ca2+] (0.062 ± 0.033) was 
significantly lower than at 0 nM [Ca2+] (0.089 ± 0.042, p=0.003).  
Genotype 0 100 300 0 vs 100 0 vs 300 100 vs 300
WT 23.5 (7.4) 17.3 (9.1) 20.4 (6.3) 0.054 0.604 0.904
G2435R-RYR1 HET 25.8 (6.0) 13.8 (5.3) 17.1 (7.2) <0.001 <0.001 0.421
G2435R-RYR1 HOM 22.3 (4.2) 14.3 (6.3) 18.2 (5.7) 0.001 0.207 0.241
T4826I-RYR1 HET 13.7 (4.1) 13.2 (6.5) 12.6 (5.6) 1.000 1.000 1.000
Pairwise comparisons (p-values)[Ca
2+
] (nM)
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Instead of the LEAK state, FCR data showed a significant interaction effect between 
[Ca2+], genotype and FCR in CI(OXPHOS) state (p=0.001). Subsequent analysis using one-way 
ANOVAs showed that CI(OXPHOS) FCR in G2435R-RYR1 HET and HOM genotypes were 
significantly affected by differences in [Ca2+] (p=0.025 and p<0.001, respectively). Post hoc 
pairwise comparisons (Table 5.4) showed that CI(OXPHOS) FCR in G2435R-RYR1 HETs was 
significantly reduced at 300 nM [Ca2+] in comparison to 0 nM [Ca2+] (p=0.024). In G2435R-
RYR1 HOMs, CI(OXPHOS) FCR at 100 nM [Ca
2+] and 300 nM [Ca2+] was significantly reduced 
in comparison to 0 nM [Ca2+] (p<0.001 and p=0.001). Comparisons between 100 and 300 nM 
[Ca2+] was not significant different in any genotype.  
 
 
 
 
 
 
Table 5.4. Raw data for CI(OXPHOS) FCR in the calcium assay. Raw FCR data is presented as means 
(SD) for each genotype across all [Ca2+]. Pairwise comparisons are also displayed with p-values 
adjusted with Bonferroni correction (p<0.05 is significant). 
 
These results show that oxygen flux through complex I can be altered by both genotype and 
increasing [Ca2+] (Figure 5.4). The G2435R-RYR1 knock-in also presents evidence of a gene-
dose dependent effect with the G2435R-RYR1 HOM genotype being the most sensitive to 
changes in [Ca2+] out of the four genotypes studied. 
 
 
 
Genotype 0 100 300 0 vs 100 0 vs 300 100 vs 300
WT 0.52 (0.07) 0.49 (0.09) 0.42 (0.14) 1.000 0.100 0.541
G2435R-RYR1 HET 0.56 (0.06) 0.48 (0.08) 0.44 (0.18) 0.218 0.024 1.000
G2435R-RYR1 HOM 0.62 (0.09) 0.44 (0.06) 0.45 (0.12) <0.001 0.001 1.000
T4826I-RYR1 HET 0.44 (0.04) 0.5 (0.08) 0.54 (0.27) 0.619 0.140 1.000
[Ca
2+
] (nM) Pairwise comparisons (p-values)
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Figure 5.4. CI(OXPHOS) response to increasing concentrations of Ca2+. This scatterplot illustrates the 
directional change of CI(OXPHOS) FCR at three different concentrations of Ca2+ (0, 100 and 300 nM). This 
data includes samples from four RYR1 mouse genotypes: A) WT (0 nM: n = 16; 100 nM: n = 12; 300 
nM: n =12), B) G2435R-RYR1 HET (0 nM: n = 16; 100 nM: n = 16; 300 nM: n =16), C) G2435R-
RYR1 HOM (0 nM: n = 16; 100 nM: n = 16; 300 nM: n =16) and D) T4826I-RYR1 HET mice (0 nM: 
n = 12; 100 nM: n = 16; 300 nM: n =16). Error bars present the median and 95% CI. Statistically 
significant pairwise comparisons are annotated by asterisks (p<0.05*, p<0.01***). 
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5.4      DISCUSSION 
 
The data presented in this chapter provides the first evidence of altered mitochondrial 
bioenergetics in the G2435R-RYR1 knock-in mouse model of MH, supporting the association 
between mitochondrial dysfunction and MH susceptibility. Overall, mass-specific respiration 
rates between G2435R-RYR1 HOM, G2435R-RYR1 HET and WT mice were 
indistinguishable at baseline, except for complex IV. Mass-specific respiration through 
complex IV, adopted as the mitochondrial biomarker, was significantly lower in G2435R-
RYR1 HOM muscle fibres in comparison to WT. This presents evidence of lower 
mitochondrial content which was not observed in G2435R-RYR1 HET mice.  
The mitochondria from G2435R-RYR1 HOM mice also showed evidence of increased 
electron flow through the ETC, as the maximum OXPHOS capacity was significantly higher 
than WT. One explanation could be that muscle from G2435R-RYR1 HOM mice have adapted 
to having less mitochondrial content by increasing electron flow to compensate and meet the 
energy demands of the muscle. This adaptation may be attributed to an increase in complex I-
facilitated OXPHOS, indicated by the elevated CI(OXPHOS) FCR which was also observed in the 
G2435R-RYR1 HOM genotype. Furthermore, complex II function was unaltered between 
genotypes which shows that G2435R-RYR1 HOM mice are more dependent on complex I 
function to satisfy bioenergetic requirements.  
In contrast to the G2435R-RYR1 mouse line, baseline data from T4826I-RYR1 HET 
mice showed evidence of improved coupling efficiency, indicated by the significantly lower 
LEAK FCR values. The LEAK FCR can be an index of ETS uncoupling, reflecting the 
proportion of ETS capacity related to non-phosphorylating respiration. This finding was 
unexpected as MHS muscle has previously been associated with mitochondrial uncoupling at 
rest, which would imply a less efficient system (Giulivi et al., 2011; Chang et al., 2019; Cheah 
et al., 1989). Previous study on T4826I-RYR1 HET myotubes reported lower basal respiration, 
lower ETS capacity and reduced mitochondrial content compared to WT (Barrientos et al., 
2012). These features were not observed in this dataset and these contrasting results may be 
due to differences in sample type, as this study used permeabilised muscle fibres which are a 
more accurate representation of muscle physiology over cultured myotubes.  
With regards to the halothane response, there was no evidence of a hypermetabolic 
reaction in any mouse genotype after halothane exposure. This was unexpected as the similar 
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study described in chapter 3 (section 3.3.2), demonstrated elevated oxygen flux in human MHS 
muscle following IVCT halothane exposure, typical of a hypermetabolic response (Chang et 
al., 2019). Instead, this mouse study showed a significant decrease in OXPHOS and ETS 
capacity after halothane treatment across all mouse genotypes. This was attributed to a 
halothane-induced reduction in complex I-facilitated OXPHOS as no effect was seen in 
complex II.  
As mentioned in the chapter 3 discussion (section 3.4), the inhibition of mitochondrial 
complex I after halothane exposure has been reported in numerous studies and supports a 
normal pharmacological response, unrelated to the MH phenotype (Britt et al., 1975; Gronert 
and Heffron, 1979; Falk et al., 2006; Kayser et al., 2004; Hanley et al., 2002). The inhibition 
effect was detected in this present mouse study but not in the human study and this may be due 
to the time delay between drug application and data collection. In this mouse study, oxygen 
flux was measured shortly after the addition of halothane (three minutes) whilst the human 
study featured a 90-120 minute time delay before measurements were taken after IVCT. This 
reinforces the idea that halothane-induced complex I inhibition is an acute effect which reverses 
over time (Chang et al., 2019; Hanley et al., 2002). 
Furthermore, there was evidence of an interaction effect between halothane, genotype 
and complex I-facilitated OXPHOS after normalising for mitochondrial content. The G2435R-
RYR1 mouse line was reported to have a gene-dose dependent increase in halothane sensitivity 
(Lopez et al., 2018), but this was not demonstrated in this present study. Results showed that 
T4826I-RYR1 HET muscle was more severely affected by halothane in comparison to WT and 
both G2435R-RYR1 genotypes. This suggests that the mitochondria from the T4826I-RYR1 
mouse line have greater sensitivity to halothane which may contribute to a more severe 
phenotype over the G2435R-RYR1 mutation. This is supported by the MH genotype-
phenotype correlation data generated from human MHS muscle, which showed individuals 
carrying the T4826I-RYR1 mutation having greater IVCT contracture strengths after exposure 
to halothane, in comparison to the human G2435R-RYR1 mutation (Carpenter et al., 2009b). 
Following the halothane experiments, an investigation into the effects of Ca2+ on 
mitochondrial respiration rates was carried out by modifying the [Ca2+] in the assay media.  
Increasing the [Ca2+] helped mimic the normal muscle physiology between genotypes, as MHS 
muscle is associated with elevated [Ca2+]rest due to mutant RYR1 channels leaking Ca
2+ from 
the SR. The concentrations chosen for this study were 0, 100 and 300 nM, which covers the 
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range in mean intracellular [Ca2+] reported in the G2435R-RYR1 mouse line (156 nM in HET 
mice and 265 nM in HOM mice) (Lopez et al., 2018). This range was also appropriate for the 
T4826I-RYR1 mouse line, in which the HET myotubes were reported to have a mean [Ca2+] 
of 278 nM (Barrientos et al., 2012).  
Results showed that the modification of assay [Ca2+] only impacted the function of 
complex I-facilitated OXPHOS across the G2435R-RYR1 mouse line, as WT and T4826I-
RYR1 mice were unaffected. The output through complex I was significantly reduced in 
G2435R-RYR1 HET mice at 300 nM [Ca2+], and a similar effect was seen in HOM mice at as 
low as 100 nM [Ca2+]. These results show a gene-dose dependent effect, with G2435R-RYR1 
HOM mice being the most sensitive to changes in intracellular Ca2+, possibly due to differences 
in mitochondrial Ca2+ uptake. This inhibition effect was surprising since Ca2+ is generally 
regarded as a positive regulator of mitochondrial function, primarily through the upregulation 
of intra-mitochondrial dehydrogenase enzymes which increases the supply of NADH (Denton, 
2009; Panov and Scaduto, 1995). However, a study using submitochondrial particles prepared 
from rat heart reported a similar inhibition of complex I by Ca2+, in which the inactivation was 
specific to complex I with no alterations in the rest of the ETS (Matsuzaki and Szweda, 2007). 
These contrasting reports highlight further complexity in the relationship between 
mitochondria and Ca2+.   
Mitochondrial Ca2+  uptake into the matrix is dictated by the MCU, which functions at 
a threshold of >500 nM [Ca2+], preventing mitochondrial stimulation in the presence of small 
fluctuations in Ca2+ (Csordas et al., 2013). The fact that mitochondrial function was altered in 
both G2435R-RYR1 HET and HOM mice at 300 nM and 100 nM [Ca2+] respectively, suggests 
that Ca2+ was able to bypass the MCU threshold and enter the mitochondrial matrix. One 
possible explanation would be that that the MCU threshold is lower in the G2435R-RYR1 
mouse line, allowing Ca2+ to enter the mitochondrial matrix at a lower [Ca2+]rest. Alternatively, 
it is possible that another means of Ca2+ transport independent of MCU may be available which 
can be accessed at a lower [Ca2+]rest. The existence of alternative Ca
2+ uptake methods is still a 
subject of debate within the field and challenges the dogma of MCU being the single mode of 
Ca2+ transport into mitochondria (De Stefani et al., 2015). Two other proposed means of 
mitochondrial Ca2+ import are rapid mode of uptake (RaM), in which Ca2+ uptake is mediated 
through cytosolic Ca2+ pulses (Bazil and Dash, 2011; Buntinas et al., 2001; Sparagna et al., 
1995) and mitochondrial RYR1, which was reported to be in rat heart mitochondria (Beutner 
et al., 2005; Altschafl et al., 2007). Despite conflicts of opinion, all three methods of Ca2+ 
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transport may exist, as the study by Bondarenko et al. identified three distinct Ca2+ currents 
with different sensitivities from electrophysiological recordings of mitoplasts (Bondarenko et 
al., 2013). 
The consequences of a lower MCU threshold or Ca2+ overload in mitochondria presents 
the risk of MPTP activation which leads to mitochondrial swelling and cell death, in addition 
to an increase in oxidative stress through constant stimulation of the ETS (Rasola and Bernardi, 
2011). Researchers using muscle from the Y522S-RYR1 mouse model, observed both those 
features which lead to a hypothesis outlining a destructive feed-forward cycle within skeletal 
muscle. This hypothesis is based around the consequences of SR Ca2+ leaks, which elevate 
[Ca2+]rest and ROS production, contributing to increased oxidative stress and mitochondrial 
dysfunction over time (Yuen et al., 2012; Boncompagni et al., 2009). This proposed mechanism 
may be present in the G2435R-RYR1 mouse line, as similar features have been observed.   
A colleague within the Leeds MH Unit, Dr Xiaochen Liu, conducted an oxidative stress 
study on the G2435R-RYR1 mouse line to address this hypothesis (Chang et al., 2020). Liu 
and colleagues measured the protein expression of two major oxidative stress proteins, NADPH 
oxidase 2 (NOX2) and superoxide dismutase 1 (SOD1), using western blots, and adopted a 
fluorescent dye (CellROX Green) to measure ROS production in adult muscle fibres. NOX2 is 
a producer of ROS in skeletal muscle (Ferreira and Laitano, 2016), and was found to be 
expressed at a significantly higher level in G2435R-RYR1 HOM mice in comparison to WT. 
In contrast, SOD1 is an antioxidative enzyme (Powers et al., 2011), which was expressed at a 
significantly lower level in G2435R-RYR1 HOM mice compared to WT, suggesting a 
deficiency in ROS regulation. Furthermore, the CellROX green assay using adult muscle fibres, 
showed that G2435R-RYR1 knock-in mice have a gene-dose dependent elevation of ROS 
production in response to H2O2 induced oxidative stress. Collectively, the data from Liu and 
colleagues provide evidence of elevated oxidative stress in G2435R-RYR1 knock-in mice 
(Chang et al., 2020), consistent with observations reported in other MHS RYR1 knock-in mice 
(Durham et al., 2008; Giulivi et al., 2011; Yuen et al., 2012; Michelucci et al., 2017). The 
elevated level of oxidative stress identified by Dr Liu, may coincide with the alterations in 
complex I function observed in this study, since it is one of the main sources of ROS production 
in mitochondria (Murphy, 2009b; Grivennikova and Vinogradov, 2006).  
In summary, the G2435R-RYR1 mouse model for MH has shown some evidence of 
mitochondrial dysfunction which appears to occur in a gene-dose dependent manner. 
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Individuals with the equivalent c.7300G>A human MH variant are generally associated with 
weaker clinical phenotypes and the lack of differences seen between WT and G2435R-RYR1 
HET mice reflect this statement. The muscle from G2435R-RYR1 HOM mice has shown 
evidence of increased electron flow through complex I which is thought to be a compensation 
mechanism for reduced mitochondrial content. Both the G2435R-RYR1 HET and HOM 
muscle had increased sensitivity to intracellular Ca2+ which may be due to a reduction in MCU 
threshold. The observations from the T4826I-RYR1 HETs provide evidence of improved 
coupling efficiency and increased sensitivity to halothane exposure. The differences in 
mitochondrial bioenergetics across RYR1 knock-in genotypes may correspond with 
differences in phenotype severity by affecting skeletal muscle sensitivity to both halothane and 
caffeine. These outcomes are thought to have been perpetuated by elevated [Ca2+]rest and 
increased oxidative stress. 
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6 GENERAL DISCUSSION 
 
MH has traditionally been regarded as an autosomal dominant disorder, but evidence now 
supports a more complex ‘multifactorial’ model of inheritance, which includes the involvement 
of additional genetic/non-genetic factors contributing to MH susceptibility. The aim of this 
thesis was to identify potential modifiers of, and contributors to, the MH phenotype. This was 
achieved by investigating differential gene expression and mitochondrial function in MHN and 
MHS skeletal muscle, before (baseline) and after drug exposure. In this final discussion 
chapter, the main findings from each results chapter will be summarised with comparisons 
between human MHS and RYR1 knock-in mouse muscle. The limitations of these studies will 
be outlined and ideas for future research development will be discussed. 
 
6.1 DIFFERENTIAL GENE EXPRESSION BETWEEN MHN AND 
MHS SKELETAL MUSCLE 
 
The results from both human and mouse RNAseq experiments identified a downregulation in 
mitochondria-related gene expression at baseline. In the human RNAseq study, many genes 
involved in the OXPHOS pathway had reduced expression in MHS muscle biopsies, with an 
emphasis on those encoding mitochondrial complex I. OXPHOS gene expression was reduced 
when human muscle biopsies were exposed to halothane through IVCT, but this was only 
observed in MHN muscle. This reduction of OXPHOS gene expression reflects a negative shift 
in metabolic activity which is perhaps a normal pharmacological response to anaesthesia that 
is absent in MHS muscle.  
Studies have shown that mitochondria are a direct target of volatile anaesthetics, and 
complex I is known to be selectively inhibited upon exposure (Hanley et al., 2002; Kayser et 
al., 2004). This interaction effect is not specific to skeletal muscle and has also been 
demonstrated in mitochondria from the heart, brain, liver, and nervous tissues (Hanley et al., 
2002; Zimin et al., 2018; Zimin et al., 2016; Harris et al., 1971). It has been proposed that 
mitochondrial complex I may modulate the anaesthetic response as research has shown that 
complex I-deficient organisms (C. elegans and knock-out mice) have heightened sensitivity to 
volatile anaesthetics (Falk et al., 2006; Quintana et al., 2012; Zimin et al., 2018). This feature 
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may extend to MHS humans since complex I-encoding gene expression was reduced, which 
needs to be confirmed at the protein level.  
With regards to MHS mice, only a few genes encoding ETC complexes were 
downregulated in G2435R-RYR1 HOM (Ndufs1, Ndufs2, Sdha and Uqcrc2) and T4826I-
RYR1 HET (Uqcrc2) genotypes at baseline. This suggests that potential deficiencies in the 
ETC expression are less marked in MHS mice. Most of the genes downregulated in RYR1 
knock-in mice were involved in fatty acid oxidation and transport, which affects OXPHOS 
indirectly. This was observed in both G2435R-RYR1 HOM and T4826I-RYR1 HET mice, but 
absent in G2435R-RYR1 HETs, indicating a gene-dose dependent effect within the G2435R-
RYR1 model, and an Ryr1 variant-specific effect between HET genotypes. Fatty acid oxidation 
was also among the top 10 downregulated pathways in MHS humans, but only five genes 
within the pathway had reduced expression.  
Defects in fatty acid metabolism were first associated with MH susceptibility, after an 
accumulation of FFA was detected in the mitochondria of MHS pigs (Cheah, 1981; Cheah and 
Cheah, 1981a; Cheah and Cheah, 1981b). A similar feature was also observed in studies using 
human MHS muscle which proposed that halothane sensitivity in MHS muscle was associated 
with elevated levels of FFA (Fletcher et al., 1991a; Fletcher and Rosenberg, 1986; Fletcher et 
al., 1991b). Aside from MHS pigs and humans, evidence of lowered fatty acid oxidation was 
also observed in the R163C-RYR1 mouse model of MH (Giulivi et al., 2011). In support of 
those findings, the baseline data from mouse, and to a lesser extent human, RNAseq 
experiments suggest that fatty acid oxidation may be deficient in MHS muscle which may 
contribute towards the MH phenotype. 
The G2435R-RYR1 HET mice, represent the most common genotype found in MHS 
humans (c.7300G>A) within the UK (Lopez et al., 2018; Miller et al., 2018). The c.7300G>A 
variant is considered a weak mutation based on IVCT contracture strengths (Carpenter et al., 
2009b), and this is reflected by the transcriptome profiles from G2435R-RYR1 HET mice, 
which were indistinguishable from WT, before and after exposure to halothane. Unlike the 
human RNAseq data, the method of halothane exposure applied to RYR1 knock-in mouse 
muscle resulted in almost no change to gene expression across all genotypes. This was 
surprising since OXPHOS gene expression was downregulated in human MHN muscle after 
IVCT halothane exposure, and a similar observation was expected to occur in WT mice. These 
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findings suggest that the method of halothane exposure may not have been appropriate for this 
study and further experiments are needed to address the shortcomings in design. 
 
6.2 MITOCHONDRIAL FUNCTION BETWEEN MHN AND MHS 
SKELETAL MUSCLE 
 
Consistent with RNAseq data, functional testing of MHS skeletal muscle revealed evidence of 
mitochondrial dysfunction in both human and RYR1 knock-in mouse muscle at baseline. 
However, some discrepancies were identified between species. Firstly, the functional 
biomarker for mitochondrial content (mass-specific CIV(MAX)) suggested an upregulation of 
mitochondrial content in human MHS muscle, which was not observed in RYR1 knock-in 
mice. The mitochondrial biomarker only differed in G2435R-RYR1 HOM mice, which was 
found to be significantly lower than WT. This HOM mouse genotype is not a model for human 
MH, since very few cases of human MHS are recessive carriers of the RYR1 mutation. 
However, the HOM mouse genotype does give insight into how RYR1 mutations affect 
biological systems with increased gene dosage. The concept of human MHS muscle having 
higher mitochondrial content, contradicts the mouse literature as studies on the Y522S-RYR1, 
T4826I-RYR1 and R163C-RYR1 variants, have all reported evidence of reduced 
mitochondrial content (Boncompagni et al., 2009; Giulivi et al., 2011; Barrientos et al., 2012). 
These conflicting data may be due to differences in muscle fibre type composition which will 
be discussed in section 6.3.  
Human respirometry data normalised for mitochondrial content, showed evidence of 
reduced OXPHOS capacity and CII deficiency in MHS mitochondria. This indicates functional 
impairment, which aligns with the study by Thompson et al. describing impaired aerobic 
metabolism and reduced ATP production in MHS individuals (Thompson et al., 2017). No 
deficiency in complex I activity was observed, despite the downregulation of complex I-
encoding gene expression identified in RNAseq data. In contrast, none of these observations 
were present in RYR1 knock-in mice. MHS humans typically do not exhibit clinical 
phenotypes in absence of anaesthetic triggers but some cases have reported muscle-related 
symptoms such as weakness, exercise intolerance and exercise-induced rhabdomyolysis 
(Timmins et al., 2015; Wappler et al., 2001; Litman et al., 2018). Certain RYR1 variants, such 
as those associated with central core disease, are known to result in central cores and 
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diminished oxidative metabolism. On that basis, it is possible that specific MH-associated 
RYR1 variants, confer varying degrees of influence on mitochondrial function and these 
myopathic features may only be associated with ‘stronger’ RYR1 variants. 
This hypothesis was supported in the mouse respirometry data, as mitochondrial 
function differed between each RYR1 knock-in genotype. Mitochondrial function at baseline, 
between G2435R-RYR1 HET (weak mutation) and WT mice was indistinguishable whilst, a 
lower LEAK respiration rate was detected in the T4826I-RYR1 HET genotype (strong 
mutation) (Carpenter et al., 2009b), providing evidence of Ryr1 variant-dependent effects on 
mitochondrial function. Mitochondrial dysfunction from the G2435R-RYR1 mouse model was 
detected primarily in the HOM genotype, showing evidence of increased complex I dependence 
and reduced mitochondrial content in permeabilised muscle fibres. 
With regards to treatment effects, mitochondria from human MHS muscle biopsies 
experienced elevated respiration rates after IVCT halothane exposure, with increased severity 
in MHShc individuals. This increase in activity is indicative of a hypermetabolic response which 
is typical of an MH reaction, but contradicts the complex I inhibition effect associated with 
volatile anaesthetics (Hanley et al., 2002; Zimin et al., 2018; Zimin et al., 2016; Harris et al., 
1971). This lack of inhibition has been attributed to the time delay (~90-120 min) between 
IVCT treatment and respirometry measurements as this effect is known to be reversible. It was 
speculated that the complex I inhibition was initiated upon first exposure to IVCT halothane 
but was reversed at the time of respirometry data collection.  
This information was used to modify the method of halothane exposure for mouse 
respirometry experiments and the data generated supported that hypothesis. Halothane was 
dissolved in DMSO and directly applied to each respirometry chamber to avoid the time delay 
experienced using human samples, and consequently the halothane-induced complex I 
inhibition was detected. Direct application of halothane inhibited complex I respiration across 
all mouse genotypes, but the effect was significantly greater in T4826I-RYR1 HET mice. The 
mitochondria from RYR1 knock-in mice did not show evidence of the hypermetabolic response 
demonstrated using human MHS muscle which implies that the MH reaction was not triggered 
using this method of halothane exposure. 
Finally, in addition to halothane treatment, the mouse respirometry experiments 
assessed the effect of Ca2+ on MHS mitochondrial function, since MHS muscle is associated 
with elevated [Ca2+]rest at baseline (Barrientos et al., 2012; Lopez et al., 2018). A [Ca
2+] range 
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(0 – 300 nM) was chosen to mimic physiological conditions in both MHN and MHS muscle 
and subsequent exposure to these [Ca2+] caused complex I inhibition in G2435R-RYR1 knock-
in mice only. This Ca2+-induced complex I inhibition also showed a gene-dose dependent 
effect, as G2435R-RYR1 HOM mice were more sensitive to [Ca2+] changes than HET 
counterparts. This inhibition effect was unexpected since Ca2+ is known to be a positive 
regulator of mitochondrial function (Denton, 2009), and these data may reflect further 
complexity in the relationship between Ca2+ and mitochondria. Furthermore, these results 
suggest that mitochondrial complex I deficiency is in fact present in G2435R-RYR1 knock-in 
mice at baseline, but only in the presence of physiologically relevant [Ca2+]rest, which needs to 
be considered in future MH research. 
 
6.3  LIMITATIONS 
 
The four studies described in this thesis all utilised skeletal muscle biopsies which are subject 
to a similar set of limitations with respect to muscle architecture and quality. These limitations 
must be taken into consideration when comparing results between studies. Firstly, skeletal 
muscle is highly plastic and muscle fibre type distribution vary between samples. The 
quadriceps of untrained individuals is composed of predominantly oxidative fibres (~41% type 
I slow-twitch oxidative, ~31% type IIA fast-twitch oxidative) (Staron et al., 2000), and a similar 
proportion has been reported in Soleus muscles from mice (~37% type I slow-twitch oxidative, 
~39% type II fast-twitch oxidative fibres) (Augusto et al., 2004).  
Due to lifestyle diversity, muscle fibre type composition in the human samples can vary 
significantly as a result of differences in fitness level and adaptations from physical training 
(e.g. type I slow-twitch oxidative bias from distance running and type IIB fast-twitch glycolytic 
bias from sprinting). Data on individual fitness level and fibre type composition was not 
collected and may account for some of the variability seen in human studies. For instance, 
measurements of mitochondrial content from the human respirometry study may have been 
influenced by individuals with a higher proportion of type I slow-twitch oxidative fibres, which 
are rich in mitochondria. This would therefore inflate the results of the mitochondrial 
biomarker, which should be considered before drawing conclusions. With respect to mouse 
studies, differences in fibre type composition is thought to be negligible, as all subjects were 
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exposed to the same living environment so any muscle fibre adaptation will have been shared 
across genotypes.  
In addition to muscle fibre type, another limitation of the human studies is the variety 
in RYR1 variants. Due to the opportunistic nature of sample availability, experiments on fresh 
muscle do not enable us to explore the effects of individual variants. The human MHS samples 
used in RNAseq, all contained different RYR1 variants which may confer different strengths in 
phenotype (Carpenter et al., 2009b). The data generated from mouse RNAseq illustrate how 
different RYR1 genotypes can alter muscle gene expression and mitochondrial function in 
different ways which will no doubt contribute to variability in human studies. Likewise, the 
human MHS samples assessed by high-resolution respirometry included 18 different RYR1 
variants, of which only one (c.1021G>A) was functionally characterised. The RYR1 
c.1021G>A is a weak variant based on IVCT contracture data (Carpenter et al., 2009b), but the 
relative strengths of the remaining 17 variants are unknown. These uncharacterised RYR1 
variants may be strong mutations, resulting in more overt defects in skeletal muscle - a variable 
which could not be factored into the analysis. 
Aside from inherent limitations within sampling, the methods of drug application in 
each study was restricted and may not have triggered the appropriate responses in MHS muscle. 
With regards to both human studies, the IVCT procedure used to administer halothane was 
complex, involving additional variables (muscle stretching, electrical stimulation, incremental 
drug dosage) that could have influenced gene expression outside of halothane-induced effects. 
There is also the issue of whether the halothane exposure time/dosage applied during the IVCT, 
is sufficient to trigger changes in gene expression and mitochondrial function associated with 
an MH reaction. These variables could not be altered as all human muscle biopsies were 
required to undergo IVCT for diagnostic purposes prior to research usage.  
The use of RYR1 knock-in mouse models, allowed greater flexibility over experimental 
conditions since halothane application was not restricted by the IVCT. The method of 
halothane exposure used for mouse RNAseq resembled the IVCT procedure, but the additional 
variables (muscle stretching, electrical stimulation, incremental drug dosage) were removed. 
Surprisingly, this modified application of halothane had almost no effect on muscle gene 
expression across all RYR1 knock-in mouse genotypes. This showed that the methodology 
needed to be amended through additional experiments to deduce whether this lack of response 
is a result of drug dose/ exposure time or additional variables not yet considered.  
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In an ideal scenario, a dose-response curve and time course experiment should have 
been conducted prior to RNAseq to optimise experimental factors. The most effective way to 
achieve this is through in vitro experiments using cultured myotubes. The use of fresh muscle 
biopsies provide a more accurate representation of muscle physiology, but cultured myotubes 
provide several advantages for experimental design. Myotubes can be prepared from the 
muscle samples of select individuals who are of similar age and fitness, carrying specific RYR1 
genotypes. Drugs can also be incorporated into culture media in a plate format to allow 
flexibility over drug exposure time and drug concentrations, all of which would be impossible 
to replicate in vivo.  
A dose response experiment can be conducted with cultured myotubes using a 
microplate reader measuring Ca2+ flux. A range of halothane concentrations can be assessed 
with this method to identify the dose which elicits a maximum response, indicated by Ca2+ flux. 
Once the ideal drug concentration is identified, the effect of halothane exposure time on gene 
expression can be assessed in a time course experiment. The optimal halothane dose can be 
applied to myotubes over a duration spanning 0 to 24-hours, before mRNA is extracted at 
multiple time points and prepared for RNAseq. Analysis of gene expression at each time point 
will reveal the optimal time point required for halothane-induced gene expression to occur. 
This same information can be used to inform the method of halothane application used 
in mouse respirometry. As previously mentioned, halothane exposure reversibly inhibits 
mitochondrial complex I, which was not detected in the human respirometry study. This was 
attributed to the time delay between treatment and assay. The direct application of halothane 
(dissolved in DMSO) in mouse respirometry, avoided this time delay, and caused a significant 
downregulation of complex I which aligns with the halothane-mitochondria interactions 
reported in literature. However, the mouse experiment failed to trigger the hypermetabolic 
response observed in the human respirometry data, indicating that the MH reaction was not 
triggered in RYR1 knock-in mouse muscle. Again, this may be due to insufficient halothane 
dosage or exposure time which can be addressed through the dose-response and time course 
experiments discussed above. 
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6.4 FUTURE DEVELOPMENT 
 
Despite the limitations, these studies have provided valuable insight into MH pathophysiology, 
which can now be used inform future MH research. Each study within this thesis has showed 
evidence of mitochondrial defect in MHS muscle, highlighting its relevance within MH 
susceptibility. This area of research should be pursued further to clarify its contribution towards 
MH. Possibilities for further development include:  
• Investigations into potential modifier loci. With regards to the human gene 
expression data, three OXPHOS genes of interest (ATP5MD, NDUFC2, COQ6) have 
already been validated using RT-PCR and followed up using bioinformatic resources. 
These genes were found to be regulated by a common set of TFs that bind to enhancer 
regions local to the genes of interest. A list of SNPs, capable of influencing gene 
expression, were subsequently identified within each enhancer using eQTL information 
available on the GTEx database. Since these OXPHOS genes are regulated by the same 
TFs, a SNP within an enhancer, could affect TF binding and influence the expression 
of the genes of interest. These SNPs therefore represent potential modifier loci capable 
of influencing the MH phenotype, which can be investigated through SNP genotyping 
experiments on wider populations of MHS individuals. The Leeds MH Unit has access 
to 6276 DNA samples (1961 MHS, 3339 MHN, 976 unknown phenotype) with the 
largest population of MHS individuals worldwide. 780 MHS DNA samples have been 
prepared on screening plates and are now available for screening. Successful 
association of these SNPs with the wider MHS population, will provide evidence of 
these loci contributing towards the MHS phenotype and demonstrate the importance of 
mitochondrial function within MH susceptibility.  
 
• Glycolytic metabolism in MHS skeletal muscle. The studies performed in this thesis 
have utilised MHS muscles from the quadriceps and Soleus which are composed 
primarily of type I and IIA muscle fibres favouring oxidative metabolism. It will be 
useful to gain insight into anaerobic metabolism for a comprehensive view of MHS 
muscle metabolism. This could be achieved by performing similar experiments using 
muscle groups composed primarily of type II fast-twitch fibres favouring glycolytic 
metabolism (such as the Extensor digitorum longus). Alternatively, glycolytic function 
could be assessed in cultured myotubes using the XF Glycolysis Stress Test Kit 
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available on the Agilent Seahorse XF Analyser. Previous respirometry experiments 
have been carried out using the Oroboros Analyser which allows detailed analyses of 
individual samples, but it is not suitable for high throughput analyses e.g. testing 
multiple cell lines. The Agilent Seahorse XF Analysers can measure oxygen 
consumption rates and extracellular acidification rate in cell culture plate formats, 
allowing different MHN and MHS cell lines to be assessed simultaneously. 
 
• Fatty acid metabolism in MHS skeletal muscle. Fatty acid metabolism should be 
investigated further in the context of MH as many genes in this pathway were 
downregulated in RYR1 knock-in mice. Follow up investigations would first involve 
selecting genes of interest within the fatty acid β-oxidation pathway and validating them 
using RT-PCR to confirm RNAseq findings. Once validated, western blotting could be 
used to confirm whether gene expression differences are consistent at the protein level 
before moving onto functional assays for fatty acid metabolism. Mitochondrial function 
and fatty acid oxidation can be assessed within myotubes cultured from RYR1 knock-
in mouse or MHS human genotypes, using the XF Cell Mito Stress test and palmitate-
BSA substrate kits developed for the Agilent Seahorse XF Analyser. Any fatty acid 
oxidation deficiency found in MHS samples will support the connection between MH 
and fatty acid oxidation suggested by the gene expression data presented. 
 
• Ryr1 variant-specific effects on muscle function. The RYR1 knock-in mouse data has 
demonstrated evidence of mutation-specific effects on mitochondrial function. This can 
be investigated in both MHS humans and RYR1 knock-in mice, by comparing 
functional differences between cultured myotubes carrying different Ryr1 variants. The 
Leeds MH Unit has myoblasts from three RYR1 knock-in mouse lines (R163C, 
G2435R and T4826I) and human myoblasts from the analogous R163C (5 patients), 
G2434R (12 patients) and T4826I (1 patient). These samples can be used in the 
glycolytic and fatty acid metabolism experiments described above, to investigate Ryr1 
variant-specific effects as a secondary objective.  
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6.5 CONCLUSION 
 
This thesis contains a comprehensive account of differential gene expression and mitochondrial 
function in MHN and MHS skeletal muscle, before and after halothane exposure. 
Transcriptome analysis of human and mouse MHS muscle have both shown a downregulation 
of OXPHOS-related gene expression which is a sign of metabolic defect. This is supported by 
the functional assessment of MHS muscle using high resolution respirometry, which has also 
demonstrated evidence of functional deficiency within mitochondria. Investigations using MH 
mouse models showed differing results between RYR1 knock-in mouse genotypes, 
demonstrating a gene-dose and variant-dependent effect on mitochondrial function. Together, 
these data provide a framework for future MH research and has highlighted the importance of 
mitochondrial function, a potential contributor of phenotype variability within MH.  
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Appendix 1 – Gene ontology analyses for MHN vs MHS (baseline) comparison 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Gene ontology results using upregulated genes. Top 10 ontology terms for biological 
process, molecular function and cellular component generated using Enrichr, in order of adjusted p-
value. 
 
 
Upregulated terms Adjusted p-value
mRNA processing (GO:0006397) 2.32E-04
RNA splicing, via transesterification reactions with bulged adenosine as nucleophile (GO:0000377) 2.32E-04
mRNA splicing, via spliceosome (GO:0000398) 2.41E-04
RNA splicing (GO:0008380) 1.25E-02
RNA processing (GO:0006396) 2.19E-02
RNA secondary structure unwinding (GO:0010501) 7.23E-02
fat cell differentiation (GO:0045444) 1.46E-01
positive regulation of cellular protein metabolic process (GO:0032270) 1.75E-01
response to tumor necrosis factor (GO:0034612) 2.19E-01
regulation of mitotic cell cycle phase transition (GO:1901990) 2.42E-01
RNA binding (GO:0003723) 4.41E-08
mRNA binding (GO:0003729) 4.04E-02
ATP-dependent helicase activity (GO:0008026) 5.43E-02
ATPase activity (GO:0016887) 7.01E-02
ATPase activity, coupled (GO:0042623) 7.52E-02
RNA-dependent ATPase activity (GO:0008186) 7.81E-02
ATP-dependent RNA helicase activity (GO:0004004) 8.34E-02
RNA helicase activity (GO:0003724) 9.72E-02
nucleoside-triphosphatase activity (GO:0017111) 1.29E-01
proteasome-activating ATPase activity (GO:0036402) 1.34E-01
nucleolus (GO:0005730) 2.58E-07
spliceosomal complex (GO:0005681) 4.07E-05
U2-type spliceosomal complex (GO:0005684) 4.50E-02
nuclear body (GO:0016604) 4.51E-02
nuclear speck (GO:0016607) 5.24E-02
preribosome (GO:0030684) 5.42E-02
spindle pole (GO:0000922) 5.82E-02
spliceosomal snRNP complex (GO:0097525) 1.19E-01
nuclear proteasome complex (GO:0031595) 1.28E-01
trans-Golgi network (GO:0005802) 1.32E-01
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Table 2. Gene ontology results using downregulated genes. Top 10 ontology terms for biological 
process, molecular function and cellular component generated using Enrichr, in order of adjusted p-
value. 
 
 
 
Downregulated terms Adjusted p-value
respiratory electron transport chain (GO:0022904) 2.84E-16
mitochondrial ATP synthesis coupled electron transport (GO:0042775) 4.62E-16
mitochondrial respiratory chain complex assembly (GO:0033108) 1.01E-11
mitochondrial respiratory chain complex I assembly (GO:0032981) 1.87E-10
mitochondrial respiratory chain complex I biogenesis (GO:0097031) 2.24E-10
NADH dehydrogenase complex assembly (GO:0010257) 2.80E-10
mitochondrial electron transport, NADH to ubiquinone (GO:0006120) 2.32E-08
mitochondrial translational elongation (GO:0070125) 3.98E-08
mitochondrial translational termination (GO:0070126) 5.28E-08
translational elongation (GO:0006414) 1.09E-07
NADH dehydrogenase (quinone) activity (GO:0050136) 1.03E-07
NADH dehydrogenase (ubiquinone) activity (GO:0008137) 2.06E-07
NADH dehydrogenase activity (GO:0003954) 3.33E-03
NEDD8 transferase activity (GO:0019788) 1.37E-01
small ribosomal subunit rRNA binding (GO:0070181) 1.56E-01
hydrogen ion transmembrane transporter activity (GO:0015078) 1.60E-01
ubiquinol-cytochrome-c reductase activity (GO:0008121) 1.83E-01
oxidoreductase activity, acting on diphenols and related substances as donors, cytochrome as acceptor 
(GO:0016681)
2.09E-01
clathrin adaptor activity (GO:0035615) 3.01E-01
endocytic adaptor activity (GO:0098748) 3.34E-01
mitochondrion (GO:0005739) 7.71E-30
mitochondrial inner membrane (GO:0005743) 8.26E-23
mitochondrial matrix (GO:0005759) 5.97E-11
mitochondrial respiratory chain complex I (GO:0005747) 8.06E-11
mitochondrial respiratory chain complex IV (GO:0005751) 9.26E-07
mitochondrial respiratory chain complex III (GO:0005750) 1.16E-04
mitochondrial large ribosomal subunit (GO:0005762) 1.19E-03
integral component of endoplasmic reticulum membrane (GO:0030176) 1.40E-03
mitochondrial envelope (GO:0005740) 1.60E-03
mitochondrial small ribosomal subunit (GO:0005763) 4.95E-03
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Appendix 2 – Pathway analysis for the MHN vs MHSh comparison (baseline) 
 
 
 
 
Table 1. Pathway analysis for MHN vs MHSh at baseline. The top 10 pathway terms generated by Enrichr, using upregulated and downregulated gene lists. 
Upregulated (Top) and downregulated (bottom) pathways are displayed in order of combined score (log of p-value from Fisher’s exact test multiplied by z score 
of deviation from expected rank). 
 
Index Upregulated pathway terms P-value Adjusted p-value Odds Ratio Combined score
1 mRNA Processing WP411 6.73E-08 3.18E-05 6.16 101.66
2 Translation Factors WP107 3.92E-05 9.25E-03 7.46 75.68
3 Leptin and adiponectin WP3934 1.33E-02 6.97E-01 11.08 47.88
4 Hippo-Yap signaling pathway WP4537 7.90E-03 6.22E-01 7.23 34.98
5 Nanoparticle triggered autophagic cell death WP2509 7.90E-03 7.46E-01 7.23 34.98
6 Parkin-Ubiquitin Proteasomal System pathway WP2359 1.65E-03 2.59E-01 4.75 30.44
7 Cysteine and methionine catabolism WP4504 2.56E-02 1.00E+00 7.91 29
8 Sulindac Metabolic Pathway WP2542 8.71E-02 1.00E+00 11.08 27.05
9 Intraflagellar transport proteins binding to dynein WP4532 1.24E-02 7.30E-01 6.16 27.04
10 Deregulation of Rab and Rab Effector Genes in Bladder Cancer WP2291 3.30E-02 1.00E+00 6.93 23.62
Index Downregulated pathway terms P-value Adjusted p-value Odds Ratio Combined score
1 Electron Transport Chain (OXPHOS system in mitochondria) WP111 1.62E-25 7.65E-23 6.84 390.66
2 Oxidative phosphorylation WP623 1.13E-18 1.78E-16 7.65 316.15
3 Nonalcoholic fatty liver disease WP4396 3.71E-19 8.74E-17 4.76 201.99
4 Mitochondrial complex I assembly model OXPHOS system WP4324 3.54E-10 3.34E-08 5.56 121.04
5 Cytoplasmic Ribosomal Proteins WP477 6.48E-11 7.65E-09 4.6 108.03
6 Proteasome Degradation WP183 1.71E-08 1.35E-06 4.76 85.11
7 Regulation of Apoptosis by Parathyroid Hormone-related Protein WP3872 2.34E-04 1.38E-02 5.22 43.61
8 Dual hijack model of Vif in HIV infection WP3300 1.01E-02 2.06E-01 6.15 28.28
9 Apoptosis Modulation and Signaling WP1772 1.13E-04 7.63E-03 2.88 26.19
10 Pyrimidine metabolism WP4022 5.94E-04 3.11E-02 2.7 20.06
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Appendix 3 - Gene ontology analyses for MHN vs MHSh (baseline) comparison 
 
 
Table 1. Gene ontology results using upregulated genes. Top 10 ontology terms for biological 
process, molecular function and cellular component generated using Enrichr, in order of adjusted p-
value. 
 
 
Upregulated terms Adjusted p-value
mRNA splicing, via spliceosome (GO:0000398) 3.29E-09
RNA splicing, via transesterification reactions with bulged adenosine as nucleophile (GO:0000377) 4.54E-09
mRNA processing (GO:0006397) 1.40E-08
RNA metabolic process (GO:0016070) 7.38E-05
RNA processing (GO:0006396) 3.84E-04
RNA splicing (GO:0008380) 2.48E-03
nucleic acid metabolic process (GO:0090304) 8.81E-03
RNA secondary structure unwinding (GO:0010501) 9.85E-03
ribonucleoprotein complex assembly (GO:0022618) 1.31E-02
Golgi to plasma membrane protein transport (GO:0043001) 2.81E-02
RNA binding (GO:0003723) 5.41E-16
mRNA binding (GO:0003729) 2.85E-07
translation initiation factor activity (GO:0003743) 1.08E-03
translation factor activity, RNA binding (GO:0008135) 6.86E-03
proteasome-activating ATPase activity (GO:0036402) 2.45E-02
ATP-dependent helicase activity (GO:0008026) 2.56E-02
RNA-dependent ATPase activity (GO:0008186) 2.56E-02
ATP-dependent RNA helicase activity (GO:0004004) 2.62E-02
RNA helicase activity (GO:0003724) 3.00E-02
ATPase activity (GO:0016887) 3.01E-02
nucleolus (GO:0005730) 1.70E-07
spliceosomal complex (GO:0005681) 3.86E-07
nuclear body (GO:0016604) 1.04E-04
nuclear speck (GO:0016607) 7.09E-04
spindle pole (GO:0000922) 1.86E-03
U2-type spliceosomal complex (GO:0005684) 6.69E-03
endoplasmic reticulum tubular network (GO:0071782) 1.23E-02
RNA polymerase II transcription factor complex (GO:0090575) 1.50E-02
nuclear proteasome complex (GO:0031595) 1.62E-02
cytosolic proteasome complex (GO:0031597) 1.92E-02
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Table 2. Gene ontology results using downregulated genes. Top 10 ontology terms for biological 
process, molecular function and cellular component generated using Enrichr, in order of adjusted p-
value. 
 
Downregulated terms Adjusted p-value
respiratory electron transport chain (GO:0022904) 1.40E-15
mitochondrial ATP synthesis coupled electron transport (GO:0042775) 1.63E-15
mitochondrial respiratory chain complex assembly (GO:0033108) 1.17E-13
mitochondrial translational elongation (GO:0070125) 1.68E-13
cellular protein metabolic process (GO:0044267) 3.45E-13
mitochondrial transport (GO:0006839) 1.90E-12
mitochondrial translational termination (GO:0070126) 2.00E-12
translational termination (GO:0006415) 2.02E-12
translation (GO:0006412) 3.77E-12
translational elongation (GO:0006414) 4.14E-12
NADH dehydrogenase (ubiquinone) activity (GO:0008137) 1.54E-08
NADH dehydrogenase (quinone) activity (GO:0050136) 7.68E-09
hydrogen ion transmembrane transporter activity (GO:0015078) 9.77E-06
NADH dehydrogenase activity (GO:0003954) 2.13E-04
ATPase activity, coupled to transmembrane movement of ions, rotational mechanism (GO:0044769) 1.94E-04
RNA binding (GO:0003723) 3.18E-04
ubiquitin protein ligase binding (GO:0031625) 1.65E-02
proton-transporting ATPase activity, rotational mechanism (GO:0046961) 3.18E-02
ubiquitin-like protein ligase binding (GO:0044389) 3.04E-02
proton-transporting ATP synthase activity, rotational mechanism (GO:0046933) 3.05E-02
mitochondrion (GO:0005739) 8.61E-31
mitochondrial inner membrane (GO:0005743) 1.10E-28
mitochondrial respiratory chain complex I (GO:0005747) 6.23E-10
mitochondrial matrix (GO:0005759) 1.37E-08
mitochondrial large ribosomal subunit (GO:0005762) 4.97E-08
cytosolic ribosome (GO:0022626) 3.04E-07
lysosomal membrane (GO:0005765) 9.41E-07
azurophil granule (GO:0042582) 1.98E-06
cytosolic part (GO:0044445) 3.65E-06
lysosome (GO:0005764) 1.32E-05
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Appendix 4 - Pathway analysis for the MHN vs MHShc comparison (baseline) 
 
 
 
 
Table 1. Pathway analysis for MHN vs MHShc at baseline. The top 10 pathway terms generated by Enrichr, using upregulated and downregulated gene lists. 
Upregulated (Top) and downregulated (bottom) pathways are displayed in order of combined score (log of p-value from Fisher’s exact test multiplied by z score 
of deviation from expected rank). 
 
Index Upregulated pathway terms P-value Adjusted p-value Odds Ratio Combined score
1 SREBF and miR33 in cholesterol and lipid homeostasis WP2011 3.93E-04 2.32E-02 67.57 529.82
2 Photodynamic therapy-induced NF-kB survival signaling WP3617 3.66E-05 5.76E-03 46.33 473.28
3 Overview of nanoparticle effects WP3287 5.58E-04 2.64E-02 56.9 426.21
4 Adipogenesis WP236 1.32E-07 6.25E-05 24.95 395.13
5 PPAR signaling pathway WP3942 6.99E-06 1.65E-03 32.27 383.1
6 Transcription factor regulation in adipogenesis WP3599 7.52E-04 3.23E-02 49.14 353.49
7 Vitamin B12 Metabolism WP1533 1.08E-04 1.02E-02 32.43 296.34
8 Eicosanoid Synthesis WP167 1.14E-03 4.47E-02 40.04 271.51
9 Composition of Lipid Particles WP3601 1.65E-02 3.12E-01 60.06 246.4
10 Role Altered Glycolysation of MUC1 in Tumour Microenvironment WP4480 1.65E-02 3.00E-01 60.06 246.4
Index Downregulated pathway terms P-value Adjusted p-value Odds Ratio Combined score
1 Oxidative phosphorylation WP623 1.97E-03 9.28E-01 30.3 188.83
2 Electron Transport Chain (OXPHOS system in mitochondria) WP111 5.67E-03 1.00E+00 17.65 91.3
3 Target Of Rapamycin (TOR) Signaling WP1471 3.89E-02 1.00E+00 25.25 82
4 Glycolysis and Gluconeogenesis WP534 4.84E-02 1.00E+00 20.2 61.19
5 Selenium Metabolism and Selenoproteins WP28 4.94E-02 1.00E+00 19.76 59.43
6 Calcium Regulation in the Cardiac Cell WP536 1.16E-02 1.00E+00 12.2 54.44
7 TGF-beta Receptor Signaling WP560 5.78E-02 1.00E+00 16.84 48
8 Mitochondrial complex I assembly model OXPHOS system WP4324 5.99E-02 1.00E+00 16.23 45.71
9 Proteasome Degradation WP183 6.61E-02 1.00E+00 14.66 39.84
10 Alzheimers Disease WP2059 8.75E-02 1.00E+00 10.95 26.69
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Table 1. Gene ontology results using upregulated genes. Top 10 ontology terms for biological 
process, molecular function and cellular component generated using Enrichr, in order of adjusted p-
value. 
 
Upregulated terms Adjusted p-value
positive regulation of acute inflammatory response (GO:0002675) 3.33E-01
fat cell differentiation (GO:0045444) 3.36E-01
regulation of inflammatory response (GO:0050727) 3.73E-01
regulation of fat cell differentiation (GO:0045598) 3.74E-01
regulation of vascular associated smooth muscle cell migration (GO:1904752) 4.47E-01
regulation of vascular endothelial growth factor production (GO:0010574) 7.84E-01
regulation of macrophage derived foam cell differentiation (GO:0010743) 7.91E-01
positive regulation of type 2 immune response (GO:0002830) 8.36E-01
internal protein amino acid acetylation (GO:0006475) 8.42E-01
regulation of transforming growth factor beta production (GO:0071634) 8.44E-01
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, 
incorporation of two atoms of oxygen (GO:0016702)
7.45E-01
manganese ion binding (GO:0030145) 1.00E+00
clathrin heavy chain binding (GO:0032050) 1.00E+00
primary amine oxidase activity (GO:0008131) 1.00E+00
RNA polymerase II core promoter proximal region sequence-specific DNA binding (GO:0000978) 1.00E+00
interleukin-6 receptor binding (GO:0005138) 1.00E+00
calcium-dependent phospholipase A2 activity (GO:0047498) 1.00E+00
phospholipase binding (GO:0043274) 1.00E+00
core promoter proximal region sequence-specific DNA binding (GO:0000987) 1.00E+00
transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific 
binding (GO:0000982)
1.00E+00
lipid droplet (GO:0005811) 1.00E+00
endoplasmic reticulum lumen (GO:0005788) 1.00E+00
extrinsic component of external side of plasma membrane (GO:0031232) 1.00E+00
nuclear speck (GO:0016607) 1.00E+00
nuclear body (GO:0016604) 1.00E+00
endolysosome membrane (GO:0036020) 1.00E+00
nucleolus (GO:0005730) 1.00E+00
endolysosome (GO:0036019) 1.00E+00
U4/U6 x U5 tri-snRNP complex (GO:0046540) 1.00E+00
brush border membrane (GO:0031526) 1.00E+00
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Table 2. Gene ontology results using downregulated genes. Top 10 ontology terms for biological 
process, molecular function and cellular component generated using Enrichr, in order of adjusted p-
value. 
 
 
 
Downregulated terms Adjusted p-value
heart trabecula formation (GO:0060347) 1.00E+00
membrane invagination (GO:0010324) 1.00E+00
negative regulation of establishment of protein localization (GO:1904950) 1.00E+00
SMAD protein complex assembly (GO:0007183) 1.00E+00
amyloid fibril formation (GO:1990000) 1.00E+00
regulation of amyloid precursor protein catabolic process (GO:1902991) 1.00E+00
vacuolar proton-transporting V-type ATPase complex assembly (GO:0070072) 1.00E+00
negative regulation of phagocytosis (GO:0050765) 1.00E+00
proton-transporting V-type ATPase complex assembly (GO:0070070) 1.00E+00
establishment of synaptic vesicle localization (GO:0097480) 1.00E+00
FK506 binding (GO:0005528) 1.03E-01
peptidyl-prolyl cis-trans isomerase activity (GO:0003755) 3.39E-01
type I transforming growth factor beta receptor binding (GO:0034713) 1.00E+00
phosphatidylinositol-5-phosphate binding (GO:0010314) 1.00E+00
activin binding (GO:0048185) 1.00E+00
proton-transporting ATP synthase activity, rotational mechanism (GO:0046933) 1.00E+00
phosphatidylinositol-3,5-bisphosphate binding (GO:0080025) 1.00E+00
phosphatidylinositol-4-phosphate binding (GO:0070273) 1.00E+00
ATPase activity, coupled to transmembrane movement of ions, rotational mechanism (GO:0044769) 1.00E+00
calcium channel regulator activity (GO:0005246) 1.00E+00
mitochondrial proton-transporting ATP synthase complex (GO:0005753) 8.71E-02
mitochondrion (GO:0005739) 4.99E-01
mitochondrial inner membrane (GO:0005743) 5.78E-01
mitochondrial proton-transporting ATP synthase complex, coupling factor F(o) (GO:0000276) 5.92E-01
early phagosome (GO:0032009) 7.39E-01
endoplasmic reticulum subcompartment (GO:0098827) 9.83E-01
early endosome (GO:0005769) 1.00E+00
sarcoplasmic reticulum (GO:0016529) 1.00E+00
intrinsic component of mitochondrial inner membrane (GO:0031304) 1.00E+00
sarcoplasm (GO:0016528) 1.00E+00
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Appendix 6 – Gene ontology analysis for MHN pre vs post IVCT (halothane) 
comparison 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Gene ontology results using upregulated genes. Top 10 ontology terms for biological 
process, molecular function and cellular component generated using Enrichr, in order of adjusted p-
value. 
Upregulated terms Adjusted p-value
regulation of transcription, DNA-templated (GO:0006355) 1.03E-15
regulation of transcription from RNA polymerase II promoter (GO:0006357) 1.15E-14
RNA splicing, via transesterification reactions with bulged adenosine as 
nucleophile (GO:0000377)
1.27E-14
mRNA splicing, via spliceosome (GO:0000398) 1.00E-13
positive regulation of transcription, DNA-templated (GO:0045893) 1.00E-13
mRNA processing (GO:0006397) 5.97E-13
transcription from RNA polymerase II promoter (GO:0006366) 1.10E-12
positive regulation of transcription from RNA polymerase II promoter 
(GO:0045944)
3.61E-09
regulation of gene expression (GO:0010468) 7.47E-09
transcription, DNA-templated (GO:0006351) 7.93E-09
RNA binding (GO:0003723) 6.33E-31
DNA binding (GO:0003677) 1.04E-05
ATP-dependent helicase activity (GO:0008026) 2.34E-05
mRNA binding (GO:0003729) 4.26E-05
purine ribonucleoside triphosphate binding (GO:0035639) 6.77E-05
transcription regulatory region DNA binding (GO:0044212) 6.85E-05
ATPase activity, coupled (GO:0042623) 8.51E-05
ATPase activity (GO:0016887) 8.91E-05
nucleoside-triphosphatase activity (GO:0017111) 1.10E-04
nuclear hormone receptor binding (GO:0035257) 1.16E-04
nuclear body (GO:0016604) 4.25E-14
nucleolus (GO:0005730) 5.65E-12
nuclear speck (GO:0016607) 6.20E-12
cytoskeleton (GO:0005856) 1.66E-06
nucleoplasm part (GO:0044451) 1.87E-06
spliceosomal complex (GO:0005681) 1.38E-05
microtubule organizing center (GO:0005815) 1.39E-05
microtubule organizing center part (GO:0044450) 8.70E-05
actin cytoskeleton (GO:0015629) 8.90E-05
centrosome (GO:0005813) 9.63E-05
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Table 2. Gene ontology results using downregulated genes. Top 10 ontology terms for biological 
process, molecular function and cellular component generated using Enrichr, in order of adjusted p-
value. 
Downregulated terms Adjusted p-value
SRP-dependent cotranslational protein targeting to membrane (GO:0006614) 3.53E-31
protein targeting to ER (GO:0045047) 1.21E-30
cotranslational protein targeting to membrane (GO:0006613) 4.69E-30
respiratory electron transport chain (GO:0022904) 6.74E-30
mitochondrial ATP synthesis coupled electron transport (GO:0042775) 7.46E-30
peptide biosynthetic process (GO:0043043) 9.43E-30
translation (GO:0006412) 3.35E-27
nuclear-transcribed mRNA catabolic process, nonsense-mediated decay (GO:0000184) 2.57E-25
viral transcription (GO:0019083) 3.93E-24
viral gene expression (GO:0019080) 4.87E-24
NADH dehydrogenase (quinone) activity (GO:0050136) 4.97E-13
NADH dehydrogenase (ubiquinone) activity (GO:0008137) 9.94E-13
rRNA binding (GO:0019843) 3.16E-03
small ribosomal subunit rRNA binding (GO:0070181) 3.63E-03
ubiquitin conjugating enzyme activity (GO:0061631) 4.58E-03
NADH dehydrogenase activity (GO:0003954) 6.25E-03
ubiquitin-like protein conjugating enzyme activity (GO:0061650) 6.56E-03
ubiquinol-cytochrome-c reductase activity (GO:0008121) 6.56E-03
oxidoreductase activity, acting on diphenols and related substances as donors, cytochrome as 
acceptor (GO:0016681)
7.50E-03
RNA binding (GO:0003723) 2.06E-02
mitochondrion (GO:0005739) 1.73E-39
mitochondrial inner membrane (GO:0005743) 2.44E-30
cytosolic ribosome (GO:0022626) 2.10E-28
cytosolic part (GO:0044445) 1.96E-21
small ribosomal subunit (GO:0015935) 5.04E-18
cytosolic small ribosomal subunit (GO:0022627) 3.37E-16
mitochondrial respiratory chain complex I (GO:0005747) 1.54E-15
ribosome (GO:0005840) 2.47E-14
large ribosomal subunit (GO:0015934) 1.08E-12
cytosolic large ribosomal subunit (GO:0022625) 1.47E-12
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Appendix 7 – Gene ontology analysis for MHS pre vs post IVCT (halothane) 
comparison 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Gene ontology results using upregulated genes. Top 10 ontology terms for biological 
process, molecular function and cellular component generated using Enrichr, in order of adjusted p-
value. 
Upregulated terms Adjusted p-value
protein kinase B signaling (GO:0043491) 6.18E-04
response to unfolded protein (GO:0006986) 6.19E-04
response to interleukin-1 (GO:0070555) 6.22E-04
cellular response to tumor necrosis factor (GO:0071356) 6.41E-04
inflammatory response (GO:0006954) 6.46E-04
chemokine-mediated signaling pathway (GO:0070098) 7.98E-04
eosinophil chemotaxis (GO:0048245) 1.07E-03
negative regulation of extrinsic apoptotic signaling pathway in absence of 
ligand (GO:2001240)
1.17E-03
chaperone mediated protein folding requiring cofactor (GO:0051085) 1.17E-03
response to tumor necrosis factor (GO:0034612) 1.24E-03
chemokine receptor binding (GO:0042379) 1.77E-04
chemokine activity (GO:0008009) 2.26E-04
cytokine activity (GO:0005125) 6.76E-04
C3HC4-type RING finger domain binding (GO:0055131) 4.32E-03
CCR chemokine receptor binding (GO:0048020) 5.64E-03
transcription corepressor activity (GO:0003714) 2.17E-02
transcription regulatory region DNA binding (GO:0044212) 3.08E-02
sequence-specific double-stranded DNA binding (GO:1990837) 8.59E-02
transcriptional repressor activity, RNA polymerase II transcription regulatory 
region sequence-specific binding (GO:0001227)
8.77E-02
ubiquitin protein ligase binding (GO:0031625) 1.07E-01
tertiary granule lumen (GO:1904724) 1.83E-01
ficolin-1-rich granule lumen (GO:1904813) 2.18E-01
ficolin-1-rich granule (GO:0101002) 2.38E-01
specific granule (GO:0042581) 3.29E-01
tertiary granule (GO:0070820) 3.67E-01
specific granule lumen (GO:0035580) 1.00E+00
nuclear speck (GO:0016607) 1.00E+00
nuclear body (GO:0016604) 1.00E+00
tertiary granule membrane (GO:0070821) 1.00E+00
specific granule membrane (GO:0035579) 1.00E+00
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Table 2. Gene ontology results using downregulated genes. Top 10 ontology terms for biological 
process, molecular function and cellular component generated using Enrichr, in order of adjusted p-
value. 
Downregulated terms Adjusted p-value
mitochondrial electron transport, NADH to ubiquinone (GO:0006120) 3.62E-02
respiratory electron transport chain (GO:0022904) 5.36E-02
mitochondrial ATP synthesis coupled electron transport (GO:0042775) 6.56E-02
mitochondrial respiratory chain complex I assembly (GO:0032981) 6.71E-02
mitochondrial respiratory chain complex I biogenesis (GO:0097031) 8.05E-02
NADH dehydrogenase complex assembly (GO:0010257) 1.01E-01
glomerulus vasculature development (GO:0072012) 1.35E-01
negative regulation of blood coagulation (GO:0030195) 1.80E-01
mitochondrial respiratory chain complex assembly (GO:0033108) 2.23E-01
endothelium development (GO:0003158) 2.80E-01
NADH dehydrogenase (quinone) activity (GO:0050136) 2.75E-01
NADH dehydrogenase (ubiquinone) activity (GO:0008137) 5.50E-01
protein tyrosine/serine/threonine phosphatase activity (GO:0008138) 1.00E+00
SH3/SH2 adaptor activity (GO:0005070) 1.00E+00
mitogen-activated protein kinase kinase binding (GO:0031434) 1.00E+00
chloride ion binding (GO:0031404) 1.00E+00
MAP kinase tyrosine/serine/threonine phosphatase activity (GO:0017017) 1.00E+00
ubiquinol-cytochrome-c reductase activity (GO:0008121) 1.00E+00
bioactive lipid receptor activity (GO:0045125) 1.00E+00
oxidoreductase activity, acting on diphenols and related substances as donors, 
cytochrome as acceptor (GO:0016681)
1.00E+00
mitochondrial respiratory chain complex I (GO:0005747) 3.52E-01
mitochondrial inner membrane (GO:0005743) 2.96E-01
intercalated disc (GO:0014704) 8.04E-01
platelet alpha granule (GO:0031091) 1.00E+00
potassium channel complex (GO:0034705) 1.00E+00
mitochondrial respiratory chain complex III (GO:0005750) 1.00E+00
platelet alpha granule membrane (GO:0031092) 1.00E+00
anchored component of external side of plasma membrane (GO:0031362) 1.00E+00
intrinsic component of external side of plasma membrane (GO:0031233) 1.00E+00
mitochondrial proton-transporting ATP synthase complex (GO:0005753) 1.00E+00
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Appendix 8 – Pathway analysis for pre vs post IVCT (caffeine) comparisons 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Pathways upregulated pre vs post IVCT caffeine. The top 10 enriched pathway terms generated by Enrichr, using upregulated gene lists. Pathway 
terms upregulated in MHN (Top) and MHS (bottom) phenotypes are displayed in order of combined score (log of p-value from Fisher’s exact test multiplied 
by z score of deviation from expected rank). 
 
Index Upregulated pathway terms P-value Adjusted p-value Odds Ratio Combined score
1 Photodynamic therapy-induced NF-kB survival signaling WP3617 1.59E-13 7.52E-11 10.87 320.36
2 miRNAs involvement in the immune response in sepsis WP4329 1.64E-09 1.93E-07 8.36 169.04
3 mRNA Processing WP411 2.05E-12 4.83E-10 5.1 137.16
4 Spinal Cord Injury WP2431 1.10E-10 1.73E-08 4.84 110.92
5 Photodynamic therapy-induced unfolded protein response WP3613 9.32E-07 4.00E-05 7.93 110.08
6 IL1 and megakaryocytes in obesity WP2865 3.81E-06 1.06E-04 7.93 98.9
7 Lung fibrosis WP3624 3.71E-08 2.92E-06 5.66 96.88
8 Hypertrophy Model WP516 1.09E-05 2.23E-04 8.32 95.13
9 Apoptosis-related network due to altered Notch3 in ovarian cancer WP2864 2.07E-07 1.22E-05 5.83 89.77
10 TNF related weak inducer of apoptosis (TWEAK) Signaling Pathway WP2036 8.81E-07 4.16E-05 6.23 86.84
MHN (pre vs post caffeine)
Index Name P-value Adjusted p-value Odds Ratio Combined score
1 miRNAs involvement in the immune response in sepsis WP4329 3.01E-11 1.42E-08 16.56 401.23
2 Photodynamic therapy-induced NF-kB survival signaling WP3617 3.78E-10 8.91E-08 15.92 345.36
3 Cells and Molecules involved in local acute inflammatory response WP4493 3.36E-07 2.27E-05 19.66 293.1
4 Platelet-mediated interactions with vascular and circulating cells WP4462 9.39E-06 3.17E-04 16.39 189.68
5 Photodynamic therapy-induced AP-1 survival signaling. WP3611 2.29E-07 2.16E-05 10.03 153.31
6 Role Altered Glycolysation of MUC1 in Tumour Microenvironment WP4480 4.45E-04 6.17E-03 18.57 143.33
7 Ethanol metabolism resulting in production of ROS by CYP2E1 WP4269 6.27E-04 8.22E-03 16.71 123.26
8 EBV LMP1 signaling WP262 4.67E-05 1.23E-03 12.11 120.76
9 Spinal Cord Injury WP2431 2.71E-08 4.26E-06 6.61 115.17
10 IL1 and megakaryocytes in obesity WP2865 5.82E-05 1.45E-03 11.61 113.19
MHS (pre vs post caffeine)
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Table 2. Pathways downregulated pre vs post IVCT caffeine. The top 10 enriched pathway terms generated by Enrichr, using downregulated gene lists. 
Pathway terms downregulated in MHN (Top) and MHS (bottom) phenotypes are displayed in order of combined score (log of p-value from Fisher’s exact test 
multiplied by z score of deviation from expected rank). 
Index Downregulated pathway terms P-value Adjusted p-value Odds Ratio Combined score
1 Electron Transport Chain (OXPHOS system in mitochondria) WP111 5.20E-12 2.46E-09 7.07 183.79
2 Oxidative phosphorylation WP623 6.12E-07 9.62E-05 6.68 95.56
3 Nonalcoholic fatty liver disease WP4396 5.32E-08 1.26E-05 4.47 74.79
4 Target Of Rapamycin (TOR) Signaling WP1471 4.72E-05 5.57E-03 7.08 70.55
5 Robo4 and VEGF Signaling Pathways Crosstalk WP3943 1.05E-02 9.90E-01 12.14 55.35
6 TCA Cycle (aka Krebs or citric acid cycle) WP78 1.24E-02 9.71E-01 6.07 26.68
7 Interleukin-1 Induced Activation of NF-kappa-B WP3656 2.93E-02 1.00E+00 7.29 25.73
8 RalA downstream regulated genes WP2290 4.14E-02 1.00E+00 6.07 19.34
9 miR-517 relationship with ARCN1 and USP1 WP3596 1.30E-01 1.00E+00 7.29 14.87
10 Metastatic brain tumor WP2249 1.54E-01 1.00E+00 6.07 11.37
MHN (pre vs post caffeine)
Index Downregulated pathway terms P-value Adjusted p-value Odds Ratio Combined score
1 miR-517 relationship with ARCN1 and USP1 WP3596 3.06E-02 1 32.26 112.45
2 exRNA mechanism of action and biogenesis WP2805 3.66E-02 1 26.88 88.89
3 miRNA Biogenesis WP2338 3.66E-02 1 26.88 88.89
4 Robo4 and VEGF Signaling Pathways Crosstalk WP3943 3.66E-02 1 26.88 88.89
5 Hfe effect on hepcidin production WP3924 4.26E-02 1 23.04 72.71
6 DDX1 as a regulatory component of the Drosha microprocessor WP2942 4.26E-02 1 23.04 72.71
7 Dual hijack model of Vif in HIV infection WP3300 4.86E-02 1 20.16 60.99
8 White fat cell differentiation WP4149 1.68E-02 1 10.08 41.22
9 Gene regulatory network modelling somitogenesis WP2854 6.61E-02 1 14.66 39.82
10 Type 2 papillary renal cell carcinoma WP4241 1.88E-02 1 9.49 37.71
MHS (pre vs post caffeine)
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Appendix 9 – Gene ontology for MHN pre vs post IVCT (caffeine) comparison 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Gene ontology results using upregulated genes. Top 10 ontology terms for biological 
process, molecular function and cellular component generated using Enrichr, in order of adjusted p-
value. 
 
Upregulated terms Adjusted p-value
regulation of transcription from RNA polymerase II promoter (GO:0006357) 1.35E-14
regulation of transcription, DNA-templated (GO:0006355) 1.72E-12
positive regulation of transcription, DNA-templated (GO:0045893) 2.75E-12
RNA splicing, via transesterification reactions with bulged adenosine as nucleophile (GO:0000377) 7.86E-11
cytokine-mediated signaling pathway (GO:0019221) 9.72E-11
mRNA splicing, via spliceosome (GO:0000398) 2.48E-10
negative regulation of transcription from RNA polymerase II promoter (GO:0000122) 5.99E-10
cellular response to cytokine stimulus (GO:0071345) 6.43E-10
positive regulation of transcription from RNA polymerase II promoter (GO:0045944) 1.44E-09
mRNA processing (GO:0006397) 3.37E-09
RNA binding (GO:0003723) 5.81E-19
transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific 
binding (GO:0000982)
3.15E-06
RNA polymerase II core promoter proximal region sequence-specific DNA binding (GO:0000978) 7.28E-06
core promoter proximal region sequence-specific DNA binding (GO:0000987) 1.08E-05
RNA polymerase II regulatory region sequence-specific DNA binding (GO:0000977) 1.10E-05
transcription regulatory region DNA binding (GO:0044212) 1.30E-05
DNA binding (GO:0003677) 2.33E-05
core promoter binding (GO:0001047) 6.93E-05
purine ribonucleoside triphosphate binding (GO:0035639) 1.06E-04
transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific 
binding (GO:0001227)
2.37E-04
nuclear body (GO:0016604) 1.61E-08
nuclear speck (GO:0016607) 9.04E-09
nucleolus (GO:0005730) 1.69E-08
cytoskeleton (GO:0005856) 4.43E-05
actin cytoskeleton (GO:0015629) 7.04E-04
spliceosomal complex (GO:0005681) 1.91E-03
focal adhesion (GO:0005925) 3.94E-03
Cajal body (GO:0015030) 1.02E-02
fibrillar center (GO:0001650) 9.50E-03
microtubule cytoskeleton (GO:0015630) 9.37E-03
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Table 2. Gene ontology results using downregulated genes. Top 10 ontology terms for biological 
process, molecular function and cellular component generated using Enrichr, in order of adjusted p-
value. 
 
 
 
 
Downregulated terms Adjusted p-value
respiratory electron transport chain (GO:0022904) 1.12E-21
mitochondrial ATP synthesis coupled electron transport (GO:0042775) 1.47E-21
mitochondrial electron transport, NADH to ubiquinone (GO:0006120) 3.38E-07
mitochondrial respiratory chain complex assembly (GO:0033108) 3.92E-07
mitochondrial electron transport, cytochrome c to oxygen (GO:0006123) 9.04E-07
cellular respiration (GO:0045333) 7.89E-06
mitochondrial respiratory chain complex I assembly (GO:0032981) 3.20E-05
mitochondrial respiratory chain complex I biogenesis (GO:0097031) 3.61E-05
NADH dehydrogenase complex assembly (GO:0010257) 4.12E-05
preassembly of GPI anchor in ER membrane (GO:0016254) 2.83E-04
NADH dehydrogenase (quinone) activity (GO:0050136) 5.29E-07
NADH dehydrogenase (ubiquinone) activity (GO:0008137) 1.06E-06
small ribosomal subunit rRNA binding (GO:0070181) 2.14E-03
ubiquinol-cytochrome-c reductase activity (GO:0008121) 3.28E-03
oxidoreductase activity, acting on diphenols and related substances as donors, cytochrome as acceptor 
(GO:0016681)
4.10E-03
ubiquitin conjugating enzyme activity (GO:0061631) 5.79E-02
ubiquitin-like protein conjugating enzyme activity (GO:0061650) 6.66E-02
rRNA binding (GO:0019843) 1.52E-01
NADH dehydrogenase activity (GO:0003954) 1.69E-01
2 iron, 2 sulfur cluster binding (GO:0051537) 1.87E-01
mitochondrion (GO:0005739) 4.13E-18
mitochondrial inner membrane (GO:0005743) 5.51E-18
mitochondrial respiratory chain complex I (GO:0005747) 1.69E-07
mitochondrial respiratory chain complex IV (GO:0005751) 1.71E-07
mitochondrial respiratory chain complex III (GO:0005750) 6.97E-06
mitochondrial matrix (GO:0005759) 1.03E-02
mitochondrial small ribosomal subunit (GO:0005763) 1.44E-02
small ribosomal subunit (GO:0015935) 1.45E-02
intrinsic component of mitochondrial inner membrane (GO:0031304) 2.06E-02
signal recognition particle (GO:0048500) 2.70E-02
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Appendix 10 – Gene ontology for MHS pre vs post IVCT (caffeine) comparison 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Gene ontology results using upregulated genes. Top 10 ontology terms for biological 
process, molecular function and cellular component generated using Enrichr, in order of adjusted p-
value. 
 
Upregulated terms Adjusted p-value
response to unfolded protein (GO:0006986) 9.40E-07
inflammatory response (GO:0006954) 8.34E-05
cellular response to tumor necrosis factor (GO:0071356) 1.45E-04
response to tumor necrosis factor (GO:0034612) 2.15E-04
regulation of NF-kappaB import into nucleus (GO:0042345) 2.83E-04
negative regulation of cellular process (GO:0048523) 3.88E-04
regulation of cell proliferation (GO:0042127) 4.16E-04
positive regulation of transcription, DNA-templated (GO:0045893) 5.71E-04
PERK-mediated unfolded protein response (GO:0036499) 7.34E-04
cellular response to heat (GO:0034605) 8.68E-04
chemokine receptor binding (GO:0042379) 2.20E-04
transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific 
binding (GO:0000982)
4.71E-04
chemokine activity (GO:0008009) 5.50E-04
cytokine activity (GO:0005125) 1.34E-03
transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific 
binding (GO:0001228)
3.75E-03
CCR chemokine receptor binding (GO:0048020) 1.05E-02
RNA polymerase II core promoter proximal region sequence-specific DNA binding (GO:0000978) 1.21E-02
transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific 
binding (GO:0001077)
1.31E-02
C3HC4-type RING finger domain binding (GO:0055131) 1.41E-02
core promoter proximal region sequence-specific DNA binding (GO:0000987) 1.87E-02
ficolin-1-rich granule lumen (GO:1904813) 1.70E-01
ficolin-1-rich granule (GO:0101002) 4.15E-01
specific granule (GO:0042581) 1.00E+00
tertiary granule (GO:0070820) 1.00E+00
tertiary granule lumen (GO:1904724) 1.00E+00
nuclear speck (GO:0016607) 1.00E+00
specific granule membrane (GO:0035579) 1.00E+00
endolysosome membrane (GO:0036020) 1.00E+00
nuclear body (GO:0016604) 1.00E+00
endocytic vesicle lumen (GO:0071682) 1.00E+00
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Table 2. Gene ontology results using downregulated genes. Top 10 ontology terms for biological 
process, molecular function and cellular component generated using Enrichr, in order of adjusted p-
value. 
Downregulated terms Adjusted p-value
regulation of nitric oxide biosynthetic process (GO:0045428) 2.26E-01
negative regulation of cellular biosynthetic process (GO:0031327) 5.21E-01
regulation of protein tyrosine kinase activity (GO:0061097) 5.22E-01
regulation of blood coagulation (GO:0030193) 5.33E-01
negative regulation of nitric oxide biosynthetic process (GO:0045019) 5.72E-01
negative regulation of binding (GO:0051100) 6.18E-01
negative regulation of cell activation (GO:0050866) 6.52E-01
mitochondrial ATP synthesis coupled electron transport (GO:0042775) 6.58E-01
negative regulation of nitric oxide metabolic process (GO:1904406) 6.67E-01
regulation of endothelial cell proliferation (GO:0001936) 6.85E-01
calcium-activated potassium channel activity (GO:0015269) 1.00E+00
calcium activated cation channel activity (GO:0005227) 1.00E+00
potassium channel regulator activity (GO:0015459) 1.00E+00
NADH dehydrogenase (quinone) activity (GO:0050136) 1.00E+00
NADH dehydrogenase (ubiquinone) activity (GO:0008137) 1.00E+00
patched binding (GO:0005113) 1.00E+00
primary miRNA binding (GO:0070878) 1.00E+00
chloride ion binding (GO:0031404) 1.00E+00
MAP kinase tyrosine/serine/threonine phosphatase activity (GO:0017017) 1.00E+00
calcium-dependent protein serine/threonine phosphatase activity 
(GO:0004723)
1.00E+00
lipid droplet (GO:0005811) 1.00E+00
mitochondrial respiratory chain complex I (GO:0005747) 1.00E+00
ruffle membrane (GO:0032587) 1.00E+00
filopodium (GO:0030175) 1.00E+00
IkappaB kinase complex (GO:0008385) 1.00E+00
condensed nuclear chromosome kinetochore (GO:0000778) 1.00E+00
actin-based cell projection (GO:0098858) 1.00E+00
nuclear telomere cap complex (GO:0000783) 1.00E+00
mitochondrial respiratory chain complex III (GO:0005750) 1.00E+00
perinuclear region of cytoplasm (GO:0048471) 1.00E+00
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Appendix 11 - Genes overlapping between MHS drug treatment gene lists 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Genes overlapping between MHS drug treatment gene lists. All genes lists in the MHS pre vs post drug treatment were compared and the genes 
within each segment of the Venn diagram displayed in Figure 2.12, are presented here. (continued next page) 
Gene lists within each Venn 
diagram segment
Number of 
genes
Genes within overlapping segment
MHSh caffeine, MHSh halothane, 
MHShc caffeine, MHShc halothane
89
ABRA, ADAMTS4, ATF3, ATP6V1FNB, BCL3, BRD2, CCDC200, CCL2, CD83, CDKN1A, CHIT1, CKS2, CXCL1, CXCL3, DCP1A, DDIT3, 
DNAJA1, DNAJB1, DNAJB5-DT, DSTNP2, DUSP2, DUSP5, DUSP6, EGFL7, EGR2, ERF, ERRFI1, GASAL1, GEM, GIMAP6, GIMAP8, H2AX, 
H2BC20P, HEXIM1, HHATL-AS1, HNRNPA1P38, HSPA1A, HSPA1B, ICAM1, ICAM4, ID1, IL1B, ING1, IQCN, IRF1, LFNG, MAFB, MAFF, 
MIR3153, MT1A, MT-ND6, MT-TA, MT-TC, MT-TE, MT-TF, MT-TK, MT-TM, MT-TN, MT-TQ, MT-TT, MT-TY, PECAM1, PPP1R10, RCAN1, 
RGS16, RND1, RPL13P5, SAT1, SELE, SERTAD1, SLC20A1, SLC2A14, SLC2A3, SNHG12, SNORA10, SNORD14C, SNORD14D, SNORD14E, 
SNORD3A, SNORD3B-1, SNORD3B-2, SNORD3C, SNORD3D, SOCS1, SRSF2, SRSF3, TNFAIP3, TNFRSF10D, TNFSF9
MHSh caffeine, MHShc caffeine, 
MHShc halothane
37
AMD1, ARHGEF15, ARID5B, ARL5B, BIRC3, BTG3, CBX4, CCL8, CLDN6, DIPK2B, FAM71A, GJA1, GPR183, ID4, IER3, INSIG1, IVNS1ABP, 
LINC01004, MT-TV, NABP1, NKX3-1, OLR1, PCF11, PHLDA1, PNP, POLG2, RNU5E-1, SERPINB9, SNORA61, THSD1, TIPARP, TNF, 
TNFAIP6, TNFAIP8L1, VSIG2, ZC3HAV1, ZNF792
MHSh caffeine, MHSh halothane, 
MHShc halothane
4 LRG1, MIR24-2, MT-TP, S1PR1
MHSh caffeine, MHSh halothane, 
MHShc caffeine
9 EGR4, HSP90AB1, MIR616, MT-TS2, MT-TW, PDE4B, PLEKHO2, SNORD99, TSPYL2
MHShc caffeine, MHShc halothane 51
A2M, ABHD5, APCDD1, ARAP3, ARHGAP31, ARL6IP1, C16orf58, CCDC71L, CDH5, CDKN2AIP, CLEC1A, COL15A1, COL4A1, 
CRNDE, CTC1, DCHS1, DONSON, GCFC2, GJA5, KCNQ1OT1, KLRA1P, LYPLAL1, MGAT4A, MIR222HG, MIR3064, NAE1, NAMPT, 
NFE2L2, NOVA2, NYNRIN, PAX7, PDGFB, PIK3R3, RASD2, RET, RFX5, RSRP1, SDC3, SFPQ, SMARCD1, SNORA31, TCIM, 
TCTE3, TDRD6, THUMPD3-AS1, TM4SF1, TRIB3, UGCG, VASH1, ZNF540, ZSCAN32
MHSh caffeine, MHShc halothane 15 ARC, BMP2, BTG1, CLK2, CYP1B1, FABP5, HAS2, IER5L, KLF5, NFIL3, RASGEF1B, RND3, S1PR3, SSTR2, USHBP1
MHSh halothane, MHShc caffeine 2 CCN2, IFIT5
MHSh caffeine, MHShc caffeine 28
ASTL, BAMBI, BCL6, CDH16, CSRP2, DHDH, DNAJA4, FUS, GLA, GTF2B, HAPLN3, HSPA1L, HSPA6, IRX2, KPNA2, LITAF, MTND2P28, 
MTND5P11, MYLIP, NAMA, NFKBIE, NKX6-3, PRSS42P, PRSS44P, STAG3L2, TUBB3, VCAM1, ZNF331
MHSh caff ine, MHSh halothane 86
APOL3, BTG2, BTN3A3, C11orf91, CAV1, CAV2, CCL3, CDK2, CSRNP1, CYB561D1, DIO3OS, EDN1, EGR3, EIF4A1, EIF4A3, ERFE, ETS2, 
FABP4, FOSL2, FZD7, GADD45B, GIMAP1, GIMAP4, GIMAP7, GRASP, H2BC19P, H4C14, HBEGF, HEY1, IER5, IL6, JMJD6, KCNJ8, LAG3, 
LDLR, LRATD2, MEPCE, MIDN, MIR22, MIR23A, MIR8085, MMP19, MT-ND2, MT-TD, MT-TG, MT-TH, MT-TI, NCOA6, NDUFB4P11, 
NFKBID, NFKBIZ, NLRP3, NOLC1, NR2F2, NR4A1, NR4A3, NRN1, OSGIN1, OTUD1, PER1, PFKFB3, PLAUR, POLR2A, PPP1R15A, PRKCG, 
RBKS, RNF122, SDC4, SERTAD3, SIK1, SIK1B, SLC16A14, SLC25A25, SMURF1, SNAI1, SNHG9, SNORA64, SNORA67, STK35, TP53INP2, 
TUBB4B, XIRP1, ZC3H12A, ZFAS1, ZFP36
MHSh halothane 40
ACTN1, ANKRD29, ARNT2, ASAP2, ASPN, ATP1A2, BATF2, CNTNAP3B, DNM3OS, GIMAP2, GNG11, GNL3L, ITM2B, JAM2, JRK, KY, LEPR, 
LINC01578, LIPA, LTC4S, MAN1A1, MAU2, MICAL3, MIR23B, MOB3C, MTND4LP30, N4BP2L2-IT2, NT5C1A, PITPNC1, PPARGC1B, RGCC, 
RPL7P3, SNAI2, SOCS7, TMEM50A, TMSB4X, TMSB4XP8, ZBTB16, ZNF559, ZNF706
MHShc halothane 60
ACOT11, ADCY4, AIF1L, ANKZF1, ARHGAP11A, C5orf51, C6orf120, C6orf47, CADM1, CHRDL2, CLDN12, CREG1, DCK, DNAJC27, FBH1, 
GDAP2, GLMN, H3-3B, HS6ST2, KCNA5, LINC00672, LSM6, MIR27A, MORC2, MRPL16, MSTO1, MTATP6P1, NDUFA1, NPR1, OSGEP, 
PCDH1, PCDH12, PKD1L1, PNRC1, POT1, PRNP, PTGR1, RAP1B, RBMS3, RLF, ROBO4, RPS13P2, RYBP, SDCBP, SH2D3C, SHF, SLC19A2, 
SLC1A7, SPSB2, TBC1D23, TGFB2, TIE1, TMEM165, TMEM167B, UBE2D3, UNG, WDR33, ZBTB21, ZBTB4, ZNF500
MHSh caffeine 181
ADAMTS1, AGER, ANKRD1, ANKRD37, AOC2, APOLD1, AREG, ARID5A, ASPRV1, ATP1A1, ATP1B3, B3GNT5, BCDIN3D, BCL2A1, 
BHLHE40, BTBD19, C11orf96, C1QTNF9, C2CD4B, C4A-AS1, C9orf170, CA4, CARMN, CBX2, CCL3L1, CCL4, CCL4L2, CCND2, CD300LG, 
CEACAM1, CENPW, CFAP97D1, CGB7, CH25H, CHMP4BP1, CPNE8-AS1, CRTC3, CSF3, CSRNP2, CSTF1, CXCL2, CXCL8, CXCR4, DACT1, 
DCUN1D3, DLC1, DLG5, DNALI1, DPPA2P4, DUSP8, DYRK3, EGR1, EMP1, ENDOU, EPOP, ETV4, EXOSC6, FAM181A-AS1, FAM72A, 
FOSL1, FOXC2, FZD5, GADD45A, GAREM1, GCH1, GDNF, GH1, GIPC3, GPIHBP1, GPR4, GPRC5A, H4C15, HARS2, HAS1, HCP5, HELB, 
HOXD8, HSP90AA2P, IDO1, IL1A, IL1RN, IRF4, IRX4-AS1, ITPKC, ITPRIPL1, JCAD, JUNB, KDM6B, KIAA0040, KLF7, KLHL15, KLHL9, 
LAD1, LBP, LINC00205, LINC01569, LUCAT1, MAP3K8, MCL1, MECOM, MED28, MIR7975, MSX1, MT-ATP8, MT-ND5, MT-TL1, MYC, 
NDRG4, NEXN-AS1, NFKB2, NFKBIA, NOCT, NPTX2, NR4A2, NUAK2, NXF1, OLIG1, OR51E1, PEG10, PIGA, PIM1, PIM2, PLAU, PLEKHG2, 
PPP1R16B, PPP1R35-AS1, PPRC1, PTPN1, RAB15, RASD1, RASSF5, REC8, RGS2, RNF151, RNU2-2P, RNU4ATAC, RRAD,SBK3, SCN3B, 
SEMA4C, SERPINA3, SERPINB1, SERPINE1, SERPINH1, SESN2, SFT2D3, SLC1A5, SLC9A1, SLC9A3R1, SLCO4A1, SLFN11, SOCS3, SPAAR, 
SSTR1, STC1, STC2, STX11, TAP1, TCF15, TENT5A, TENT5C, TEX14, TGFB3, THBD, THBS1, TIGD3, TMEM229B, TMEM26, TMEM80, 
TNFAIP2, TSPAN13, TTYH3, TUSC3, UBE2E1, VAMP1, VMO1, ZNF433-AS1, ZNF442, ZNF486, ZNF580, ZSWIM8-AS1
MHShc caffeine 147
AGRN, AHNAK, AP5B1, APP, ARHGAP30, ARPIN, ARRB1, ASXL1, ATP2A3, ATP8B4, AXIN2, BAZ2A, BCL9L, C4orf46, CARD6, CASKIN2, 
CCDC8, CCNH, COL6A3, CXCL10, DIPK1A, DNAJB4, DOK4, DTL, ECE1, EDA, ENPP5, EPAS1, EVC, EZH2, FBXW7, FGD5, FHDC1, FLNA, 
FLNB, GAS1, GAS2L1, GLI1, GLI2, GNRH1, HBA1, HBB, HMCN2, HSP90AA1, HSPG2, HSPH1, IGFBP5, IGHG2, IGSF3, IL15, IL17RA, 
IL1RL1, INTS6, IQSEC1, ITGB4, ITPR3, KANK2, KCNC4, KCNE4, KIF21B, KMT2D, LGALSL, LGR5, LINC00467, LINC01355, LRIF1, LRP1, 
LRRC66, MAGEH1, MALINC1, MAP3K2-DT, MAPK13, MAST3, MED4, METTL5, MICAL2, MTATP8P1, MXRA5, MYO9B, NAV1, NID2, 
NOTCH1, NOTCH2, NOTCH3, NPTXR, NUDT13, OLFML2A, PDGFRB, PGAM1P8, PHF12, PIGP, PIK3IP1, PLEKHG3, PLK1, PMAIP1, 
PODXL, PPCS, PPM1F, PPP1R3C, PPP2CA, PPP2R3C, PSMG1, PTPN9, PXDN, RAB11FIP4, REM1, RGP1, SALL2, SCUBE1, SIRT1, 
SLC30A5, SLC46A1, SLC46A3, SLIT2, SMIM10L1, SMIM3, SNHG1, SPTAN1, SULF2, SVEP1, SYDE1, SYT15, TAF1D, TGFB1I1, TLN1, 
TMEM131L, TMEM60, TNS1, TPD52L1, TRH, TRIL, TSPYL5, TYW1, UCHL3, VANGL1, WASF2, WDR89, ZBTB39, ZC3H7B, ZMIZ1, ZNF112, 
ZNF142, ZNF267, ZNF394, ZNF525, ZNF644, ZNF91
218 
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Gene lists within each Venn 
diagram segment
Number of 
genes
Genes within overlapping segment
MHSh caffeine, MHSh halothane, 
MHShc caffeine, MHShc halothane
89
ABRA, ADAMTS4, ATF3, ATP6V1FNB, BCL3, BRD2, CCDC200, CCL2, CD83, CDKN1A, CHIT1, CKS2, CXCL1, CXCL3, DCP1A, DDIT3, 
DNAJA1, DNAJB1, DNAJB5-DT, DSTNP2, DUSP2, DUSP5, DUSP6, EGFL7, EGR2, ERF, ERRFI1, GASAL1, GEM, GIMAP6, GIMAP8, H2AX, 
H2BC20P, HEXIM1, HHATL-AS1, HNRNPA1P38, HSPA1A, HSPA1B, ICAM1, ICAM4, ID1, IL1B, ING1, IQCN, IRF1, LFNG, MAFB, MAFF, 
MIR3153, MT1A, MT-ND6, MT-TA, MT-TC, MT-TE, MT-TF, MT-TK, MT-TM, MT-TN, MT-TQ, MT-TT, MT-TY, PECAM1, PPP1R10, RCAN1, 
RGS16, RND1, RPL13P5, SAT1, SELE, SERTAD1, SLC20A1, SLC2A14, SLC2A3, SNHG12, SNORA10, SNORD14C, SNORD14D, SNORD14E, 
SNORD3A, SNORD3B-1, SNORD3B-2, SNORD3C, SNORD3D, SOCS1, SRSF2, SRSF3, TNFAIP3, TNFRSF10D, TNFSF9
MHSh caffeine, MHShc caffeine, 
MHShc halothane
37
AMD1, ARHGEF15, ARID5B, ARL5B, BIRC3, BTG3, CBX4, CCL8, CLDN6, DIPK2B, FAM71A, GJA1, GPR183, ID4, IER3, INSIG1, IVNS1ABP, 
LINC01004, MT-TV, NABP1, NKX3-1, OLR1, PCF11, PHLDA1, PNP, POLG2, RNU5E-1, SERPINB9, SNORA61, THSD1, TIPARP, TNF, 
TNFAIP6, TNFAIP8L1, VSIG2, ZC3HAV1, ZNF792
MHSh caffeine, MHSh halothane, 
MHShc halothane
4 LRG1, MIR24-2, MT-TP, S1PR1
MHSh caffeine, MHSh halothane, 
MHShc caffeine
9 EGR4, HSP90AB1, MIR616, MT-TS2, MT-TW, PDE4B, PLEKHO2, SNORD99, TSPYL2
MHShc caffeine, MHShc halothane 51
A2M, ABHD5, APCDD1, ARAP3, ARHGAP31, ARL6IP1, C16orf58, CCDC71L, CDH5, CDKN2AIP, CLEC1A, COL15A1, COL4A1, 
CRNDE, CTC1, DCHS1, DONSON, GCFC2, GJA5, KCNQ1OT1, KLRA1P, LYPLAL1, MGAT4A, MIR222HG, MIR3064, NAE1, NAMPT, 
NFE2L2, NOVA2, NYNRIN, PAX7, PDGFB, PIK3R3, RASD2, RET, RFX5, RSRP1, SDC3, SFPQ, SMARCD1, SNORA31, TCIM, 
TCTE3, TDRD6, THUMPD3-AS1, TM4SF1, TRIB3, UGCG, VASH1, ZNF540, ZSCAN32
MHSh caffeine, MHShc halothane 15 ARC, BMP2, BTG1, CLK2, CYP1B1, FABP5, HAS2, IER5L, KLF5, NFIL3, RASGEF1B, RND3, S1PR3, SSTR2, USHBP1
MHSh halothane, MHShc caffeine 2 CCN2, IFIT5
MHSh caffeine, MHShc caffeine 28
ASTL, BAMBI, BCL6, CDH16, CSRP2, DHDH, DNAJA4, FUS, GLA, GTF2B, HAPLN3, HSPA1L, HSPA6, IRX2, KPNA2, LITAF, MTND2P28, 
MTND5P11, MYLIP, NAMA, NFKBIE, NKX6-3, PRSS42P, PRSS44P, STAG3L2, TUBB3, VCAM1, ZNF331
MHSh caffeine, MHSh halothane 86
APOL3, BTG2, BTN3A3, C11orf91, CAV1, CAV2, CCL3, CDK2, CSRNP1, CYB561D1, DIO3OS, EDN1, EGR3, EIF4A1, EIF4A3, ERFE, ETS2, 
FABP4, FOSL2, FZD7, GADD45B, GIMAP1, GIMAP4, GIMAP7, GRASP, H2BC19P, H4C14, HBEGF, HEY1, IER5, IL6, JMJD6, KCNJ8, LAG3, 
LDLR, LRATD2, MEPCE, MIDN, MIR22, MIR23A, MIR8085, MMP19, MT-ND2, MT-TD, MT-TG, MT-TH, MT-TI, NCOA6, NDUFB4P11, 
NFKBID, NFKBIZ, NLRP3, NOLC1, NR2F2, NR4A1, NR4A3, NRN1, OSGIN1, OTUD1, PER1, PFKFB3, PLAUR, POLR2A, PPP1R15A, PRKCG, 
RBKS, RNF122, SDC4, SERTAD3, SIK1, SIK1B, SLC16A14, SLC25A25, SMURF1, SNAI1, SNHG9, SNORA64, SNORA67, STK35, TP53INP2, 
TUBB4B, XIRP1, ZC3H12A, ZFAS1, ZFP36
MHSh halothane 40
ACTN1, ANKRD29, ARNT2, ASAP2, ASPN, ATP1A2, BATF2, CNTNAP3B, DNM3OS, GIMAP2, GNG11, GNL3L, ITM2B, JAM2, JRK, KY, LEPR, 
LINC01578, LIPA, LTC4S, MAN1A1, MAU2, MICAL3, MIR23B, MOB3C, MTND4LP30, N4BP2L2-IT2, NT5C1A, PITPNC1, PPARGC1B, RGCC, 
RPL7P3, SNAI2, SOCS7, TMEM50A, TMSB4X, TMSB4XP8, ZBTB16, ZNF559, ZNF706
MHShc halothane 60
ACOT11, ADCY4, AIF1L, ANKZF1, ARHGAP11A, C5orf51, C6orf120, C6orf47, CADM1, CHRDL2, CLDN12, CREG1, DCK, DNAJC27, FBH1, 
GDAP2, GLMN, H3-3B, HS6ST2, KCNA5, LINC00672, LSM6, MIR27A, MORC2, MRPL16, MSTO1, MTATP6P1, NDUFA1, NPR1, OSGEP, 
PCDH1, PCDH12, PKD1L1, PNRC1, POT1, PRNP, PTGR1, RAP1B, RBMS3, RLF, ROBO4, RPS13P2, RYBP, SDCBP, SH2D3C, SHF, SLC19A2, 
SLC1A7, SPSB2, TBC1D23, TGFB2, TIE1, TMEM165, TMEM167B, UBE2D3, UNG, WDR33, ZBTB21, ZBTB4, ZNF500
MHSh caffeine 181
ADAMTS1, AGER, ANKRD1, ANKRD37, AOC2, APOLD1, AREG, ARID5A, ASPRV1, ATP1A1, ATP1B3, B3GNT5, BCDIN3D, BCL2A1, 
BHLHE40, BTBD19, C11orf96, C1QTNF9, C2CD4B, C4A-AS1, C9orf170, CA4, CARMN, CBX2, CCL3L1, CCL4, CCL4L2, CCND2, CD300LG, 
CEACAM1, CENPW, CFAP97D1, CGB7, CH25H, CHMP4BP1, CPNE8-AS1, CRTC3, CSF3, CSRNP2, CSTF1, CXCL2, CXCL8, CXCR4, DACT1, 
DCUN1D3, DLC1, DLG5, DNALI1, DPPA2P4, DUSP8, DYRK3, EGR1, EMP1, ENDOU, EPOP, ETV4, EXOSC6, FAM181A-AS1, FAM72A, 
FOSL1, FOXC2, FZD5, GADD45A, GAREM1, GCH1, GDNF, GH1, GIPC3, GPIHBP1, GPR4, GPRC5A, H4C15, HARS2, HAS1, HCP5, HELB, 
HOXD8, HSP90AA2P, IDO1, IL1A, IL1RN, IRF4, IRX4-AS1, ITPKC, ITPRIPL1, JCAD, JUNB, KDM6B, KIAA0040, KLF7, KLHL15, KLHL9, 
LAD1, LBP, LINC00205, LINC01569, LUCAT1, MAP3K8, MCL1, MECOM, MED28, MIR7975, MSX1, MT-ATP8, MT-ND5, MT-TL1, MYC, 
NDRG4, NEXN-AS1, NFKB2, NFKBIA, NOCT, NPTX2, NR4A2, NUAK2, NXF1, OLIG1, OR51E1, PEG10, PIGA, PIM1, PIM2, PLAU, PLEKHG2, 
PPP1R16B, PPP1R35-AS1, PPRC1, PTPN1, RAB15, RASD1, RASSF5, REC8, RGS2, RNF151, RNU2-2P, RNU4ATAC, RRAD,SBK3, SCN3B, 
SEMA4C, SERPINA3, SERPINB1, SERPINE1, SERPINH1, SESN2, SFT2D3, SLC1A5, SLC9A1, SLC9A3R1, SLCO4A1, SLFN11, SOCS3, SPAAR, 
SSTR1, STC1, STC2, STX11, TAP1, TCF15, TENT5A, TENT5C, TEX14, TGFB3, THBD, THBS1, TIGD3, TMEM229B, TMEM26, TMEM80, 
TNFAIP2, TSPAN13, TTYH3, TUSC3, UBE2E1, VAMP1, VMO1, ZNF433-AS1, ZNF442, ZNF486, ZNF580, ZSWIM8-AS1
MHShc caffeine 147
AGRN, AHNAK, AP5B1, APP, ARHGAP30, ARPIN, ARRB1, ASXL1, ATP2A3, ATP8B4, AXIN2, BAZ2A, BCL9L, C4orf46, CARD6, CASKIN2, 
CCDC8, CCNH, COL6A3, CXCL10, DIPK1A, DNAJB4, DOK4, DTL, ECE1, EDA, ENPP5, EPAS1, EVC, EZH2, FBXW7, FGD5, FHDC1, FLNA, 
FLNB, GAS1, GAS2L1, GLI1, GLI2, GNRH1, HBA1, HBB, HMCN2, HSP90AA1, HSPG2, HSPH1, IGFBP5, IGHG2, IGSF3, IL15, IL17RA, 
IL1RL1, INTS6, IQSEC1, ITGB4, ITPR3, KANK2, KCNC4, KCNE4, KIF21B, KMT2D, LGALSL, LGR5, LINC00467, LINC01355, LRIF1, LRP1, 
LRRC66, MAGEH1, MALINC1, MAP3K2-DT, MAPK13, MAST3, MED4, METTL5, MICAL2, MTATP8P1, MXRA5, MYO9B, NAV1, NID2, 
NOTCH1, NOTCH2, NOTCH3, NPTXR, NUDT13, OLFML2A, PDGFRB, PGAM1P8, PHF12, PIGP, PIK3IP1, PLEKHG3, PLK1, PMAIP1, 
PODXL, PPCS, PPM1F, PPP1R3C, PPP2CA, PPP2R3C, PSMG1, PTPN9, PXDN, RAB11FIP4, REM1, RGP1, SALL2, SCUBE1, SIRT1, 
SLC30A5, SLC46A1, SLC46A3, SLIT2, SMIM10L1, SMIM3, SNHG1, SPTAN1, SULF2, SVEP1, SYDE1, SYT15, TAF1D, TGFB1I1, TLN1, 
TMEM131L, TMEM60, TNS1, TPD52L1, TRH, TRIL, TSPYL5, TYW1, UCHL3, VANGL1, WASF2, WDR89, ZBTB39, ZC3H7B, ZMIZ1, ZNF112, 
ZNF142, ZNF267, ZNF394, ZNF525, ZNF644, ZNF91
219 
 
 
 
 
 
 
 
Gene lists within each Venn 
diagram segment
Number of 
genes
Genes within overlapping segment
MHSh caffeine, MHSh halothane, 
MHShc caffeine, MHShc halothane
89
ABRA, ADAMTS4, ATF3, ATP6V1FNB, BCL3, BRD2, CCDC200, CCL2, CD83, CDKN1A, CHIT1, CKS2, CXCL1, CXCL3, DCP1A, DDIT3, 
DNAJA1, DNAJB1, DNAJB5-DT, DSTNP2, DUSP2, DUSP5, DUSP6, EGFL7, EGR2, ERF, ERRFI1, GASAL1, GEM, GIMAP6, GIMAP8, H2AX, 
H2BC20P, HEXIM1, HHATL-AS1, HNRNPA1P38, HSPA1A, HSPA1B, ICAM1, ICAM4, ID1, IL1B, ING1, IQCN, IRF1, LFNG, MAFB, MAFF, 
MIR3153, MT1A, MT-ND6, MT-TA, MT-TC, MT-TE, MT-TF, MT-TK, MT-TM, MT-TN, MT-TQ, MT-TT, MT-TY, PECAM1, PPP1R10, RCAN1, 
RGS16, RND1, RPL13P5, SAT1, SELE, SERTAD1, SLC20A1, SLC2A14, SLC2A3, SNHG12, SNORA10, SNORD14C, SNORD14D, SNORD14E, 
SNORD3A, SNORD3B-1, SNORD3B-2, SNORD3C, SNORD3D, SOCS1, SRSF2, SRSF3, TNFAIP3, TNFRSF10D, TNFSF9
MHSh caffeine, MHShc caffeine, 
MHShc halothane
37
AMD1, ARHGEF15, ARID5B, ARL5B, BIRC3, BTG3, CBX4, CCL8, CLDN6, DIPK2B, FAM71A, GJA1, GPR183, ID4, IER3, INSIG1, IVNS1ABP, 
LINC01004, MT-TV, NABP1, NKX3-1, OLR1, PCF11, PHLDA1, PNP, POLG2, RNU5E-1, SERPINB9, SNORA61, THSD1, TIPARP, TNF, 
TNFAIP6, TNFAIP8L1, VSIG2, ZC3HAV1, ZNF792
MHSh caffeine, MHSh halothane, 
MHShc halothane
4 LRG1, MIR24-2, MT-TP, S1PR1
MHSh caffeine, MHSh halothane, 
MHShc caffeine
9 EGR4, HSP90AB1, MIR616, MT-TS2, MT-TW, PDE4B, PLEKHO2, SNORD99, TSPYL2
MHShc caffeine, MHShc halothane 51
A2M, ABHD5, APCDD1, ARAP3, ARHGAP31, ARL6IP1, C16orf58, CCDC71L, CDH5, CDKN2AIP, CLEC1A, COL15A1, COL4A1, 
CRNDE, CTC1, DCHS1, DONSON, GCFC2, GJA5, KCNQ1OT1, KLRA1P, LYPLAL1, MGAT4A, MIR222HG, MIR3064, NAE1, NAMPT, 
NFE2L2, NOVA2, NYNRIN, PAX7, PDGFB, PIK3R3, RASD2, RET, RFX5, RSRP1, SDC3, SFPQ, SMARCD1, SNORA31, TCIM, 
TCTE3, TDRD6, THUMPD3-AS1, TM4SF1, TRIB3, UGCG, VASH1, ZNF540, ZSCAN32
MHSh caffeine, MHShc halothane 15 ARC, BMP2, BTG1, CLK2, CYP1B1, FABP5, HAS2, IER5L, KLF5, NFIL3, RASGEF1B, RND3, S1PR3, SSTR2, USHBP1
MHSh halothane, MHShc caffeine 2 CCN2, IFIT5
MHSh caffeine, MHShc caffeine 28
ASTL, BAMBI, BCL6, CDH16, CSRP2, DHDH, DNAJA4, FUS, GLA, GTF2B, HAPLN3, HSPA1L, HSPA6, IRX2, KPNA2, LITAF, MTND2P28, 
MTND5P11, MYLIP, NAMA, NFKBIE, NKX6-3, PRSS42P, PRSS44P, STAG3L2, TUBB3, VCAM1, ZNF331
MHSh caffeine, MHSh halothane 86
APOL3, BTG2, BTN3A3, C11orf91, CAV1, CAV2, CCL3, CDK2, CSRNP1, CYB561D1, DIO3OS, EDN1, EGR3, EIF4A1, EIF4A3, ERFE, ETS2, 
FABP4, FOSL2, FZD7, GADD45B, GIMAP1, GIMAP4, GIMAP7, GRASP, H2BC19P, H4C14, HBEGF, HEY1, IER5, IL6, JMJD6, KCNJ8, LAG3, 
LDLR, LRATD2, MEPCE, MIDN, MIR22, MIR23A, MIR8085, MMP19, MT-ND2, MT-TD, MT-TG, MT-TH, MT-TI, NCOA6, NDUFB4P11, 
NFKBID, NFKBIZ, NLRP3, NOLC1, NR2F2, NR4A1, NR4A3, NRN1, OSGIN1, OTUD1, PER1, PFKFB3, PLAUR, POLR2A, PPP1R15A, PRKCG, 
RBKS, RNF122, SDC4, SERTAD3, SIK1, SIK1B, SLC16A14, SLC25A25, SMURF1, SNAI1, SNHG9, SNORA64, SNORA67, STK35, TP53INP2, 
TUBB4B, XIRP1, ZC3H12A, ZFAS1, ZFP36
MHSh halothane 40
ACTN1, ANKRD29, ARNT2, ASAP2, ASPN, ATP1A2, BATF2, CNTNAP3B, DNM3OS, GIMAP2, GNG11, GNL3L, ITM2B, JAM2, JRK, KY, LEPR, 
LINC01578, LIPA, LTC4S, MAN1A1, MAU2, MICAL3, MIR23B, MOB3C, MTND4LP30, N4BP2L2-IT2, NT5C1A, PITPNC1, PPARGC1B, RGCC, 
RPL7P3, SNAI2, SOCS7, TMEM50A, TMSB4X, TMSB4XP8, ZBTB16, ZNF559, ZNF706
MHShc halothane 60
ACOT11, ADCY4, AIF1L, ANKZF1, ARHGAP11A, C5orf51, C6orf120, C6orf47, CADM1, CHRDL2, CLDN12, CREG1, DCK, DNAJC27, FBH1, 
GDAP2, GLMN, H3-3B, HS6ST2, KCNA5, LINC00672, LSM6, MIR27A, MORC2, MRPL16, MSTO1, MTATP6P1, NDUFA1, NPR1, OSGEP, 
PCDH1, PCDH12, PKD1L1, PNRC1, POT1, PRNP, PTGR1, RAP1B, RBMS3, RLF, ROBO4, RPS13P2, RYBP, SDCBP, SH2D3C, SHF, SLC19A2, 
SLC1A7, SPSB2, TBC1D23, TGFB2, TIE1, TMEM165, TMEM167B, UBE2D3, UNG, WDR33, ZBTB21, ZBTB4, ZNF500
MHSh caffeine 181
ADAMTS1, AGER, ANKRD1, ANKRD37, AOC2, APOLD1, AREG, ARID5A, ASPRV1, ATP1A1, ATP1B3, B3GNT5, BCDIN3D, BCL2A1, 
BHLHE40, BTBD19, C11orf96, C1QTNF9, C2CD4B, C4A-AS1, C9orf170, CA4, CARMN, CBX2, CCL3L1, CCL4, CCL4L2, CCND2, CD300LG, 
CEACAM1, CENPW, CFAP97D1, CGB7, CH25H, CHMP4BP1, CPNE8-AS1, CRTC3, CSF3, CSRNP2, CSTF1, CXCL2, CXCL8, CXCR4, DACT1, 
DCUN1D3, DLC1, DLG5, DNALI1, DPPA2P4, DUSP8, DYRK3, EGR1, EMP1, ENDOU, EPOP, ETV4, EXOSC6, FAM181A-AS1, FAM72A, 
FOSL1, FOXC2, FZD5, GADD45A, GAREM1, GCH1, GDNF, GH1, GIPC3, GPIHBP1, GPR4, GPRC5A, H4C15, HARS2, HAS1, HCP5, HELB, 
HOXD8, HSP90AA2P, IDO1, IL1A, IL1RN, IRF4, IRX4-AS1, ITPKC, ITPRIPL1, JCAD, JUNB, KDM6B, KIAA0040, KLF7, KLHL15, KLHL9, 
LAD1, LBP, LINC00205, LINC01569, LUCAT1, MAP3K8, MCL1, MECOM, MED28, MIR7975, MSX1, MT-ATP8, MT-ND5, MT-TL1, MYC, 
NDRG4, NEXN-AS1, NFKB2, NFKBIA, NOCT, NPTX2, NR4A2, NUAK2, NXF1, OLIG1, OR51E1, PEG10, PIGA, PIM1, PIM2, PLAU, PLEKHG2, 
PPP1R16B, PPP1R35-AS1, PPRC1, PTPN1, RAB15, RASD1, RASSF5, REC8, RGS2, RNF151, RNU2-2P, RNU4ATAC, RRAD,SBK3, SCN3B, 
SEMA4C, SERPINA3, SERPINB1, SERPINE1, SERPINH1, SESN2, SFT2D3, SLC1A5, SLC9A1, SLC9A3R1, SLCO4A1, SLFN11, SOCS3, SPAAR, 
SSTR1, STC1, STC2, STX11, TAP1, TCF15, TENT5A, TENT5C, TEX14, TGFB3, THBD, THBS1, TIGD3, TMEM229B, TMEM26, TMEM80, 
TNFAIP2, TSPAN13, TTYH3, TUSC3, UBE2E1, VAMP1, VMO1, ZNF433-AS1, ZNF442, ZNF486, ZNF580, ZSWIM8-AS1
MHShc caffeine 147
AGRN, AHNAK, AP5B1, APP, ARHGAP30, ARPIN, ARRB1, ASXL1, ATP2A3, ATP8B4, AXIN2, BAZ2A, BCL9L, C4orf46, CARD6, CASKIN2, 
CCDC8, CCNH, COL6A3, CXCL10, DIPK1A, DNAJB4, DOK4, DTL, ECE1, EDA, ENPP5, EPAS1, EVC, EZH2, FBXW7, FGD5, FHDC1, FLNA, 
FLNB, GAS1, GAS2L1, GLI1, GLI2, GNRH1, HBA1, HBB, HMCN2, HSP90AA1, HSPG2, HSPH1, IGFBP5, IGHG2, IGSF3, IL15, IL17RA, 
IL1RL1, INTS6, IQSEC1, ITGB4, ITPR3, KANK2, KCNC4, KCNE4, KIF21B, KMT2D, LGALSL, LGR5, LINC00467, LINC01355, LRIF1, LRP1, 
LRRC66, MAGEH1, MALINC1, MAP3K2-DT, MAPK13, MAST3, MED4, METTL5, MICAL2, MTATP8P1, MXRA5, MYO9B, NAV1, NID2, 
NOTCH1, NOTCH2, NOTCH3, NPTXR, NUDT13, OLFML2A, PDGFRB, PGAM1P8, PHF12, PIGP, PIK3IP1, PLEKHG3, PLK1, PMAIP1, 
PODXL, PPCS, PPM1F, PPP1R3C, PPP2CA, PPP2R3C, PSMG1, PTPN9, PXDN, RAB11FIP4, REM1, RGP1, SALL2, SCUBE1, SIRT1, 
SLC30A5, SLC46A1, SLC46A3, SLIT2, SMIM10L1, SMIM3, SNHG1, SPTAN1, SULF2, SVEP1, SYDE1, SYT15, TAF1D, TGFB1I1, TLN1, 
TMEM131L, TMEM60, TNS1, TPD52L1, TRH, TRIL, TSPYL5, TYW1, UCHL3, VANGL1, WASF2, WDR89, ZBTB39, ZC3H7B, ZMIZ1, ZNF112, 
ZNF142, ZNF267, ZNF394, ZNF525, ZNF644, ZNF91
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Appendix 12 – Pathway analysis for WT vs G2435R-RYR1 HOM comparison 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Pathway analysis for WT vs G2435R-RYR1 HOM comparison. The top 10 pathway terms generated by Enrichr, using upregulated and 
downregulated gene lists. Upregulated (Top) and downregulated (bottom) pathways are displayed in order of combined score (log of p-value from Fisher’s 
exact test multiplied by z score of deviation from expected rank). 
 
Index Downregulated pathway terms P-value Adjusted p-value Odds Ratio Combined score
1 Fatty Acid Beta Oxidation WP1269 8.44E-16 1.49E-13 25.92 899.71
2 Mitochondrial LC-Fatty Acid Beta-Oxidation WP401 1.44E-09 1.27E-07 29.66 603.77
3 Fatty Acid Biosynthesis WP336 1.45E-05 5.09E-04 15.41 171.71
4 Fatty acid oxidation WP2318 3.53E-04 8.88E-03 20.34 161.68
5 TCA Cycle WP434 5.28E-06 2.32E-04 13.12 159.44
6 PPAR signaling pathway WP2316 3.12E-07 1.83E-05 8.37 125.38
7 Amino Acid metabolism WP662 8.16E-05 2.39E-03 5.71 53.75
8 Retinol metabolism WP1259 2.54E-03 5.59E-02 6.95 41.55
9 Synthesis and Degradation of Ketone Bodies WP543 7.16E-02 6.30E-01 13.56 35.75
10 Acetylcholine Synthesis WP175 9.88E-02 6.96E-01 9.69 22.42
Index Upregulated pathway terms P-value Adjusted p-value Odds Ratio Combined score
1 MAPK Cascade WP251 3.42E-04 6.02E-02 21.87 174.51
2 Notch Signaling Pathway WP29 1.49E-03 5.23E-02 13.31 86.66
3 Novel Jun-Dmp1 Pathway WP3654 7.15E-03 1.57E-01 15.7 77.55
4 Delta-Notch Signaling Pathway WP265 7.41E-04 6.52E-02 9.84 70.89
5 Signaling of Hepatocyte Growth Factor Receptor WP193 1.20E-02 2.35E-01 12 53.06
6 Primary Focal Segmental Glomerulosclerosis FSGS WP2573 5.33E-03 1.56E-01 8.5 44.51
7 Insulin Signaling WP65 1.12E-03 6.55E-02 6.42 43.62
8 MAPK signaling pathway WP493 1.12E-03 4.92E-02 6.42 43.62
9 Osteoclast WP454 6.65E-02 5.57E-01 14.58 39.52
10 Splicing factor NOVA regulated synaptic proteins WP1983 1.80E-02 2.64E-01 9.72 39.03
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Appendix 13 - Pathway analysis for WT vs T4826I-RYR1 HET comparison 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Pathway analysis for WT vs T4826I-RYR1 HET comparison. The top 10 pathway terms generated by Enrichr, using upregulated and downregulated 
gene lists. Upregulated (Top) and downregulated (bottom) pathways are displayed in order of combined score (log of p-value from Fisher’s exact test multiplied 
by z score of deviation from expected rank). 
Index Upregulated pathway terms P-value Adjusted p-value Odds Ratio Combined score
1 Glycolysis and Gluconeogenesis WP157 1.20E-03 2.11E-01 14.35 96.49
2 Osteoblast WP238 4.03E-02 1.00E+00 24.39 78.35
3 Osteoclast WP454 5.59E-02 1.00E+00 17.42 50.24
4 Orphan GPCRs WP1398 7.51E-02 1.00E+00 12.84 33.23
5 Calcium Regulation in the Cardiac Cell WP553 2.26E-02 1.00E+00 4.98 18.87
6 One Carbon Metabolism WP435 1.12E-01 1.00E+00 8.41 18.38
7 Wnt Signaling in Kidney Disease WP3857 1.41E-01 1.00E+00 6.59 12.91
8 TNF-alpha NF-kB Signaling Pathway WP246 4.16E-02 1.00E+00 3.91 12.44
9 DNA Replication WP150 1.55E-01 1.00E+00 5.95 11.08
10 IL-7 Signaling Pathway WP297 1.66E-01 1.00E+00 5.54 9.97
Index Downregulated pathway terms P-value Adjusted p-value Odds Ratio Combined score
1 Fatty acid oxidation WP2318 1.66E-03 9.74E-02 32.26 206.46
2 Fatty Acid Biosynthesis WP336 3.29E-04 5.78E-02 21.99 176.4
3 Fatty Acid Beta Oxidation WP1269 1.21E-03 1.06E-01 14.23 95.6
4 Heme Biosynthesis WP18 5.45E-02 7.99E-01 17.92 52.16
5 Irinotecan Pathway WP475 6.03E-02 8.17E-01 16.13 45.29
6 TCA Cycle WP434 1.58E-02 6.94E-01 10.41 43.18
7 Toll Like Receptor signaling WP88 1.78E-02 6.25E-01 9.78 39.4
8 Tryptophan metabolism WP79 3.05E-02 6.70E-01 7.33 25.6
9 ErbB signaling pathway WP1261 3.31E-02 6.46E-01 7.01 23.91
10 Mitochondrial LC-Fatty Acid Beta-Oxidation WP401 9.48E-02 1.00E+00 10.08 23.76
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Appendix 14 – Gene ontology for WT vs G2435R-RYR1 HOM comparison 
(upregulated terms only) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Gene ontology analyses for the WT vs G2435R-RYR1 HOM comparison (upregulated 
terms). Top 10 ontology terms for biological process, molecular function and cellular component 
generated using Enrichr, in order of adjusted p-value. 
Upregulated terms Adjusted p-value
Plasma membrane organization (GO:0007009) 1.89E-01
Positive regulation of protein autophosphorylation (GO:0031954) 4.72E-01
Regulation of protein autophosphorylation (GO:0031952) 7.32E-01
Response to thyroid hormone (GO:0097066) 8.77E-01
Platelet degranulation (GO:0002576) 8.94E-01
Transmembrane receptor protein tyrosine kinase signaling pathway (GO:0007169) 9.00E-01
Positive regulation of actin cytoskeleton reorganization (GO:2000251) 9.08E-01
Stress-activated MAPK cascade (GO:0051403) 9.09E-01
Mitotic cytokinesis (GO:0000281) 9.11E-01
Basement membrane organization (GO:0071711) 9.25E-01
Collagen binding (GO:0005518) 1.77E-01
Vinculin binding (GO:0017166) 6.49E-01
Hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in cyclic amides 
(GO:0016812)
1.00E+00
Transforming growth factor beta-activated receptor activity (GO:0005024) 1.00E+00
Estradiol 17-beta-dehydrogenase activity (GO:0004303) 1.00E+00
Acetylcholine receptor regulator activity (GO:0030548) 1.00E+00
Superoxide-generating NADPH oxidase activator activity (GO:0016176) 1.00E+00
Protein kinase C activity (GO:0004697) 1.00E+00
Platelet-derived growth factor binding (GO:0048407) 1.00E+00
Immunoglobulin binding (GO:0019865) 1.00E+00
Cytoskeleton (GO:0005856) 1.10E-03
Cell cortex part (GO:0044448) 1.80E-02
Secretory granule lumen (GO:0034774) 2.51E-02
Caveola (GO:0005901) 3.04E-02
Focal adhesion (GO:0005925) 4.34E-02
Polymeric cytoskeletal fiber (GO:0099513) 7.22E-02
Platelet alpha granule (GO:0031091) 7.73E-02
Septin filament array (GO:0032160) 1.00E-01
Septin ring (GO:0005940) 1.12E-01
Septin cytoskeleton (GO:0032156) 1.26E-01
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Appendix 15 – Gene ontology for WT vs T4826I-RYR1 HET comparison 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Gene ontology analyses for the WT vs T4826I-RYR1 HET comparison (upregulated 
terms). Top 10 ontology terms for biological process, molecular function and cellular component 
generated using Enrichr, in order of adjusted p-value. 
Upregulated terms Adjusted p-value
Glucose catabolic process to pyruvate (GO:0061718) 3.38E-01
Canonical glycolysis (GO:0061621) 5.08E-01
Apoptotic process (GO:0006915) 7.15E-01
Glycolytic process through glucose-6-phosphate (GO:0061620) 1.00E+00
Positive regulation of catecholamine secretion (GO:0033605) 1.00E+00
Cerebral cortex cell migration (GO:0021795) 1.00E+00
Negative regulation of keratinocyte differentiation (GO:0045617) 1.00E+00
Regulation of cytokine production involved in immune response (GO:0002718) 1.00E+00
Peptidyl-proline hydroxylation (GO:0019511) 1.00E+00
Response to manganese ion (GO:0010042) 1.00E+00
MHC class II protein complex binding (GO:0023026) 1.00E+00
1-phosphatidylinositol-3-kinase regulator activity (GO:0046935) 1.00E+00
Coreceptor activity involved in Wnt signaling pathway, planar cell polarity pathway 
(GO:1904929)
1.00E+00
Calcium:sodium antiporter activity (GO:0005432) 1.00E+00
C3HC4-type RING finger domain binding (GO:0055131) 1.00E+00
Ubiquitin-dependent protein binding (GO:0140036) 1.00E+00
Hydroxymethyl-, formyl- and related transferase activity (GO:0016742) 1.00E+00
MHC protein complex binding (GO:0023023) 1.00E+00
Satellite DNA binding (GO:0003696) 1.00E+00
Wnt-activated receptor activity (GO:0042813) 1.00E+00
Flotillin complex (GO:0016600) 1.00E+00
Clathrin-sculpted gamma-aminobutyric acid transport vesicle membrane (GO:0061202) 1.00E+00
Perinuclear endoplasmic reticulum (GO:0097038) 1.00E+00
Clathrin-sculpted gamma-aminobutyric acid transport vesicle (GO:0061200) 1.00E+00
NpBAF complex (GO:0071564) 1.00E+00
SWI/SNF complex (GO:0016514) 1.00E+00
BAF-type complex (GO:0090544) 1.00E+00
Dendrite membrane (GO:0032590) 1.00E+00
Intrinsic component of external side of plasma membrane (GO:0031233) 1.00E+00
Axon (GO:0030424) 1.00E+00
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Table 2. Gene ontology analyses for the WT vs T4826I-RYR1 HET comparison (downregulated 
terms). Top 10 ontology terms for biological process, molecular function and cellular component 
generated using Enrichr, in order of adjusted p-value. 
 
Downregulated terms Adjusted p-value
Fatty acid catabolic process (GO:0009062) 4.12E-01
Response to alkaloid (GO:0043279) 8.03E-01
Cardiolipin acyl-chain remodeling (GO:0035965) 8.38E-01
Fatty acid beta-oxidation (GO:0006635) 9.62E-01
Sarcoplasmic reticulum calcium ion transport (GO:0070296) 1.00E+00
Regulation of acyl-CoA biosynthetic process (GO:0050812) 1.00E+00
Cardiolipin metabolic process (GO:0032048) 1.00E+00
Acetyl-CoA metabolic process (GO:0006084) 1.00E+00
Regulation of acetyl-CoA biosynthetic process from pyruvate (GO:0010510) 1.00E+00
Fatty acid beta-oxidation using acyl-CoA dehydrogenase (GO:0033539) 1.00E+00
Acetylcholine-gated cation-selective channel activity (GO:0022848) 1.00E+00
CoA hydrolase activity (GO:0016289) 1.00E+00
1-acylglycerol-3-phosphate O-acyltransferase activity (GO:0003841) 1.00E+00
Exoribonuclease activity (GO:0004532) 1.00E+00
Lysophosphatidic acid acyltransferase activity (GO:0042171) 1.00E+00
Primary miRNA binding (GO:0070878) 1.00E+00
DEAD/H-box RNA helicase binding (GO:0017151) 1.00E+00
Leucine binding (GO:0070728) 1.00E+00
Wnt-activated receptor activity (GO:0042813) 1.00E+00
NAD binding (GO:0051287) 1.00E+00
Mitochondrial matrix (GO:0005759)* 5.23E-04
Mitochondrion (GO:0005739) 3.18E-01
Cytoplasmic vesicle membrane (GO:0030659) 6.67E-01
Acetylcholine-gated channel complex (GO:0005892) 8.43E-01
NURF complex (GO:0016589) 1.00E+00
RISC complex (GO:0016442) 1.00E+00
Junctional sarcoplasmic reticulum membrane (GO:0014701) 1.00E+00
RNAi effector complex (GO:0031332) 1.00E+00
Sarcoplasmic reticulum (GO:0016529) 1.00E+00
Sarcoplasm (GO:0016528) 1.00E+00
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